Pharmacology Books

Book SynopsisThe detection and evaluation of adverse drug reactions is crucial for understanding the safety of medicines and for preventing harm in patients. Not only is it necessary to detect new adverse drug reactions, but the principles and practice of pharmacovigilance apply to the surveillance of a wide range of medicinal products. Stephens'' Detection and Evaluation of Adverse Drug Reactions provides a comprehensive review of all aspects of adverse drug reactions throughout the life cycle of a medicine, from toxicology and clinical trials through to pharmacovigilance, risk management, and legal and regulatory requirements. It also covers the safety of biotherapeutics and vaccines and includes new chapters on pharmacogenetics, proactive risk management, societal considerations, and the safety of drugs used in oncology and herbal medicines. This sixth edition of the classic text on drug safety is an authoritative reference text for all those who work in pharmacovigilance or haTrade Review“A vast array of experts in the science of pharmacovigilance contribute to this book, but the editors have maintained a clarity of presentation, keeping in mind that communication is a key factor in pharmacovigilance.” (Doody’s, 27 July 2012)Table of ContentsForeword xi Preface to the Sixth Edition xiii List of Contributors xv Acknowledgements xvii 1 Adverse Drug Reactions: History, Terminology, Classification, Causality, Frequency, Preventability 1 Jeffrey K. Aronson 1.1 Introduction 1 1.2 Defining pharmacovigilance 1 1.3 The modern history of pharmacovigilance 3 1.4 Terminology and definitions in pharmacovigilance 6 1.5 Medication errors 25 1.6 Pharmacological classification of adverse drug reactions 32 1.7 Drug interactions 53 1.8 Reporting suspected adverse drug reactions 59 1.9 Causality assessment 64 1.10 Frequencies of adverse drug reactions 69 1.11 Risk perception and adverse drug reactions 77 1.12 Class effects of drugs 78 1.13 Unlicensed indications, off-label uses, and orphan drugs 80 1.14 Preventing adverse drug reactions 84 1.15 Publishing accounts of adverse drug reactions 95 References 101 2 Pharmacogenetics of Adverse Drug Reactions 121 Sudeep P. Pushpakom and Munir Pirmohamed 2.1 Introduction 121 2.2 Historical review 121 2.3 Sources of genetic variability 122 2.4 Role of pharmacogenetic factors in drug pharmacokinetics 123 2.5 Role of pharmacogenetic factors in drug pharmacodynamics 133 2.6 The role of pharmacogenetics in pharmaceutical companies 139 2.7 The impact of pharmacogenetics on regulatory agencies 141 2.8 The impact of pharmacogenetics on clinical practice 143 2.9 Conclusions 145 References 145 3 Toxicology and Adverse Drug Reactions 157 D. J. Snodin and A. Suitters 3.1 Introduction 157 3.2 Toxicity testing 157 3.3 Drug discovery and development 168 3.4 Data interpretation and risk assessment 174 3.5 Adverse drug reactions detected after marketing authorization 186 3.6 Examples of toxicological investigation of ADRs 199 3.7 Conclusions 200 Acknowledgements 201 References 201 4 Clinical Trials—Collecting Safety Data and Establishing the Adverse Drug Reactions Profile 215 John Talbot, Marianne Keisu, and Lars St°ahle 4.1 Introduction 215 4.2 Adverse events 216 4.3 Clinical studies and safety 236 4.4 The emerging safety profile 267 4.5 Presentation of safety data 271 4.6 Conclusions 280 References 281 5 Clinical Laboratory Safety Data 291 Alan Craig 5.1 Introduction 291 5.2 Factors that influence the interpretation of clinical laboratory data 294 5.3 Sample collection procedure 300 5.4 Analytical variation 301 5.5 Reference ranges 304 5.6 Intra-individual biological variation 307 5.7 Detecting adverse events during drug development 309 5.8 Test selection 333 5.9 Exclusion criteria and “panic levels” 335 5.10 Harmonization of data from different laboratories 337 5.11 Data analysis and presentation 339 5.12 Conclusions 344 5.13 Appendix 345 References 346 6 Statistics: Analysis and Presentation of Safety Data 349 Stephen J. W. Evans and Dorothea Nitsch 6.1 Introduction and background 349 6.2 Problems with efficacy trials for detecting adverse drug reactions 352 6.3 Analysis and presentation of data from trials 355 6.4 Statistical measures of the occurrence of adverse events 356 6.5 Combining data from several trials—meta-analysis 364 6.6 Use of statistical methods for signal detection from spontaneous reports 365 6.7 Analysis and presentation of data from observational studies 373 6.8 Summary and conclusions 384 Acknowledgements 385 References 386 7 Proactive Pharmacovigilance and Risk Management 389 June Raine, Lesley Wise, John Talbot, and Jeffrey K. Aronson 7.1 Introduction 389 7.2 Risk management—definition and general principles 390 7.3 Defining the knowledge base—the safety specification 391 7.4 Extending the knowledge of safety and characterizing risk—the pharmacovigilance plan 394 7.5 Minimizing risks 395 7.6 Special challenges for risk management 397 7.7 Experience with risk evaluation and mitigation strategies (REMS) in the USA 398 7.8 A possible method for risk management when a new adverse reaction is discovered after marketing 399 7.9 Future challenges for risk management 405 7.10 Conclusions 406 References 407 8 Regulatory Aspects of Pharmacovigilance 411 Kristina Leila Strutt and Barry David Charles Arnold 8.1 Introduction 411 8.2 The standardization and harmonization of safety data collection and reporting: CIOMS and ICH 412 8.3 The European Union 447 8.4 The UK 481 8.5 France 483 8.6 Germany 485 8.7 USA 487 8.8 Japan 500 Acknowledgements 505 References 506 Useful web sites 509 9 Legal Aspects of Pharmacovigilance in the European Union 511 Christine H. Bendall 9.1 Introduction 511 9.2 Application of EU legislation in Member States 511 9.3 Interpretation of EU law 514 9.4 Relationship between law and guidelines 515 9.5 Issues in interpreting EU pharmacovigilance legislation 517 9.6 Legal responsibility for pharmacovigilance activities 519 9.7 Failures to meet pharmacovigilance requirements 522 9.8 Enforcement and sanctions 524 9.9 European powers and procedures in the event of a product safety issue 528 9.10 Civil liability 534 9.11 Personal data privacy 537 9.12 Safety in research products 538 References 541 10 Dictionaries and Coding in Pharmacovigilance 545 E. G. Brown and J. E. Harrison 10.1 Introduction 545 10.2 Scope of this chapter 546 10.3 What is a dictionary? 546 10.4 Drug dictionaries 547 10.5 Disease classifications 554 10.6 Medical Dictionary for Regulatory Activities, MedDRA R557 10.7 Common Terminology Criteria for Adverse Events (CTCAE) 567 10.8 Definition of adverse reaction terms 567 10.9 Dictionaries used in electronic health records 568 10.10 Use of dictionaries in standard product information 570 10.11 Conclusions 571 Acknowledgements 571 References 571 11 Adverse Drug Reactions: Societal Considerations 573 Nicky Britten 11.1 Introduction 573 11.2 Adverse drug reactions at the population level 574 11.3 The social production of ADRs 576 11.4 Trust 579 11.5 Information about ADRs 581 11.6 Conclusions 583 References 583 12 Safety of Biotherapeutics 585 Andrew Erdman, James Nickas, and Benton Brown 12.1 Introduction 585 12.2 Properties of proteins 586 12.3 Classification of biotherapeutics 587 12.4 Monitoring for adverse events due to biotherapeutics 589 12.5 Conclusions 598 References 598 13 Vaccine Safety Surveillance 603 E. Miller and J. Stowe 13.1 Introduction 603 13.2 What is special about vaccine safety compared with other drugs? 604 13.3 Pathogenesis of vaccine reactions 605 13.4 Criteria for establishing causality after vaccine-related adverse events 608 13.5 Pre-licensing evaluation of vaccine safety 610 13.6 Objectives of an ideal post-licensing vaccine safety surveillance system 611 13.7 Conclusions 620 References 620 14 Assessing the Safety of Drugs Used in Oncology 625 Anne Kehely 14.1 Introduction 625 14.2 Factors to consider when assessing the safety of drugs used in oncology 627 14.3 Sources of adverse effect data 632 14.4 Nature of the data 634 14.5 Assessment of adverse effects data in oncology 635 14.6 Conclusions 641 References 642 15 Adverse Drug Reactions and Pharmacovigilance of Herbal Medicines 645 Joanne Barnes 15.1 Introduction 645 15.2 Herbal medicines: definitions and descriptions 646 15.3 Characteristics of herbal medicines 647 15.4 Regulation of herbal medicines and pharmacovigilance requirements 648 15.5 Access to and use of herbal medicines 655 15.6 Adverse reactions associated with herbal medicines 656 15.7 Methods for pharmacovigilance of herbal medicines 666 15.8 Responding to safety concerns associated with herbal medicines 673 15.9 The future for pharmacovigilance of herbal medicines 674 15.10 Conclusions 675 References 676 Appendix 1 Web Sites Relevant to Pharmacovigilance—An Analysis of Contents 685 Charlotte I. S. Barker, John Talbot, and Jeffrey K. Aronson A1.1 Introduction 685 A1.2 Ten national pharmacovigilance web sites 685 A1.3 Twelve institutional web sites 689 Acknowledgements 697 References 697 Appendix 2 Guidelines and a Checklist for Reporting Suspected Adverse Drug Reactions Anecdotally in Journals 699 Jeffrey K. Aronson A2.1 Introduction 699 A2.2 Notes on the checklist 700 A2.3 Conclusions 706 Note 706 References 706 Index 709

Read more less

Book SynopsisThe new time-saving revolution in drug discovery. Combinatorial chemistry, a method for synthesizing millions of chemical compounds much faster than usual, is becoming one of the most useful technical tools available to chemists and researchers working today. Using current advances in computer and laboratory techniques, combinatorial chemistry has freed professionals from the drudgery of piecemeal experimental work and opened new creative possibilities for experimentation. Combinatorial Chemistry: Synthesis and Application details critical aspects of the technique, featuring the work of some of the world''s leading chemists, many of whom played a key role in its development. Including examples of both solution-phase and solid-phase approaches as well as the full complement of organic chemistry technologies currently available, the book describes: * Concepts and terms of combinatorial chemistry * Polymer-supported synthesis of organic compounds * Macro beadTable of ContentsPartial table of contents: Parallel Organic Synthesis Using Parke-Davis Diversomer Technology (S. DeWitt & A. Czarnik). Polymer-Supported Synthesis of Organic Compounds and Libraries (M. Kurth). Macro Beads as Microreactors: New Solid- Phase Synthesis Methodology (W. Rapp). Combinatorial Libraries in Solution: Polyfunctionalized Core Molecules (E. Wintner & J. Rebek). Solid-Phase Methods in Combinatorial Chemistry (I. Sucholeiki). Combinatorial Synthesis Exploiting Multiple-Component Condensations, Microchip Encoding, and Resin Capture (R. Armstrong, et al.). Indexed Combinatorial Libraries: Nonoligomeric Chemical Diversity for the Discovery of Novel Enzyme Inhibitors (M. Pirrung, et al.). Combinatorial Libraries of Peptides, Proteins, and Antibodies Using Biological Systems (S. Benkovic, et al.). Index.

Read more less

Book SynopsisAiming to cover the major therapeutic applications of purinergic receptors and reflect the very latest developments in this area of therapeutic research, this book is authored by an international group of contributors who are authorities in the field.Table of ContentsPartial table of contents: HISTORICAL PERSPECTIVE. Purinergic Neurotransmission and Neuromodulation: A HistoricalPerspective (M. Williams & G. Burnstock). MOLECULAR PHARMACOLOGY. Adenosine Receptor Subtypes: New Insights From Cloning andFunctional Studies (G. Stiles). MEDICINAL CHEMISTRY. Development of Selective Purinoceptor Agonists and Antagonists (K.Jacobson & A. van Rhee). THERAPEUTIC IMPLICATIONS. Cardiac Electrophysiology of Adenosine: Antiarrhythmic andProarrhythmic Actions (L. Belardinelli, et al.). The Role of Adenosine in Asthma (M. Jacobson and T. Bai). Psychomotor Aspects of Adenosine Receptor Activation (M.Jarvis). Adenosine Effects in Sleep Apnea (D. Carley & M.Radulovacki). ATP in the Treatment of Cancer (E. Rapaport). Index.

Read more less

Book SynopsisCOMBINATORIAL CHEMISTRY AND MOLECULAR DIVERSITY IN DRUG DISCOVERY Edited by Eric M. Gordon and James F. Kerwin, Jr. Increasing pressure to identify, optimize, develop, and commercialize novel drugs more rapidly and more cost-effectively has led to an urgent demand for technologies that can reduce the time to market for new products. Molecular diversity, of both natural and synthetic materials, provides a valuable source of compounds for identifying and optimizing new drug leads. Through the rapidly evolving technology of combinatorial chemistry, it is now possible to produce libraries of small molecules to screen for novel bioactivities. This powerful new technology has begun to help pharmaceutical companies find new drug candidates quickly, save significant dollars in preclinical development costs, and ultimately change their fundamental approach to drug discovery. Comprising the work of the leading authorities in the area of molecular diversity Trade Review"This monograph does an excellent job summarizing many of the important aspects regarding the synthesis, manipulation, and screening of combinatorial molecules for pharmacological activity...The editors are to be commended on assembling an admirable resource..." (The Quarterly Review of Biology Vol. 76, No. 2, June 2001)Table of ContentsPartial table of contents: COMBINATORIAL CHEMISTRY AND MOLECULAR DIVERSITY: AN INTRODUCTION. Historical Overview of the Developing Field of Molecular Diversity (J. Chabala, et al.). Solid-Phase Peptide Synthesis, Lead Generation, and Optimization (B. Seligman, et al.). Oligonucleotide Libraries as a Source of Molecular Diversity (H.-Y. Mei, et al.). SMALL MOLECULAR LIBRARIES. Protease Inhibitor Libraries (D. Patel & D. Campbell). Scaffolds for Small Molecule Libraries (M. Pavia). Encoded Combinatorial Chemistry (J. Jacobs & Z.-J. Ni). Parallel Organic Synthesis in Array Format (S. Hall). AUTOMATION, ANALYTICAL, AND COMPUTATIONAL METHODS. Automation of Combinatorial Chemistry for Large Libraries (M. Needels & J. Sugarman). Quantifying Diversity (Y. Martin, et al.). BIOLOGICAL DIVERSITY. Protein Scaffolds for Peptide Libraries (R. Hoess). SCREENING. Strategies for Screening Combinatorial Libraries (B. Beutel). COMBINATORIAL DRUG SCREENING AND DEVELOPMENT. Combinatorial Technologies: Prospects and Future Issues (J. Kerwin). Appendix. Index.

Read more less

Book SynopsisExplores the way in which peptides, proteins, nucleic acids and carbohydrates use therapeutically. With help of illustrations, this book covers both compounds and how therapeutics exert their influence through an understanding of biological processes.Trade Review"...an excellent introduction to biomacromolecular drugs..." (Chemistry in Britain, July 2002) "...a welcome addition to the library of any pharmacy student, chemistry instructor, or laboratory researcher." (The Annals of Pharmacotherapy, Vol. 36, October 2002 "...this is an excellent book..." (Organic Process Research and Development) "...many interesting snippets..." (Chemistry & Industry, 2 December 2002)Table of ContentsPreface. Abbreviations. Introduction. Endogenous Peptides and Proteins. Modification of Endogenous Peptides and Proteins. The Immune System. Oligonucleotides. Oligosaccharides. Appendix. Glossary. Index.

Read more less

Book SynopsisProviding a broad introduction to the growing field, this book explores the way in which peptides, proteins, nucleic acids and carbohydrates used therapeutically. With help of numerous illustrations, it covers both the compounds and how therapeutics exert their influence throuhg an understanding of biological processes. * Includes the latest developments in the field * Covers the various strategies behind the development and production of a range of key clinically useful compounds * Focuses on the concepts and ideas of why compounds are developed as pharmaceuticals * Provides many examples and problems Invaluable to all students of chemistry, medicinal and pharmaceutical chemistry, pharmacy and pharmacology. Will also be of interest to researchers and professionals needing a concise, up-to-date account of this subject.Trade Review"...explains the synthesis and applications of peptides, proteins, nucleic acids, and oligosaccharides as therapeutic agents..." (SciTech Book News, Vol. 26, No. 2, June 2002) "...an excellent introduction to biomacromolecular drugs..." (Chemistry in Britain, July 2002) "...a very good value...a useful addition to the personal library of many biomedical and pharmaceutical scientistscould serve as a textbook or as supplemental reading.... This book...should be in the holdings of academic and pharmaceutical industry libraries." (Journal of Medicinal Chemistry, Vol. 45, No. 19, 2002) "...a welcome addition to the library of any pharmacy student, chemistry instructor, or laboratory researcher." (The Annals of Pharmacotherapy, Vol. 36, October 2002) "...this is an excellent book..." (Organic Process Research and Development) "...readable and interesting...recommended..." (Angewandte Chemie International Edition, Vol. 41, No. 20, 2002) "...many interesting snippets..." (Chemistry & Industry, 2 December 2002)Table of ContentsIntroduction Endogenous Peptides and Proteins Modification of Endogenous Peptides and Proteins The Immune System Oligonucleotides Oligosaccharides Appendix Index

Read more less

Book SynopsisThis text look at cross-over trials which are experiments in which subjects, whether patients or healthy volunteers, are each given a number of treatments with the object being to study the differences between these treatments. They are used extensively in clinical research.Trade Review"…clearly written…mode of presentation is very effective…I recommend this book as a useful resource…" (Journal of the American Statistical Association, December 2004) "The book by Senn was the very first volume in Wiley's excellent series, "Statistics in Practice". Here, 10 years later, it is now the first of the books in that series to reappear in a second addition.” (Technometrics, May 2004) "...well structured and easy to read...incredibly useful..." (Applied Clinical Trials, December 2002) "...an excellent reference source and is easily readable." (The Statistician) "...explanation are kept as non-technical as possible, although they do not lack statistical rigour...well worth reading..." (Pharmaceutical Statistics, Vol 2, 2003) “…the main additions can be seen as …adding to the arguments for the author’s view on carryover affects...” (Clinical Trials, No.1 2004) Table of ContentsPreface to the Second Edition. Preface to the First Edition. 1. Introduction. 2. Some Basic Considerations Concerning Estimation in Clinical Trials. 3. The AB/BA Design with Normal Data. 4. Other Outcomes and the AB/BA Design. 5. Normal Data from Designs with Three or More Treatments. 6. Other Outcomes from Designs with Three or More Treatments. 7. Some Special Designs. 8. Graphical and Tabular Presentation of Cross-over Trials. 9. Various Design Issues. 10. Mathematical Approaches to Carry-over. References. Author Index. Subject Index.

Read more less

Book SynopsisOrganized by body system and ailment makes it easy to locate appropriate therapies. Includes background on the physiology of major systems and ailments so readers can understand how and why a pharmaceutical, botanical, or dietary supplement works. Broad coverage includes green plants, fungi, and microorganisms.Trade Review"...an extremely good read...a productive mine of information...laced liberally with humour, human observation and practical examples..." (Plant Talk, May 2004)Table of ContentsProprietary Registered and Trademark Names and Owners. Preface. Acknowledgements. 1. Introduction. 2. Complementary and Alternative Medicine. PART I: INJURIOUS PLANTS. 3. Internal Poisons. 4. Immune System and Cell Modifiers. 5. Allergies. PART II: REMEDIAL PLANTS. 6. Cancer. 7. Musculoskeletal System. 8. Peripheral Nervous System. 9. Heart and Circulation. 10. Metabolism. 11. Sensory Organs: Eye and Ear. 12. Oral Hygiene. 13. Gastrointestinal Tract. 14. Respiratory System. 15. Urogenital System. 16. Skin. 17. Deterrents: Antibiotics, Antiseptics, Pesticides, and Herbicides. 18. Panaceas, Adaptogens, and Tonics. PART III: PSYCHOACTIVE PLANTS. 19. Central Nervous System and Psychiatry. 20. Stimulants. 21. Hallucinogens. 22. Depressants. Appendix A: Outline Classification of Plants. Appendix B: Bibliography of Traditional and Herbal Medicine and Ethnobotany. Glossary. Index.

Read more less

Book SynopsisUpdated every five years, the series represents the optimal compromise between currency and a sufficient body of material for cohesive and comprehensive treatment in a monograph. Provides a quick yet thorough overview of the synthetic routines that have been used to access specific classes of therapeutic agents. Materials are organized by chemical class, and syntheses are taken back to available starting materials. Discusses disease state, rational for method of drug therapy, biological activities of each compound and preparation. Coverage also includes those generic pharmaceutical compounds not accorded clinical status. A glossary defines biological terms.Table of ContentsAliphatic and Alicyclic Compounds. Monocyclic Aromatic Compounds. Polycyclic Aromatic Compounds and Their Reduction Products. Steroids. Five-Membered Ring Heterocycles. Six-Membered Ring Heterocycles. Five-Membered Ring Benzofused Heterocycles. Six-Membered Ring Benzofused Heterocycles. Bicyclic Fused Heterocycles. beta-Lactam Antibiotics. Miscellaneous Heterocycles. Indexes.

Read more less

Book SynopsisProvides a sound theoretical basis for understanding chemical kinetics and its uses in studying drug stability. Treats the calculations, approximations, and estimates that are useful to the pharmacist in professional practice, and presents a collection of selected drug-stability data from the pharmaceutical literature. This Handbook makes accessible to the pharmacist much of the information necessary to make pharmaceutical decisions about drug stability. Changes in this edition include thorough revision of the chapter on oxidation, addition of a new chapter on solid-state stability, and a tripling of the number of stability monographs. All monographs figures have been redrawn, most of them from published data, and all sources are cited.Table of ContentsPRINCIPLES. Stability Calculations. Interpretation of Kinetic Data. Hydrolysis and Other Acyl Transfers. Oxidation and Photolysis. Solid-State Chemical Decompostion. Strategy and Tactics of Stability Testing. STABILITY MONOGRAPHS. Appendixes. Index.

Read more less

Book SynopsisTable of ContentsThe Use of Plant Remedies in Indigenous Medical Systems. Presentation of Results. Preparation of Plant Material. The Gastro-Intestinal Tract. The Liver and Biliary System. The Cardiovascular System. The Respiratory System. Anti-Inflammatory and Analgesic Activity. Diabetes Mellitus. The Nervous System. Endocrine Activity: Antifertility and Sex Hormones. Appendices. Index.

Read more less

Book SynopsisMeta--analysis is one of the main statistical methods used in clinical trials. Previous accounts of meta--analysis have given the impression that the topic is a series of separate techniques. This book provides a unified approach, developing the subject from mathematical theory through to practical discussions of implementation.Trade Review"…highly recommended as essential reading for medical statisticians…" (Short Book Reviews, April 2003) "...comprehensive and well illustrated contribution to the subject...useful for graduate students of medical statistics..." (Statistics in Medicine, Vol 23(3), 15 February 2004)Table of ContentsIntroduction Protocol development Estimating the treatment difference in an individual trial Combining estimates of a treatment difference across trials Meta-analysis using individual patient data Dealing with heterogeneity Presentation and interpretation of results Selection bias Dealing with non-standard datasets Inclusion of trials with different study designs A Bayesian approach to meta-analysis Sequential methods for meta-analysis Appendix Methods of estimation and hypothesis testing

Read more less

Book SynopsisConducting GCP-Compliant Clinical Research Wendy Bohaychuk and Graham Ball Good Clinical Research Practices, UK and Canada The overall aim of this work is to provide a reference book which describes the general framework for conducting GCP-compliant clinical research, particularly pharmaceutical industry clinical research. Wendy Bohaychuk and Graham Ball run a consultancy, GCRP Ltd., which has conducted over 820 GCP audits involving more than 200 companies in the last 10 years. More than 5,000 individuals have been involved in their training courses to help people perform GCP-compliant clinical research. They have authored several books and articles including: Standard operating procedures for investigators Standard operating procedures for sponsors and CROs GCP - an indexed reference Drawing on their wealth of experience, they have produced this enlightening and practical reference work which fills an educational gap in the understanding of GCP atTable of ContentsThe Current Roles for Conducting Clinical Research - Setting up Clinical Studies - Ethical Considerations - Monitoring and Safety Reporting - Collecting Data with Integrity - Managing Study Medications/Devices - Final Stages in Clinical Studies.

Read more less

Book SynopsisVolume I is divided into two parts. Part A of volume 1 in theBen cao gang museries offers a translation of chapters 1 and 2 and portions of chapter 3. Chapters 1 and 2 are devoted to introducing the history of materia medica. Chapter 3 is devoted to pharmaceutical drugs for diseases. Chapter 3 is continued, along with chapter 4, in part B of volume I. TheBen cao gang muis a sixteenth-century Chinese encyclopedia of medical matter and natural history by Li Shizhen (15181593). The culmination of a sixteen-hundred-year history of Chinese medical and pharmaceutical literature, it is considered the most important and comprehensive book ever written in the history of Chinese medicine and remains an invaluable resource for researchers and practitioners. This nine-volume series reveals an almost two-millennia-long panorama of wide-ranging observations and sophisticated interpretations, ingenious manipulations, and practical applications of natural substances for the benefit of human health. Paul U. Unschuld's annotated translation of theBen cao gang mu, presented here with the original Chinese text, opens a rare window into viewing the people and culture of China's past.Table of ContentsContents 1. Prolegomena. 1.1 History of Chinese materia medica literature. 1.2 Structure and contents of the Ben cao gang mu. 1.3 Biographical sketch of Li Shizhen (1518 – 1593). 2. Notes on the translation. 3. Wang Shizhen’s preface of 1590 4. Detailed survey of contents chapters 1 through 4 5. (Original) Complete Contents, ch. 1 through 52 6. Translation of the Ben cao gang mu, chapters 1 through 3-49

Read more less

Book SynopsisVolume I is divided into two parts. Part B of volume I in theBen cao gang museries offers a translation of portions of chapter 3 and the complete chapter 4, devoted to pharmaceutical drugs for diseases. This volume is a continuation of volume I, part A. The first portion of chapter 3 is found in part A. TheBen cao gang muis a sixteenth-century Chinese encyclopedia of medical matter and natural history by Li Shizhen (15181593). The culmination of a sixteen-hundred-year history of Chinese medical and pharmaceutical literature, it is considered the most important and comprehensive book ever written in the history of Chinese medicine and remains an invaluable resource for researchers and practitioners. This nine-volume series reveals an almost two-millennia-long panorama of wide-ranging observations and sophisticated interpretations, ingenious manipulations, and practical applications of natural substances for the benefit of human health. Paul U. Unschuld's annotated translation of theBen cao gang mu, presented here with the original Chinese text, opens a rare window into viewing the people and culture of China's past.

Read more less

Book SynopsisDrugs used in the treatment of cardiovascular disease are disseminated widely in western industrialized countries. In the US alone, nearly $18 billion was spent on drugs for the treatment of cardiovascular disease and stroke in 1999. This handbook contains records for various major drugs that directly affect the cardiovascular system.Table of ContentsPreface. Acknowledgements. How to Use This Book. Glossary of Units. Abbreviations and Symbols. Part I: Main Entries. Vasoactive Agents. Antihypertensive Agents. Antianginal, Antiarrhythmic, and Cardiotonic Agents. Antihypercholesterolemic Agents. Blood Formation and Coagulation Agents. Water and Electrolyte Balancing Agents. Part II: Indexes. CAS Registry Number Index. EINECS Number Index. Name and Synonym Index. Part III: Manufacturers and Suppliers Directory.

Read more less

Book SynopsisIn the early twentieth century the relevance of chirality to the pharmaceutical industry was established by the fact that one enantiomer of hyoscyamine possessed greater pharmacological activity than the other.Table of ContentsPreface. Further Reading. Acknowledgements. How to Use This Book. Glossary of Units. Abbreviations and Symbols. Part I: Chirality. Chapter 1: Overview of Chirality. Chapter 2: Drivers for the Chiral Market. Chapter 3: Sources of Chiral Compounds. Chapter 4: Methodologies for Obtaining Chiral Compounds: Some Examples. Part II: Main Entries. Part III: Indexes. CAS Registry Number Index. EINECS Number Index. Name and Synonym Index. Part IV: Manufacturer and Supplier Directory.

Read more less

Book SynopsisProposed changes in practice legislation will allow podiatrists to prescribe a limited range of drugs and dressings. It is therefore now imperative that students and practitioners understand pharmacology. Not only the mechanisms of action of drugs, but also their potential side--effects and interactions with other drugs taken by the patient.Table of ContentsPreface; Contents; Common Abbreviations; Introduction; How Drugs Work; The Role of the Podiatrist in Patient Care; Drugs affecting the Peripheral Nervous System; Drugs affecting the Central Nervous System; Drugs affecting the Gastrointestinal System; Drugs affecting the Cardiovascular System; Drugs affecting the Respiratory System; Chemotherapeutic Drugs; Drugs affecting the Endocrine System; Drugs affecting the Urinary System; Drugs affecting the Reproductive System; Drugs affecting the Musculo-Skeletal System; Drugs affecting the Eye and Ear; Drugs acting on the Skin; Local Anaesthetics; Cytotoxic Drugs; Appendix.

Read more less

Book Synopsis

Read more less

Book Synopsis

Read more less

Book SynopsisIn the treatment of neurocritical disease states, pharmacotherapeutic strategies are increasingly relevant. This is the first book to provide this information in a high-yield format for the busy healthcare provider. This book provides practitioners with clinical pearls on neuropharmacology, dosing strategies, monitoring, adverse events, drug interactions, and evidence-based pharmacotherapy.Table of ContentsTABLE OF CONTENTS 1. Hyperosmolar Therapy in Traumatic Brain InjuryH. Gibbs, J. Garcia, and R. Neyens 2. Sedation and Neuromuscular Blockade for Neurocritical Care PatientsK. Chester and K. Greene 3. Antithrombotic Therapy for Ischemic StrokeE.P. Tesoro and E. Durr 4. Coagulopathy Reversal Agents for Intracranial HemorrhageK. Berger, N.G. Panos, and J.J. Lewin III 5. Pharmacotherapy for Cerebral Vasospasm Prophylaxis and Treatment in Subarachnoid HemorrhageD.H. Rhoney, K. Morbitzer, and J. Hatton-Kolpek 6. Pharmacotherapy of Acute Spinal Cord InjuryK. Bledsoe and C. Morrison 7. Hemodynamic ManagementT.A. Allison and A. Castle 8. Antiepileptic Agents for the Prevention and Treatment of SeizuresA.M. Cook, N. Liang, and V. Nguyen 9. Neuropharmacologic Therapies for Recovery Following Traumatic Brain Injury and Ischemic StrokeA. Shaun Rowe and L. Kurczewski 10. Intracerebroventricular and Intrathecal Drug TherapiesT. Human, J. Bushwitz, and O. Falana Index

Read more less

Book SynopsisAntioxidants play an important role in the progression of major human degenerative diseases and conditions. This book covers antioxidants and their mechanisms of action; their role in a whole array of conditions including coronary heart disease, malignant disease, diabetes, cataracts, respiratory disease, cystic fibrosis, cognitive functions, and aging; their indicators for oxidative stress; and consumer issues. The majority of chapters have been developed from papers presented at the 6th World Congress in Clinical Nutrition, held in Banff, Canada, July 1997.Table of ContentsSection 1: Antioxidants and Their Mechanisms of Action Section 2: Food Factors as Antioxidants Section 3: Coronary Heart Disease Section 4: Malignant Disease Section 5: Other Diseases Section 6: Indicators of Oxidative Stress Section 7: Consumer Issues

Read more less

Book SynopsisMacrocyclic lactones are chemical compounds that represent the main treatment for parasitic diseases of animals, not only for helminth infections, but also a number of major ectoparasitic infestations.There has been no comprehensive book on this subject for more than a decade and this book fills this gap and provides detailed coverage of the basic science of these drugs and their mode of action, as well as their clinical use in farm and companion animals and in humans.Table of Contents1: Chemistry, Pharmacology and Safety of the Macrocylic Lactones 2: Ivermectin, abamectin, eprinomectin, W L Shoop, Merck & Co., USA and M D Soll, Merial, USA 3: Doramectin, selamectin, G A Conder, Pfizer Central Research, USA and W J Baker, Pfizer Central Research, USA 4: Milbemycin oxime, M Jung, J Saito, G Buescher, M Maurer and J F Graff, Novartis Animal Health, Switzerland 5: Moxidectin, D W Rock, R Delay, and M Glidden, Fort Dodge Animal Health, Agricultural Research Center, USA 6: Pharmacokinetics of the Macrocyclic Lactones: Conventional Wisdom and New Paradigms, D R Hennessy, CSIRO Animal Production, Sydney, Australia and M R Alvinerie, INRA Laboratoire de Phamacologie, Toulouse, France 7: Mode of Action of the Macrocyclic Lactones, R J Martin, Iowa State University, USA and A P Robertson 8: Ecological Impact of Macrocyclic Lactones in Dung Fauna, J W Steel, CSIRO Animal Production, Sydney, Australia and K Wardaugh, CSIRO Entomology, Australia 9: Resistance against Macrocyclic Lactones, R Pritchard, McGill University, Canada 10: The Use of ML's to Control Parasites of Cattle 11: General, J Vercruysse and R Rew 12: Use of MLs to control cattle parasites in Europe, J Vercruysse and R Rew 13: Use of MLs to control cattle parasites in North America, R Rew and J Vercruysse 14: Use of MLs to control cattle parasites in South America, C Eddi, Argentina, A Nari, Rome, Italy and J Carancostogolo, Buenos Aires, Argentina 15: Use of MLs to control cattle parasites in Australia and New Zealand, P Holdsworth, Director Scientific & Regulatory Affairs, Avcare, Australia 16: The Use of MLs to Control Parasites of Sheep and Goats, R L Coop, Moredun Research Institute, Edinburgh, UK, I Barger, Armidale, Australia and F Jackson, Moredun Research Institute, Edinburgh, UK 17: The Use of MLs to Control Parasites of Horses, C Monahan and T Klei, Louisiana State University, USA 18: The Use of MLs to Control Parasites of Pigs, J Arends, S&J Farms Animal Health, USA and J Vercruysse 19: The Use of MLs in the Control and Prevention of Heartworm and Other Parasites in Dogs and Cats, J Guerrero, University of Pennsylvania, USA, C Genchi, Universita degli Studi di Milano, Italy and J W McCall, University of Georgia, USA 20: The Use of MLs to Control Parasites of Domesticated Wild Ruminants, S Marley, Merial, Duluth, USA and G A Conder, Pfizer Central Research, USA 21: The Use of MLs to Control Parasites of Exotic Pets, S E Little, University of Georgia, USA, C B Greenacre, University of Tennessee, USA and R Kaplan 22: The Use of MLs to Control Parasites of Humans, K R Brown, Philadelphia, USA n Macrocylic Lactones as Antiparasitic Agents in the Future,T Geary, Pharmacia & Upjohn Co, Michigan, USA

Read more less

Book SynopsisThis is an introduction for students and practitioners of medicine and science who have difficulty in understanding cardiac electrophysiology and pharmacology. Relating these to cardiac mechanics and therapy, the book integrates the basic sciences with clinical medicine.Trade Review"If you are a Medical or Science undergraduate, a young Cardiology Registrar starting a Calman training post, or a research student starting a PhD or MD in Cardiovascular Physiology - Look no further than this excellent book!" Black Bag, Medical Student's Society of Bristol University, March 1998 issue "I cannot praise this book highly enough. It is written in excellent concise style, and with great and admirable clarity. The pictures and diagrams are superb.....The authors should be greatly congratulated on producing the best textbook of cardiac Physiology that I have so far encountered." Dr Allan Levi, Department of Physiology, Bristol "suitable for students of the new curriculum. Consider this as an addition to your bookshelf." Surgo, Glasgow University Medical JournalTable of Contents1. Functional Anatomy of the Heart; 2. Mechanical Events During the Cardiac Cycle; 3. The Excitatory Pathway; 4. Cardiac Cellular Electrophysiology: Ventricle and Atrium; 5. Cardiac Cellular Electrophysiology: Pacemaking and Conducting Tissue; 6. The Electrocardiogram; 7. Arrhythmias: Electrophysiological basis; 8. Antiarrhythmic Drugs 9. Arrhythmias: Clinical considerations; 10. Excitation-Contraction Coupling and Mechanoelectrical Feedback; 11. Functional Aspects of Cardiac Muscle Contraction; 12. The Nervous Control of Heart Rate and Force; 13. Measurement of Cardiac Output; 14. The Cardiac Environment: Effects of Altered Ion Concentrations on the Heart; 15. Coronary Flow and Coronary Thrombosis; 16. Drugs used to Treat Ischaemic Heart Disease; 17. Cardiac Failure; 18. Drugs Used for Cardiac Failure; 19. Molecular Biology of Cardiac Ion Channels; 20. Growing Points in Cardiac Research; Further Reading; Index

Read more less

Book SynopsisThis book describes methods and procedures for preparing PET radiopharmaceuticals, and highlights new methods for conducting radiochemical reactions with carbon-11 (C11) and fluorine-18 (F18), which are two of the most commonly used radionuclides in positron emission tomography (PET) imaging. Provides reliable methods for radiochemical syntheses and reactions, including all essential information to duplicate the procedure Eliminates the time-consuming process of searching journal articles and extracting pertinent details from lengthy experimental sections or supporting information Focuses on an emerging and important area for pharmaceutical and medical applications Encompasses technical, regulatory, and application aspects Includes solid-phase radiochemistry, transition-metal catalyzed radiochemistry, microfluidics, click chemistry, green radiochemistry and new strategies for radiopharmaceutical quality controlTable of ContentsContributors xi Editorial Preface xvii Abbreviations xix PART I FLUORINE-18 LABELED RADIOPHARMACEUTICALS 1 1. Synthesis of (−)-[18F]Flubatine ([18F]FLBT) 3Megan N. Stewart, Brian G. Hockley, and Peter J. H. Scott 2. Synthesis of [18F]-(−)Fluoroethoxy Benzovesamicol ([18F]FEOBV) 13Brian G. Hockley, Megan N. Stewart, and Peter J. H. Scott 3. Synthesis of [18F]Fluoromethylcholine ([18F]FCH) via [18F]Fluoromethyl Tosylate 21Melissa E. Rodnick, Allen F. Brooks, Brian G. Hockley, Bradford D. Henderson, and Peter J. H. Scott 4. Radiosynthesis of [18F]Flotegatide ([18F]RGD-K5) 29Hartmuth C. Kolb, Fanrong Mu, Umesh Gangadharmath, Vani P. Mocharla, Zhihong Zhu, Ashok Chaudhary, and Joseph C. Walsh 5. Synthesis of 3-[18F]Fluoro-5-(2-Pyridinylethynyl) Benzonitrile ([18F]FPEB) 41Steven H. Liang, Daniel L. Yokell, Raul N. Jackson, Peter A. Rice, Eli Livni, David Alagille, Gilles Tamagnan, Thomas Lee Collier, and Neil Vasdev 6. Radiosynthesis of 2′-Deoxy-2′-[18F]Fluoro-5-Methyl-1-β-d-Arabinofuranosyluracil ([18F]FMAU) 53Kai Chen and Peter S. Conti PART II CARBON-11 LABELED RADIOPHARMACEUTICALS 63 7. Synthesis of N-[11C]Methyl-4-Piperidinyl Propionate ([11C]PMP) 65Xia Shao and Peter J. H. Scott 8. Synthesis of 1-(2,4-Dichlorophenyl)-4-Cyano-5-(4-[11C]methoxyphenyl)-N-(Piperidin-1-yl)-1H-Pyrazole-3-Carboxamide ([11C]OMAR) 73Xia Shao, Keunsam Jang, and Peter J. H. Scott 9. Synthesis of Carbon-11 Labeled (+)-4-Propyl-3,4,4a,5,6,10b-Hexahydro-2H-Naphtho[1,2-b][1,4]Oxazin-9-Ol ([11C]-(+)-PHNO) 81Christophe Plisson, Joaquim Ramada-Magalhaes, and Jan Passchier 10. Synthesis of (R)-[N-Methyl-11C]PK11195 93Vítor H. Alves, Antero J. Abrunhosa, and Miguel Castelo-Branco PART III OTHER RADIOPHARMACEUTICALS 103 11. Synthesis of Oxygen-15 Water ([15O]H2O) 105David W. Dick and G. Leonard Watkins PART IV NEW METHODS FOR THE SYNTHESIS AND QUALITY CONTROL OF RADIOPHARMACEUTICALS 115 12. Direct, Nucleophilic Radiosynthesis of [18F]Trifluoroethyl Tosylate 117Patrick J. Riss, Waqas Rafique, and Franklin I. Aigbirhio 13. Synthesis of [18F]N-Methyl Lansoprazole via Generation of a [18F]Trifluoromethyl Group 123Allen F. Brooks, Melissa E. Rodnick, Garret M. Carpenter, and Peter J. H. Scott 14. [18F]Fluorination of (Mesityl)(Aryl)Iodonium Salts 129Naoko Ichiishi, Allen F. Brooks, Joseph J. Topczewski, Melissa E. Rodnick, Melanie S. Sanford, and Peter J. H. Scott 15. Pd(IV)-Mediated Fluorination of Arenes with [18F]F– for PET Imaging 139Nathan J. Schauer, Stephen M. Carlin, Hong Ren, and Jacob M. Hooker 16. Silicon Fluoride Acceptors (SIFAs) for Peptide and Protein Labeling with 18F 149Ralf Schirrmacher, Alexey Kostikov, Carmen Wängler, Klaus Jurkschat, Vadim Bernard-Gauthier, Esther Schirrmacher, and Björn Wängler 17. Solid Phase Synthesis of [18F]-2-Fluoro-2-Deoxy-d-Glucose: A Resin-Linker-Vector (RLV) Approach 163Lynda J. Brown, Imtiaz Khan, Harry J. Wadsworth, Alexander Jackson, Nianchun Ma, Nicolas Millot, Sue M. Champion, Denis R. Bouvet, Alex M. Gibson, and Richard C. D. Brown 18. Production and Reaction of [11C]Carbon Disulfide for the Synthesis of [11C]Dithiocarbamates 177Philip W. Miller 19. One-Pot, Direct Incorporation of [11CO2] into Carbamates 185Christian K. Moseley and Jacob M. Hooker 20. Radiosynthesis of [11C]Carboxamides via Reaction of [11C]CO2 Captured by a Cu(I)-Based Catalyst System with Boronic Acid Ester Precursors 197Patrick J. Riss, Shuiyu Lu, Sanjay Telu, Franklin I. Aigbirhio, and Victor W. Pike 21. Ethanol as a Solvent for Carbon-11 Radiochemistry 207Xia Shao, Maria V. Fawaz, Keunsam Jang, and Peter J. H. Scott 22. Synthesis and Applications of [11C]Hydrogen Cyanide 233Xia Shao, Melissa E. Rodnick, Allen F. Brooks, and Peter J. H. Scott 23. Determination of Radiochemical Purity and Radiochemical Identity of [13N]NH3 Using Thin Layer Chromatography 241Peter A. Rice and Daniel L. Yokell Appendix 1: Supplier Information 247 Index 253

Read more less

Book SynopsisEdited by a team of the world's leading interventional cardiologists and educators, this book gives the reader a clinically focused understanding of this important class of drugs, from basic science to a clear-headed discussion of complex topics such as combination therapies, drug-to-drug interactions, and resistance to antiplatelet agents.Trade Review“Written by an international who's-who of experts in the field, Antiplatelet Therapy also includes an entire section covering the use of antiplatelet drugs in PCIs, including percutaneous valve repair, which makes this text particularly essential to Interventional Cardiologists.” (Kingbook73's Medical Ebook and Video Collection, 20 August 2014)Table of ContentsList of Contributors, viii Foreword, xix Preface, xxi Section I: Platelet biology and pathophysiology 1 Platelet Pathophysiology and its Role in Thrombosis, 3 Paul A. Gurbel and Udaya S. Tantry 2 Platelet Receptors and Drug Targets: COX-1, 8 Thomas Hohlfeld and Karsten Schror 3 Platelet Receptors and Drug Targets: P2Y12, 14 Marco Cattaneo 4 Platelet Receptors and Drug Targets: GP IIb/IIIa, 21 Eliano Pio Navarese and Jacek Kubica 5 Platelet Receptors and Drug Targets: PAR1, Collagen, vWF, Thromboxane, and Other Novel Targets, 29 Ping Zhang, Lidija Covic, and Athan Kuliopulos 6 Role of Inflammation and Hypercoagulability in Thrombosis, 45 Paul A. Gurbel, Nachiket Apte, and Udaya S. Tantry Section II: Platelet function tests 7 Light Transmission Aggregometry, 53 Paul A. Gurbel, Martin Gesheff, Kevin P. Bliden, and Udaya S. Tantry 8 Vasodilator-Stimulated Phosphoprotein (VASP) Assay, 58 Marc Laine, Franck Paganelli, and Laurent Bonello 9 VerifyNow P2Y12 and Plateletworks Assays, 65 Matthew J. Price, Nicoline J. Breet, and Jurriën M. ten Berg 10 Multiplate Analyzer, 82 Martin Orban and Dirk Sibbing 11 Shear Stress-Based Platelet Function Tests, 92 Nicoline J. Breet and Jurriën M. ten Berg 12 Thrombelastography and Other Novel Techniques, 102 Udaya S. Tantry, Vijay A. Doraiswamy, Glenn Stokken, Marvin J. Slepian, and Paul A. Gurbel Section III: Antiplatelet pharmacology 13 Aspirin, 111 Karsten Schrör and Thomas Hohlfeld 14 Cilostazol, 117 Seung-Whan Lee, Duk-Woo Park, and Seung-Jung Park 15 Abciximab, 125 J. Emilio Exaire and Jorge F. Saucedo 16 Tirofiban, 131 Marco Valgimigli, Arnoud W.J. van't Hof, and Christian Hamm 17 Eptifibatide, 142 Nevin C. Baker and Ron Waksman 18 Ticlopidine, 150 Fabiana Rollini, Francesco Franchi, Ana Muñiz-Lozano, and Dominick J. Angiolillo 19 Clopidogrel, 160 Andrzej Budaj 20 Prasugrel, 166 Christoph Varenhorst, Anna Oskarsson, and Stefan James 21 Elinogrel, 173 Matthew J. Chung and Sunil V. Rao 22 Cangrelor, 180 Francesco Franchi, Fabiana Rollini, Ana Muñiz-Lozano, and Dominick J. Angiolillo 23 Ticagrelor, 193 Anna Oskarsson, Christoph Varenhorst, and Stefan James 24 Thrombin Receptor Antagonists, 198 Flavio de Souza Brito and Pierluigi Tricoci Section IV: Percutaneous Coronary Intervention and Antiplatelet Therapy 25 Dual Antiplatelet Therapy Prior to Percutaneous Coronary Intervention, 209 Fabio Mangiacapra, Annunziata Nusca, Rosetta Melfi, and Germano di Sciascio 26 Duration of Dual Antiplatelet Therapy after Drug-Eluting Stent Implantation, 220 Joshua P. Loh and Ron Waksman 27 Antiplatelet Therapy for Patients with Acute Coronary Syndromes, 229 Michael A. Gaglia, Jr. and Ray V. Matthews 28 Antiplatelet Therapy in Stable Coronary Artery Disease, 237 Ana Laynez and Ron Waksman 29 Antiplatelet Therapy for Patients with Peripheral Arterial Disease, 245 Aung Myat, Yousif Ahmad, and Simon R. Redwood 30 Bleeding Risk and Outcomes of Patients Undergoing Percutaneous Coronary Intervention Treated with Antiplatelets, 253 Sa'ar Minha and Ron Waksman 31 Bleeding Definitions, 259 Sameer Bansilal, Deborah E. Aronson, and Roxana Mehran Section V: Antiplatelet Responsiveness 32 Personalizing Antiplatelet Therapy, 269 Paul A. Gurbel, Young-Hoon Jeong, and Udaya S. Tantry 33 Aspirin Resistance, 277 Muthiah Vaduganathan and Eli I. Lev 34 Clopidogrel Resistance, 285 Udaya S. Tantry, Kevin P. Bliden, Talha Meeran, and Paul A. Gurbel 35 Genetics of Clopidogrel Poor Response, 293 Pierre Fontana and Jean-Luc Reny 36 Proton Pump Inhibitors and Clopidogrel, 300 Michael A. Gaglia, Jr 37 Other Drug Interactions with Clopidogrel, 306 Eric R. Bates Index, 314

Read more less

Book SynopsisBy guiding in the application of techniques and tools for predicting ADMET outcomes in drug candidates, Predictive ADMET offers a road map for drug discovery scientists to generate effective and safe drugs for unmet medical needs.Trade Review“In conclusion, this volume fulfills its promise of being a very useful tool for guidance and diagnosis on ADMET matters, and I would recommend it to any scientist in the field.” (ChemMedChem, 1 June 2015) Table of ContentsPreface ix Contributors xi I Introduction to the Current Scientific, Clinical, and Social Environment of Drug Discovery and Development 1 Current Social, Clinical, and Scientific Environment of Pharmaceutical R&D 3Laszlo Urban, Jean-Pierre Valentin, Kenneth I Kaitin, and Jianling Wang 2 Polypharmacology and Adverse Bioactivity Profiles Predict Potential Toxicity and Drug-related ADRs 23Teresa Kaserer, Veronika Temml, and Daniela Schuster II Intelligent Integration and Extrapolation of Admet Data 3 ADMET Diagnosis Models 49Bernard Faller, Suzanne Skolnik, and Jianling Wang 4 PATH (Probe ADME and Test Hypotheses): A Useful Approach Enabling Hypothesis-driven ADME Optimization 63Leslie Bell, Suzanne Skolnik, and Dallas Bednarczyk 5 PK-MATRIX—A Permeability: Intrinsic Clearance System for Prediction, Classification, and Profiling of Pharmacokinetics and Drug–drug Interactions 89Urban Fagerholm 6 Maximizing the Power of a Local Model for ADMET-property Prediction 103Sebastien Ronseaux, Jeremy Beck, and Clayton Springer 7 Chemoinformatic and Chemogenomic Approach to ADMET 125Virginie Y. Martiny, Ilza Pajeva, Michael Wiese, Andrew M. Davis, and Maria A. Miteva 8 Multiparameter Optimization of ADMET for Drug Design 145Matthew D. Segall and Edmund J. Champness 9 PBPK: Integrating In Vitro and In Silico Data in Physiologically Based Models 167Hannah M. Jones and Neil Parrott 10 Emerging Full Mechanistic Physiologically Based Modeling 189Kiyohiko Sugano 11 Pharmacokinetic/Pharmacodynamic Modeling in Drug Discovery: A Translational Tool to Optimize Discovery Compounds Toward the Ideal Target-specific Profile 211Patricia Schroeder III Assessment and Mitigation of Critical Clinically Relevant Admet Risks in Drug Discovery and Development 12 In Vitro–In Silico Tools to Predict Pharmacokinetics of Poorly Soluble Drug Compounds 235Christian Wagner and Jennifer B. Dressman 13 Evaluation of the Collective Impact of Passive Permeability and Active Transport on In Vivo Blood-brain Barrier and Gastrointestinal Drug Absorption 263Donna A. Volpe, Hong Shen, and Praveen V. Balimane 14 Integrated Assessment of Drug Clearance and Cross-Species Scalability 291Kevin Beaumont, James R. Gosset, and Chris E. Keefer 15 Practical Anticipation of Human Efficacious Doses and Pharmacokinetics using Preclinical In Vitro and In Vivo Data 319Tycho Heimbach, Rakesh Gollen, and Handan He 16 Management and Mitigation of Human Drug–drug Interaction Risks in the Drug Discovery and Development Phases 353Heidi J. Einolf and Imad Hanna 17 Integrated Assessment and Clinical Translation of In Vitro Off-target Safety Pharmacology Risks 397Patrick Y. Muller and Christian F. Trendelenburg 18 Integrated Risk Assessment of Cardiovascular Safety in Drug Discovery 407Gül Erdemli and Ruth L. Martin 19 Drug-induced Hepatotoxicity: Advances in Preclinical Predictive Strategies and Tools 433Donna M. Dambach 20 Carcinogenicity and Teratogenicity Assessment 467Hans-Jörg Martus, David Beckman, and Lutz Mueller 21 Nephrotoxicity: Development of Biomarkers for Preclinical and Clinical Application 491Frank Dieterle and Estelle Marrer IV Success Stories and Lessons Learned 22 Early Intervention with Formulation Strategies for Multidimensional Problems to Optimize for Success 507Stephanie Dodd, Christina Capacci-Daniel, Christopher Towler, Riccardo Panicucci, and Keith Hoffmaster 23 Cytochrome P450-mediated Drug Interaction and Cardiovascular Safety: The Seldane to Allegra Transformation 523F. Peter Guengerich 24 Clinical Toxicity Profile of VEGF Inhibitors 535Mark P. S. Sie and Ferry A. L. M. Eskens 25 Cardiomyopathy: Drug Induced and Predisposed 555Shirley A. Aguirre and Eileen R. Blasi 26 Safety Management by Pharmacokinetic Considerations: Ranibizumab (Lucentis) and Bevacizumab (Avastin) 569Nicole H. Siegel and Manju L. Subramanian Index 583

Read more less

Book SynopsisThis book describes a broad area of nanomedicine which involves mainly applications, diseases, and diagnostics. The comprehensive coverage provides researchers, academics, and health specialists with a great tool, that includes techniques applicable to various uses.Table of ContentsPreface xv Part 1: Nanomedicine 1 1 High-technology Therapy Using Biomolecules or Synthetic Compounds for HIV Inhibition 3 Elvis Fosso-Kankeu, Pascaline Fontehand Ajay K.Mishra 1.1 Gene Therapy Including RNAHigh-Technology Against HIV 4 1.2 Metals and HIV Therapy 16 1.3 Conclusions 26 References 27 2 Emerging Nanomedicine Approaches for Osteochondral Tissue Regeneration 39 Author Lineis Missing 2.1 Introduction 39 2.2 Emerging NanomedicineApproaches 42 References 54 3 Synthesis of Poly(Methacrylate) Encapsulated Magnetite Nanoparticles via Phosphonic Acid Anchoring Chemistry and Its Applications Toward Biomedicine 63 B. Kothandapaniand Ajay K. Mishra 3.1 Introduction 64 3.2 Synthesis of Magnetite Nanoparticles 73 3.3 Application in Biomedical Fields 82 3.4 Conclusions 84 References 85 4 Potentiometric PVC Membrane Sensors and Their Analytical Applications in Pharmaceuticals and Environmental Samples at Micro- and Nano-level 87 Gamal Abel-Hafiz Mostafa 4.1 Introduction 87 4.2 Ion Selective Electrode 88 4.3 Glass Membrane Electrode 89 4.4 Characteristics of ISE 90 4.5 Preparation of PVC Membrane 94 4.6 Method of Preparation of the Liquid Membrane ISEs 96 4.7 Application of Ion Selective Electrodes in Pharmaceutical and Environmental Analysis Using 97 4.8 Conclusion 123 References 127 5 Bioceramics: Silica-based Organic-Inorganic Hybrid Materials for Medical Applications 135 Sadanand Pandey and Shivani B. Mishra 5.1 Introduction 136 5.2 Organic-Inorganic Hybrid Materials 141 5.3 Tissue Engineering 146 5.4 Other Organic-Inorganic Bioceramics for Medical Applications 150 5.5 Conclusion 156 5.6 Considerations and Future Directions 157 Acknowledgement 157 References 158 6 Recent Advances of Multifunctional Nanomedicines 163 Pradeep Pratap Singh and Ambika 6.1 Introduction 163 6.2 Nanomaterials of Biomedical Interest 164 6.3 Target-specificPharmacotherapy: Need for Nanocarrier Delivery Systems 165 6.4 Engineering of Pharmaceutical Nanosystems 166 6.5 Applications of Pharmaceutical Nanotools 180 6.6 Nanotoxicity 181 6.7 Future prospects 182 6.8 Conclusion 183 References 184 7 Nanomedicinal Approaches for Diabetes Management 189 Prashant Kumar Raiand Ajay Kumar Mishra 7.1 Introduction: The Motivation behind the Chapter 189 7.2 Type of Diabetes 191 7.3 Treatments for Diabetes 192 7.4 Why the Interest in Nanomedicine Research? 193 7.5 The Vision of Nanotechnology and its Clinical Applications for Diabetes 194 7.6 Summary 195 Acknowledgements 195 References 195 8 Polymeric Nanofibersin Regenerative Medicine 197 Narayan Chandra Mishra and Sharmistha Mitra (Majumder) 8.1 Introduction 197 8.2 Preparation of Nanofibers 199 8.3 RecentAdvances onApplication of Polymeric Nanofibersin Regenerative Medicine 201 8.4 Conclusions 222 References 222 Part 2: Drug Delivery and Therapeutics 227 9 Multifunctional Nano/Micro Polymer Capsules as Potential 229 Haider Sami, J. Jaishree, Ashok Kumar and Sri Sivakumar 9.1 Introduction 230 9.2 Synthesis of Polymer Capsules 232 9.3 Properties of Multilayered Polymer Capsules 237 9.4 Loading of Therapeutics 239 9.5 Stimuli-responsive Polymer Capsules 242 9.6 Multifunctional Hybrid Capsules 255 9.7 Targeted Polymer Capsules 267 9.8 BiomedicalApplications 268 9.9 Outlook and Future Prospects 274 References 274 10 Nanophosphors-Nanogold Immunoconjugates in Isolation of Biomembranes and in Drug Delivery 285 Dwijendra Gupta, Dhruv Kumar, Manish Dwivedi, Vijay Tripathi, Pratibha Phadke-Gupta and Surya Pratap Singh 10.1 Introduction 286 10.2 Nanoparticle Technology 287 10.3 The Versatility of Nanoparticles in Biological Sciences 288 10.4 Materials and Methods 293 10.5 Nanotags for Bio-labeling and Targeting: Nanophosphors or Quantum Dots 297 10.6 AFM Study of CdS and BSATagged ZnS-Mn Nanoparticles 302 10.7 Nano-Conjugates in Drug Delivery 304 10.8 Nanoparticle-mediated Drug Delivery and Nanotherapeutics 305 10.9 The Limitations of QDs 306 10.10 Summary 307 Acknowledgements 308 References 309 11 Cyclodextrin-based Nanoengineered Drug Delivery System 313 Jaya Lakkakula and Rui Werner Maçedo Krause 11.1 Introduction 314 11.2 Inclusion Complex Formation 316 11.3 Phase Solubility Relationships 318 11.4 Effect of Cyclodextrin on Drug Formulation 321 11.5 Cyclodextrin-based Drug Delivery 324 11.6 Cyclodextrins in Novel Drug Delivery Systems (DDS) 331 11.7 Conclusion 335 Acknowledgements 335 References 338 12 Medicinal Patches and Drug Nanoencapsulation 343 María H. Lissarrague, Hernan Garate, Melisa E. Lamanna, Norma B. D’Accorso and Silvia N.Goyanes 12.1 Introduction 343 12.2 Overview of Passive Skin Permeation (Passive Patches) 344 12.3 Recent Development on Skin Permeation 357 12.4 Drug Encapsulation 361 12.5 Triggered Release 369 12.6 Conclusions 374 References 374 13 Dendrimers: AClass of Polymer in the Nanotechnology for the Drug Delivery 379 Sunil K.Singh and Vivek K. Sharma 13.1 Introduction 379 13.2 Historical Origin of Dendrimers 380 13.3 Structure of Dendrimers 381 13.4 Terms Used in Dendrimer Chemistry 383 13.5 Types of Dendrimers 385 13.6 Application of Dendrimers 392 13.7 Dendrimers in Oral Drug Delivery 394 13.8 Dendrimers in Transdermal Drug Delivery 396 13.9 Dendrimers in Ocular Drug Delivery 398 13.10 Dendrimers inAnticancer Drug Delivery 399 13.11 Dendrimers in Cancer Diagnosis and Treatment 401 13.12 Conclusion 411 References 411 14 Designing Nanocarriers for Drug Delivery 417 Munishwar N. Gupta and Joyeeta Mukherjee 14.1 Introduction 417 14.2 Sizes, Shapes andAdvantages of Nanomaterials 418 14.3 Bioconjugation Strategies 421 14.4 Carbon Nanotubes 429 14.5 Drug Targeting 434 14.6 Future Perspectives 436 Acknowledgements 437 References 437 15 Multifunctional Polymeric Micelles for Drug Delivery and Therapeutics 443 Alicia Sawdon and Ching-An Peng 15.1 Introduction 443 15.2 Composition, Formation and Characterization of Polymeric Micelles 444 15.3 Polymeric Micelles for Cancer Chemotherapy 450 15.4 Targeting Schemes 457 15.5 Polymeric Micelles for Diagnostics and Imaging 465 15.6 Conclusions 467 References 467 16 Nanoparticles-based Carriers for Gene Therapy and Drug Delivery 477 Marketa Ryvolova, Jana Drbohlavova, Kristyna Smerkova, Jana Chomoucka, Pavlina Sobrova,Vojtech Adam, PavelKopel, Jaromir Hubalek and Rene Kizek 16.1 Introduction 478 16.2 Targeted Delivery 478 16.3 Conclusion 494 References 494

Read more less

Book SynopsisAn expert''s view on solving the challenges confronting today''s pharmaceutical industry Author John LaMattina, a thirty-year veteran of the pharmaceutical industry and former president of Pfizer''s Global R&D Division, is internationally recognized as an expert on the pharmaceutical industry. His first book, Drug Truths: Dispelling the Myths About Pharma R&D, was critically acclaimed for clearing up misconceptions about the pharmaceutical industry and providing an honest account of the contributions of pharmaceutical research and development to human health and well-being. As he toured the country discussing Drug Truths, Dr. LaMattina regularly came across people who were filled with anger, accusing the pharmaceutical industry of making up diseases, hiding dangerous side effects, and more. This book was written in response to that experience, critically examining public perceptions and industry realities. Starting with 4 Secrets that Drug CTrade Review"Oz should invite LaMattina back on his show. Since LaMattina treats all concerns respectfully, Oz needn’t worry about feeling devalued or distrusted." (Barron's, 5 May 2014) “This is an honest book by an insider who believes in the basic good that the industry does.” (The Quarterly Review of Biology, 1 September 2013) “Summing Up: Recommended. General audiences.” (Choice, 1 September 2013) “For those more loosely associated or aspiring to work with in it, I particularly recommend this book as a balanced and informative read on the pressures the industry faces. It should also provide the basis for more reasoned argument and forewarn anyone else potentially ambushed by a TV show.” (ChemMedChem, 19 July 2013) “That said, the suggestions made by LaMattina for improvements in productivity and transparency are timely, and the book makes interesting if unexciting reading.” (Chemistry & Industry, 1 June 2013) “John LaMattina (ex-head of Pfizer's global R&D) has a new book out about the industry, called Devalued and Distrusted. He tells Pharmalot that he got the idea to write a sequel to his earlier book, Drug Truths, when he appeared on the "Dr. Oz" show.” (In The Pipeline, 1 December 2012) Table of ContentsACKNOWLEDGMENTS ix INTRODUCTION 1 CHAPTER 1 THE FOUR SECRETS THE DRUG COMPANIES DON’T WANT YOU TO KNOW 4 Drug Companies Underestimate Dangerous Side Effects 5 Drug Companies Control Much of the Information Your Doctor Gets 10 You’re Often Prescribed Drugs That You Don’t Need 14 Drugs Target the Symptoms, Not the Cause 19 Conclusion 22 References 23 CHAPTER 2 WHAT HAS HAPPENED TO R&D PRODUCTIVITY? 25 Impact of Mergers on R&D Productivity 26 Heightened FDA Requirements for NDAs 34 Higher Hurdles Set by Payers 41 Conclusion 46 References 48 CHAPTER 3 KEY THERAPEUTIC AREAS FOR IMPROVING HEALTH 49 Cancer 51 Diseases of the Brain 54 Cardiovascular Disease (CVD) 60 Diabetes 63 Bacterial Infections 65 Conclusion 68 References 69 CHAPTER 4 IMPROVING R&D OUTPUT 71 The Views of Others 72 Pharma’s Blockbuster Mentality Needs to Change 72 Can “Predictive Innovation” Lead to Greater Success Rates? 76 Would Royalties Make Scientists More Productive? 78 Will Drug Repositioning Help Fill the R&D Pipeline? 80 Consultants Don’t Always Have the Facts 82 Personal Views 84 Discovery Must Focus on Productivity 85 Does Size Help or Hinder R&D Productivity? 87 To Outsource or Not to Outsource? That’s the Pharma R&D Question 89 Big Pharma Early Research Collaborations 92 Conclusion 93 References 95 CHAPTER 5 RESTORING PHARMA’S IMAGE 96 Illegal Detailing of Drugs 97 Pharmaceutical Companies Should Drop TV Ads 98 The Need for Greater Transparency 100 How Committed Is Big Pharma to Rare Diseases? 102 Pharmaceutical Companies and Philanthropy 104 Pharma Needs to Have Its Scientists Tell Their Stories 105 Conclusion 106 References 107 CHAPTER 6 FINAL THOUGHTS 109 References 114 INDEX 115

Read more less

Book SynopsisPrescribing Scenarios at a Glance is an innovative resource which allows medical students and junior doctors to practise prescribing skills safely for themselves. Supporting those who wish to develop their prescribing knowledge and clinical reasoning, this book features 50 acute and on call scenarios in a hospital setting.Table of ContentsAcknowledgements 7 Dedication 7 List of abbreviations 8 How to use your textbook 10 About the companion website 13 Introduction: Practical prescribing scenarios 14 Please note that the prepared drug charts can be found in the accompanying workbook. Case Page Section 1: The acute take Case Drug chart Answer 1 An 82-year-old woman who requires venous thromboembolism prophylaxis 30 1.1 38 2 A 104-year-old woman with respiratory failure 30 2.1 40 3 A 64-year-old man with severe acute abdominal pain 31 3.1 41 4 A 55-year-old woman with atrial fi brillation 31 4.1 43 5 A 32-year-old man with community-acquired pneumonia 32 5.1 45 6 A 45-year-old woman with status epilepticus 32 6.1 47 7 A 27-year-old woman with suspected bacterial meningitis 33 7.1 48 8 A 31-year-old woman with paracetamol overdose 34 8.1 50 9 A 59-year-old man with acute pulmonary oedema 35 9.1 52 10 A 24-year-old woman with acute asthma 35 10.1 54 11 A 57-year-old man who has suddenly deteriorated 36 11.1 57 12 An 84-year-old man taking warfarin who has a headache 36 12.1 59 13 A 66-year-old man with acute coronary syndrome 37 13.1 61 14 A 67-year-old man with an exacerbation of COPD 37 14.1 64 Section 2: On call in the hospital Case Drug chart Answer 15 A 91-year-old man with hypoglycaemia 68 15.1 82 16 A 60-year-old woman requesting night sedation 68 16.1 83 17 A 62-year-old man with suspected opioid toxicity 69 17.1 84 18 A 58-year-old man who has low blood pressure 69 18.1 86 19 A 44-year-old woman who is ‘nil by mouth’ 70 19.1 88 20 A 59-year-old man with circulatory compromise 70 20.1 90 21 A 15-month-old girl with gastroenteritis 71 21.1 93 22 A 5-year-old boy with a painful right arm 71 22.1 94 23 A 12-hour-old boy with signs of sepsis 72 23.1 96 24 A 60-year-old man who has developed a hot joint 72 24.1 97 25 A 65-year-old man with hypokalaemia 73 25.1 99 26 A 69-year-old woman being treated with gentamicin 73 26.1 102 27 A 69-year-old man anticoagulated with warfarin 74 27.1 104 28 A 28-year-old woman with nausea 74 28.1 105 29 A 29-year-old man who is in pain following an operation 75 29.1 107 30 A 49-year-old man due to undergo surgery 75 30.1 110 31 A 79-year-old woman with acute kidney injury 76 31.1 112 32 An 85-year-old woman with hospital-acquired pneumonia 77 32.1 114 33 A 47-year-old man who has developed an abnormal liver profile 78 33.1 116 34 An 83-year-old man who develops diarrhoea 79 34.1 118 35 An 88-year-old man with hyperkalaemia 80 35.1 121 36 A 69-year-old woman with acute alcohol withdrawal 81 36.1 123 Section 3: Routine inpatient review Case Drug chart Answer 37 A 69-year-old woman with constipation 128 37.1 135 38 A 71-year-old man who has developed a tremor 128 38.1 136 39 An 81-year-old woman at risk of fragility fractures 129 39.1 138 40 A 23-year-old pregnant woman with pulmonary embolism 129 40.1 140 41 A 31-year-old man with increased seizure frequency 130 41.1 141 42 A 58-year-old man with diabetes mellitus treated with insulin 130 42.1 143 43 A 53-year-old man who wants to stop smoking 131 43.1 146 44 A 90-year-old woman on numerous medications 131 44.1 148 45 A 54-year-old woman with a peptic ulcer 132 45.1 150 46 A 64-year-old woman with chronic kidney disease 132 46.1 152 47 A 66-year-old man with palpitations 133 47.1 154 48 A 70-year-old man with ST-elevation acute coronary syndrome 133 48.1 156 49 A 49-year-old woman with chronic liver disease complaining of pain 134 49.1 158 50 An 89-year-old man approaching the end of life 134 50.1 160 Appendix 1 Antibiotic guidelines 163 Appendix 2 Case summaries 164 Index 166

Read more less

Book SynopsisThis research book covers the major aspects relating to the use of novel delivery systems in enhancing both transdermal and intradermal drug delivery.Table of ContentsAbout the Editors xiii Contributors xv Advances in Pharmaceutical Technology: Series Preface xvii Preface xix 1 Introduction 1Gary P.J. Moss 1.1 The Subcutis (Subcutaneous Fat Layer) 1 1.2 The Dermis 2 1.3 Skin Appendages 2 1.4 The Subcutaneous Sensory Mechanism 3 1.5 The Epidermis 5 1.6 The stratum germinativum 5 1.7 The stratum spinosum 5 1.8 The stratum granulosum 6 1.9 The stratum lucidum 6 1.10 The stratum corneum 6 1.10.1 Routes of Absorption 9 1.10.2 Transdermal Permeation – Mechanisms of Absorption 9 1.11 Theoretical Considerations 11 1.12 Physicochemical Properties of the Penetrant 13 1.12.1 Partition Coefficient 13 1.12.2 Molecular Size and Shape 14 1.12.3 Applied Concentration/Dose 15 1.12.4 Solubility and Melting Point 15 1.12.5 Ionisation 15 1.12.6 Physiological Factors Affecting Percutaneous Absorption 16 1.13 Physiological Properties of the Skin 16 1.13.1 Skin Condition 16 1.13.2 Skin Hydration and Occlusion 17 1.13.3 Skin Age 17 1.13.4 Regional Variation (Body Site) 18 1.13.5 Race 19 1.13.6 Skin Temperature 19 1.14 Vehicle Effects 19 1.15 Modulation and Enhancement of Topical and Transdermal Drug Delivery 20 1.15.1 Chemical Modulation of Permeation 21 1.15.2 Physical Methods of Enhancement 26 2 Application of Spectroscopic Techniques to Interrogate Skin 41Jonathan Hadgraft, Rita Mateus and Majella E. Lane 2.1 Introduction 41 2.2 Vibrational Spectroscopic Methods 42 2.3 Electronic Spectroscopic Methods 46 2.3.1 UV and Fluorescence 46 2.3.2 Nuclear Magnetic Resonance 47 2.4 Miscellaneous Spectroscopic Methods 48 2.4.1 Opto]Thermal Transient Emission Radiometry 48 2.4.2 Electron Spin Resonance 48 2.4.3 Impedance Spectroscopy 49 2.4.4 Laser]Induced Breakdown Spectroscopy 49 2.4.5 Photoacoustic Spectroscopy 50 2.4.6 Mass Spectrometry Imaging 50 2.5 Conclusions and Future 50 3 Analysis of the Native Structure of the Skin Barrier by Cryo]TEM Combined with EM]Simulation 57Lars Norlén 3.1 Introduction 57 3.2 Our Approach: In Situ Biomolecular Structure Determination in Near]Native Skin 58 3.2.1 Step 1: Cryo]Electron Microscopy of Vitreous Sections 60 3.2.2 Steps 2–3: Molecular Model Building and Electron Microscopy Simulation 66 3.2.3 Step 4: Confrontation of Observed Data with Simulated Data 66 3.3 Molecular Organisation of the Horny Layer’s Fat Matrix 67 3.4 Molecular Organisation of the Horny Layer’s Keratin Filament Matrix 67 3.5 Final Remark 68 4 Intradermal Vaccination 71Marija Zaric and Adrien Kissenpfennig 4.1 Vaccination 71 4.1.1 Disadvantages Associated with Conventional Vaccination 72 4.2 Dendritic Cells Immunobiology 73 4.3 Skin Anatomy and Physiology 74 4.3.1 The Role of Skin in Vaccine Delivery 75 4.4 The Skin Dendritic Cell Network 76 4.4.1 Langerhans Cells and the ‘Langerhans Cell Paradigm’ 76 4.4.2 Dermal Dendritic Cell Network 77 4.4.3 Dendritic Cell Subsets in the Skin]Draining Lymph Node 79 4.4.4 Human Dendritic Cells in the Skin 80 4.4.5 The Role of Skin Dendritic Cells Subsets in Transdermal Immunisation 81 4.5 The DTR]DT Depletion System 82 4.5.1 Langerin]DTR Mouse Models 83 4.6 Dendritic Cells and the Differentiation of T Lymphocytes 84 4.6.1 CD8+ T Cell Activation 85 4.6.2 CD4+ T Cell Polarisation 85 4.7 Summary 88 5 Film]Forming and Heated Systems 97William J. McAuley and Francesco Caserta 5.1 Film]Forming Systems 97 5.1.1 The Design of Film]Forming Systems 98 5.1.2 Advantages of Using Film]Forming Systems for Drug Delivery 99 5.1.3 Production of a Supersaturated State 101 5.1.4 Use with Chemical Penetration Enhancers 103 5.1.5 Advantages of Film]Forming Systems for Patient Use 105 5.1.6 Therapeutic Applications 105 5.2 Heated Systems 107 5.2.1 Mechanisms of Drug Penetration Enhancement 107 5.2.2 Partitioning 108 5.2.3 Effects of Heat on Skin 110 5.2.4 Dermal Clearance 111 5.2.5 The Effects of Heat on the Permeation of Drugs Across Skin 112 5.2.6 Strategies for Generating Heat 113 5.2.7 Therapeutic Applications 115 5.3 Conclusions 116 6 Nanotechnology]Based Applications for Transdermal Delivery of Therapeutics 125Venkata K. Yellepeddi 6.1 Introduction 125 6.1.1 Skin Structure 126 6.1.2 Skin Sites for Nanoparticle Delivery 127 6.1.3 Skin as a Barrier for Nanoparticle Penetration 128 6.1.4 Physicochemical Characteristics of NPs for Penetration through Skin 129 6.2 Nanocarriers for Topical and Transdermal Delivery 129 6.2.1 Polymeric Nanoparticles 130 6.2.2 Lipid Based Nanocarriers 134 6.2.3 Metallic and Mineral Nanoparticles 135 6.2.4 Carbon]Based Nanomaterials 137 6.3 Interactions of Nanoparticles with the Skin 137 6.4 Limitations of Nanotechnology for Skin Delivery 138 6.5 Conclusions 139 7 Magnetophoresis and Electret]Mediated Transdermal Delivery of Drugs 147Abhijeet Maurya, Cui Lili and S. Narasimha Murthy 7.1 Introduction 147 7.2 Physical Permeation Enhancement Techniques 149 7.3 Magnetophoresis 150 7.3.1 Drug Delivery Applications 151 7.3.2 Mechanism of Permeability Enhancement 152 7.3.3 Magnetophoretic Transdermal Patch 154 7.3.4 Conclusion 154 7.4 Electret]Mediated Drug Delivery 155 7.4.1 Electrets for Cutaneous Drug Delivery 156 7.4.2 Electret Layer in a Patch 158 7.4.3 Mechanism of Permeability Enhancement 158 7.4.4 Conclusion 159 8 Microporation for Enhanced Transdermal Drug Delivery 163Thakur Raghu Raj Singh and Chirag Gujral 8.1 Introduction 163 8.2 High]Pressure Gas or Liquid Microporation 164 8.3 Ultrasound (Phonophoresis and Sonophoresis) Microporation 166 8.4 Iontophoresis 168 8.5 Electroporation 169 8.6 Laser Microporation 170 8.7 Thermal Microporation 171 8.8 RF Microporation 173 8.9 Microneedles 173 8.10 Conclusion 174 9 Microneedle Technology 179Helen L. Quinn, Aaron J. Courtenay, Mary]Carmel Kearney and Ryan F. Donnelly 9.1 Introduction 179 9.2 MN Materials and Fabrication 182 9.3 MN]Mediated Drug Delivery 185 9.3.1 Combinational Approaches 187 9.4 MN Vaccination 188 9.4.1 Polymeric MNs and Vaccination 188 9.4.2 Solid MNs and Vaccination 189 9.4.3 Hollow MNs and Vaccination 190 9.4.4 MN Vaccination Moving Forwards 190 9.5 Further MN Applications 191 9.5.1 Therapeutic Drug Monitoring 192 9.5.2 Cosmetic Applications 193 9.5.3 Other Potential Applications 194 9.6 Patient Factors Relating to MN Use 194 9.6.1 Effects of MN Insertion on the Skin 194 9.6.2 Patient Safety 196 9.6.3 Acceptability to Patients and Healthcare Providers 197 9.6.4 Patient Application 197 9.7 The Next Steps in MN Development 198 9.7.1 Manufacturing Considerations 199 9.7.2 Regulatory Considerations 199 9.7.3 Commercialisation of MN Technologies 200 9.8 Conclusion 201 10 Intradermal Delivery of Active Cosmeceutical Ingredients 209Andrzej M. Bugaj 10.1 Introduction 209 10.2 Emulsions 210 10.2.1 Microemulsions 211 10.2.2 Nanoemulsions 212 10.2.3 Quick]Breaking Emulsions 213 10.2.4 Pickering Emulsions 214 10.2.5 Gel Emulsions 214 10.2.6 Liquid Crystal Emulsions 214 10.2.7 Multiple Emulsions 215 10.3 Vesicular Systems 216 10.3.1 Liposomes 216 10.3.2 Niosomes 221 10.3.3 Sphingosomes 221 10.3.4 Multiwalled Delivery Systems 221 10.4 Solid Particulate Systems 222 10.4.1 Microparticles 222 10.4.2 Solid Nanoparticles 225 10.4.3 Fullerenes 228 10.4.4 Cyclodextrins 228 10.4.5 Fibrous Matrices 229 10.5 Cosmetic Foams 229 10.6 Cosmetic Patches 230 10.7 Cosmeceuticals: The Future 230 11 Commercial and Regulatory Considerations in Transdermal and Dermal Medicines Development 243Marc. B. Brown, Jon Lenn, Charles Evans and Sian Lim 11.1 Introduction 243 11.2 Dermal and Transdermal Product/Device Development 245 11.2.1 Drug Candidate Selection 246 11.2.2 Dosage/Device Form 246 11.2.3 Pre]formulation and Formulation/Device Development 248 11.2.4 Performance Testing 250 11.3 Product Scale]Up and Process Optimisation, Validation and Stability Testing 253 11.3.1 Product Scale]Up, Process Optimisation and Specification Development 253 11.3.2 Analytical Method Validation 253 11.3.3 ICH Stability Testing 254 11.4 The Commercial Future of Transdermal Devices 254 Index 259

Read more less

Book SynopsisEthnopharmacology is one of the world s fastest-growing scientific disciplines encompassing a diverse range of subjects. It links natural sciences research on medicinal, aromatic and toxic plants with socio-cultural studies and has often been associated with the development of new drugs.Trade Review"Ethnopharmacology is a remarkable book that comprises cutting-edge research from a range of world-class authorities from many countries across the world. This makes it one of the most authoritative books ever written on this subject and on phytotherapy in general"...."in my opinion, the real appeal of the book is the diversity of the subjects covered, which include the comparative and quantitative methods of ethnopharmacological research; biodiversity, conservation, and ethnopharmacology; ecopharmacognosy; the use of novel nuclear magnetic resonance techniques in natural product research; and ethnopharmacology and intellectual property rights"....."Ethnopharmacology is indeed a valuable book for natural-product researchers, especially those interested in novel approaches for uncovering new leads for the development of essential medicines from plant and animal sources.I have no doubt in my mind that it will serve the purpose for which it is intended: a cutting-edge text meant to equip postgraduate students in pharmacy, pharmaceutical sciences, and other related disciplines, anywhere in the world, with sound knowledge of the newly developing field of ethnopharmacology" Bioscience, July 2016Table of ContentsContributors xvii Series Foreword xxi Preface xxiii Abbreviations xxvii Ethnopharmacology: The Fundamental Challenges 1 Ethnopharmacology: A Short History of a Multidisciplinary Field of Research 3Michael Heinrich 1.1 Introduction 3 Acknowledgements 8 References 8 2 Medicinal Plant Research: A Reflection on Translational Tasks 11Anna K Jäger 2.1 Introduction 11 2.2 Translational research: preclinical research 12 2.3 Translational research: clinical research 13 2.4 Reaching the patient 14 2.5 A ‘developed’ traditional medicine system 14 References 16 3 The Anthropology of Ethnopharmacology 17Ina Vandebroek and Daniel E. Moerman 3.1 Introduction 17 3.2 Primary example: Traditional medicine in New York City 18 3.3 An example from ancient Roman architecture 22 3.4 An example from native North America 23 3.5 Comparative ethnobotany 24 3.6 Conclusions 26 References 27 4 Quantitative and Comparative Methods in Ethnopharmacology 29Marco Leonti and Caroline S. Weckerle 4.1 Introduction 29 4.2 Research questions 31 4.3 Field research 33 4.4 Analyzing the data 34 4.5 Pharmacological research 35 4.6 Contextualization 36 4.7 Conclusion 37 References 37 5 Biodiversity, Conservation and Ethnopharmacology 41Vernon H. Heywood 5.1 Introduction 41 5.2 Changing attitudes to the ownership of biodiversity 42 5.3 Medicinal and aromatic plants as resources 43 5.4 How many species? 44 5.5 Chemical diversity 45 5.6 Wild harvesting and over-collection 45 5.7 Medicinal plant conservation 46 5.8 Conservation approaches 46 5.9 Protected areas 47 5.10 Community conservation 47 5.11 Genetic conservation 47 5.12 Cultivation 48 5.13 Conclusions 48 References 49 6 Ecopharmacognosy 53Geoffrey A. Cordell 6.1 Introduction 53 6.2 Sustainable medicines and pharmacognosy 54 6.3 Ecopharmacognosy: background 55 6.4 Ecopharmacognosy practices 55 6.5 Conclusions 60 Acknowledgements 60 References 60 7 NMR-based Metabolomics and Hyphenated NMR Techniques: A Perfect Match in Natural Products Research 63Joachim Møllesøe Vinther, Sileshi Gizachew Wubshet and Dan Staerk 7.1 Introduction 63 7.2 Metabolomics 64 7.3 Principles of NMR-based metabolomics 65 7.4 NMR-based metabolomics in natural products research 66 7.5 Hyphenated NMR techniques 68 7.6 Principle of HPLC-SPE-NMR 69 7.7 High-resolution bioassay-coupled HPLC-SPE-NMR 70 7.8 Combining metabolomics and hyphenated NMR techniques 71 7.9 Perspectives in ethnopharmacology 72 7.10 Conclusions 72 References 72 8 New Medicines Based On Traditional Knowledge: Indigenous and Intellectual Property Rights from an Ethnopharmacological Perspective 75Michael Heinrich 8.1 Introduction 75 8.2 The legal framework 76 8.3 Industrial research in an ethnopharmacological context 77 8.4 Some case studies 79 8.5 Conclusions 83 Note 84 References 84 9 Ethnopharmacology and Intellectual Property Rights 87Alan Hesketh 9.1 Introduction 87 9.2 Indigenous community rights and traditional knowledge 88 9.3 Identifying a partner 89 9.4 Hurdles in considering IP 91 9.5 Building an effective IP portfolio 91 9.6 The patentability of products of nature 93 9.7 Conclusion 95 References 95 10 Ethnopharmacology in Elementary, Primary and Secondary Education: CurrentPerspectives and Future Prospects 97Alonso Verde, Diego Rivera, José Ramón Vallejo, José Fajardo, Concepción Obón and Arturo Valdés 10.1 Introduction 97 10.2 Ethnopharmacology: a multidisciplinary subject for education 99 10.3 Developing an ethnopharmacological curriculum: some strategies 101 10.4 Conclusions 104 References 105 The Pharmacological Angle 11 Anti-infective Agents: The Example of Antibacterial Drug Leads 111Maíra Bidart de Macedo, Sofie Clais, Ellen Lanckacker, Louis Maes, Emerson Silva Lima and Paul Cos 11.1 Introduction 111 11.2 Bacterial resistance 112 11.3 Plant-derived antibacterial agents 112 11.4 Basic requirements for successful antimicrobial drug discovery (Cos et al., 2006) 118 11.5 Conclusion 119 References 120 12 Searching for New Treatments of Malaria 123Colin W. Wright 12.1 Introduction 123 12.2 Traditional herbal remedies as a source of antimalarial lead compounds 123 12.3 Developments from established antimalarials 126 12.4 Non-traditional medicine sources of potential antimalarials 127 12.5 Alternative strategies in the search for natural antimalarial compounds 129 12.6 Herbal preparations for the treatment of malaria 130 12.7 Conclusion and future prospects 132 References 132 13 CNS Disorders 135Anna K Jäger 13.1 Introduction 135 13.2 Epilepsy 135 13.3 Depression and anxiety 137 13.4 Insomnia 139 13.5 Sedatives 139 13.6 Dementia 139 13.7 Conclusion 142 References 142 14 Respiratory Conditions 147Adolfo Andrade-Cetto and Jorge García-Alvarez 14.1 Introduction 147 14.2 Case studies 151 14.3 Conclusions 155 Acknowledgments 156 References 156 15 Can there be an Ethnopharmacology of Inflammation? 159Michael Heinrich and Anthony Booker 15.1 Introduction 159 15.2 Ethnopharmacology of inflammation: some examples 161 15.3 Conclusions 166 References 166 16 Epidermal Growth Factor Receptors and Downstream Signalling Pathways as Cancer Treatment Targets for Medicinal Plants 169Ean-Jeong Seo, Ching-Fen Wu, Henny J. Greten and Thomas Efferth 16.1 Role of epidermal growth factor receptors for cancer biology 169 16.2 Inhibition of epidermal growth factor signalling by phytochemicals and medicinal plants 171 16.3 Conclusions and perspectives 173 References 174 17 From Ethnopharmacological Field Study to Phytochemistry and Preclinical Research: The Example of Ghanaian Medicinal Plants for Improved Wound Healing 179Andreas Hensel, Emelia Kisseih, Matthias Lechtenberg, Frank Petereit, Christian Agyare and Alex Asase 17.1 Introduction 179 17.2 Results 180 17.3 Conclusion 196 References 196 18 Gynaecological, Andrological and Urological Problems: An Ethnopharmacological Perspective 199Tinde van Andel, Hugo de Boer and Alexandra Towns 18.1 Introduction 199 18.2 Menstrual disorders 200 18.3 Postpartum use 201 18.4 Vaginal applications 202 18.5 Female infertility 204 18.6 Andrology 204 18.7 Urology 206 References 207 19 Ethnopharmacological Aspects of Bone and Joint Health 213Elizabeth M. Williamson 19.1 Introduction 213 19.2 Current views of bone and joint disorders 214 19.3 Traditional views of bone disorders 216 19.4 Conclusions 224 References 224 20 Diabetes and Metabolic Disorders: An Ethnopharmacological Perspective 227Adolfo Andrade Cetto 20.1 Introduction 227 20.2 Type-2 diabetes 228 20.3 Metabolic syndrome 230 20.4 Case studies 231 20.5 Conclusions 236 Acknowledgments 236 References 237 21 The Ethnopharmacology of the Food–Medicine Interface: The Example of Marketing Traditional Products in Europe 239Gunter P. Eckert 21.1 Introduction 239 21.2 Medicinal products for human use 241 21.3 Food 243 21.4 Consumer protection - security and protection against fraud 245 21.5 Intended normal use: the distinction between medicinal products and foods 247 21.6 Conclusion 248 References 248 22 Retrospective Treatment-Outcome as a Method of Collecting Clinical Data in Ethnopharmacological Surveys 251Bertrand Graz, Merlin Willcox and Elaine Elisabetsky 22.1 Introduction 251 22.2 Key concepts: clinical data, outcome and patient progress 252 22.3 Evaluation of the effectiveness and safety of traditional medicines 253 22.4 The role of ethnopharmacologists and ethnobotanists 254 22.5 Collection of clinical data during ethnopharmacological field studies 255 22.6 Example of a method for gathering clinical data during field surveys 255 22.7 Conclusion: clinical data and field surveys for a positive impact on health 259 References 260 Ethnopharmacology: Regional Perspectives 23 Ethnopharmacology in Sub-Sahara Africa: Current Trends and Future Perspectives 265Mack Moyo, Adeyemi O. Aremu and Johannes van Staden 23.1 Introduction 265 23.2 Role of traditional medicine in Africa 266 23.3 Ethnopharmacological research in sub-Saharan Africa 267 23.4 Challenges of traditional medicine in Africa 269 23.5 Future perspectives 272 23.6 Conclusions 273 Acknowledgements 273 References 273 24 Ethnopharmacology and Integrative Medicine: An Indian Perspective 279Pulok K. Mukherjee, Sushil K. Chaudhary, Shiv Bahadur and Pratip K. Debnath 24.1 Ethnopharmacology and the development of traditional medicine in India 279 24.2 Biological wealth and ancient wisdom 281 24.3 Indian systems of medicine 281 24.4 Ayurveda: the Indian system of medicine 282 24.5 Siddha 286 24.6 Unani 287 24.7 Traditional knowledge digital library 287 24.8 Integrated approaches for the development of Indian traditional medicine 288 24.9 Conclusion 289 Acknowledgements 290 References 290 25 Chinese Medicine: Contentions and Global Complexities 293Anthony Booker 25.1 Introduction 293 25.2 Ancient concepts meet scientific understanding 294 25.3 Traditional and modern dosage forms and application 296 25.4 Medicinal plant production in China 296 25.5 Quality and safety 297 25.6 Aristolochic acids 298 25.7 Regulatory requirements 298 25.8 Training practitioners of TCM 299 25.9 Future prospects 300 References 301 26 Chinese Medicinal Processing: A Characteristic Aspect of the Ethnopharmacology of Traditional Chinese Medicine 303Ping Guo, Eric Brand and Zhongzhen Zhao 26.1 Introduction 303 26.2 Definition, methods and historical changes in Chinese medicinal processing 304 26.3 Present state of Chinese medicinal processing 310 26.4 Prospect for future developments in Chinese medicinal processing 315 References 315 27 A South-East Asian Perspective on Ethnopharmacology 317Pravit Akarasereenont, Marianne J.R. Datiles, Natchagorn Lumlerdkij, Harisun Yaakob, Jose M. Prieto and Michael Heinrich 27.1 Introduction 317 27.2 Ethnopharmacology in Thailand 319 27.3 Ethnopharmacology in Malaysia 322 27.4 Ethnopharmacology in Indonesia 325 27.5 Ethnopharmacology in the Philippines 326 27.6 Ethnopharmacology in Vietnam 328 27.7 Ethnopharmacology in Myanmar, Lao PDR and Cambodia 328 27.8 Ethnopharmacology in Singapore and Brunei 328 27.9 Conclusion 328 Acknowledgement 329 References 329 28 Historical Approaches in Ethnopharmacology 333Andreas Lardos 28.1 Introduction 333 28.2 Historical texts in ethnopharmacological research 334 28.3 Methodological aspects 335 28.4 Challenges in the analysis of historical texts 335 28.5 Opportunities offered by a historical approach 337 28.6 Conclusions 338 References 339 29 Medical Ethnobotany and Ethnopharmacology of Europe 343Manuel Pardo-de-Santayana, Cassandra L. Quave, Renata Sõukand and Andrea Pieroni 29.1 Introduction 343 29.2 A brief history of European medicinal plants studies 344 29.3 Modern European medico-ethnobotanical studies 345 29.4 European ethnomedicinal flora 350 29.5 Adaptation, syncretism and resilience of traditional pharmacopoeias 351 29.6 Pharmacological studies of European medicinal plants 351 29.7 Concluding remarks 352 References 352 30 Ethnopharmacology in the Eastern Mediterranean and the Middle East: ‘The Sun Rises from the East, but Shines on the Eastern Mediterranean’ 357Erdem Yesilada 30.1 Introduction 357 30.2 Ethnobotany and ethnopharmacology in the Balkan region 358 30.3 Modern ethnobotany and ethnopharmacology in the Middle East 359 30.4 Ethnobotany and ethnopharmacology in Turkey 361 30.5 Concluding remarks 362 References 362 31 Ethnopharmacology in Australia and Oceania 365Graham Lloyd Jones and Nicholas J. Sadgrove 31.1 Introduction 365 31.2 Ethnopharmacological ‘classics’ 367 31.3 Australian aromatic plants 369 31.4 Recent developments: aromatic plants 371 31.5 Recent developments: cancer and HIV 376 31.6 Conclusion 376 References 377 32 Ethnopharmacology in Central and South America 379Salvador Cañigueral and Jaume Sanz-Biset 32.1 Introduction 379 32.2 The development of drugs 381 32.3 Beyond the development of new drugs 386 32.4 Bridging indigenous and western knowledge 387 32.5 Hallucinogens 388 32.6 Conclusion 389 References 389 33 Perspectives on Ethnopharmacology in Mexico 393Robert Bye and Edelmira Linares 33.1 Introduction 393 33.2 Mexican tradition 394 33.3 Compilation of medicinal plants 396 33.4 Medicinal plant complex 398 33.5 Markets and medicinal plants 399 33.6 Bioprospection and conservation 399 33.7 Conclusions 401 Acknowledgements 401 References 401 34 Encounters with Elephants: A Personal Perspective on Ethnopharmacology 405Peter J. Houghton 34.1 Introduction 405 34.2 The primacy of plants 406 34.3 Sources: dirty hands and databases 406 34.4 From cultural use to chemistry 407 34.5 Chemistry as a starter 407 34.6 Botany as a basis 408 34.7 Of mice and men and microwell plates 408 34.8 Aims and ethics 409 34.9 Molecules and mixtures 410 34.10 Tales of the unexpected 410 34.11 The end of the matter 411 References 411 Index 415

Read more less

Book SynopsisRetaining the successful previous editions'' programmed instructional format, this book improves and updates an authoritative textbook to keep pace with compounding trends and calculations addressing real-world calculations pharmacists perform and allowing students to learn at their own pace through examples. Connects well with the current emphasis on self-paced and active learning in pharmacy schools Adds a new chapter dedicated to practical calculations used in contemporary compounding, new appendices, and solutions and answers for all problems Maintains value for teaching pharmacy students the principles while also serving as a reference for review by students in preparation for licensure exams Rearranges chapters and rewrites topics of the previous edition, making its content ideal to be used as the primary textbook in a typical dosage calculations course for any health care professional Reviews of the prior edition: ...a well-stTable of ContentsPreface xiii Chapter 1 Review of Basic Mathematical Principles1 1.1. Significant Figures 2 1.2. Rounding Off 4 1.3. Fractions 5 1.4. Exponents and Powers 8 1.5. Estimation 10 1.6. Units 12 1.7. Ratio 15 1.8. Proportion 15 1.9. Dimensional Analysis 18 Practice Problems 21 Chapter 2 Systems of Measurement 31 2.1. Metrology 31 2.2. The Metric System 32 2.3. The English Systems 33 2.3.1. The Avoirdupois System 33 2.3.2. The Apothecary or Troy System 33 2.4. Measurement of Weight 33 2.4.1. Metric Weight 33 2.4.2. English Weight 35 2.4.2.1. Avoirdupois Weight 35 2.4.2.2. Apothecary Weight 36 2.4.3. Practical Weight Equivalents 36 2.5. Measurement of Volume 38 2.5.1. Metric Volume 38 2.5.2. English Volume 39 2.5.3. Practical Volume Equivalents 39 2.6. Measurement of Length 41 2.7. Intersystem Relationships 43 2.8. Household Equivalents and Metric Estimation 44 Practice Problems 49 Chapter 3 Prescriptions and Medication Orders 54 3.1. Prescribing Authority 55 3.2. Components 57 3.3. Practices to Prevent Medication Errors 58 3.4. Common Abbreviations 60 3.5. Outpatient Prescription Drug Orders 69 3.5.1. Prescriptions for Manufactured Drug Products 69 3.5.2. Prescriptions for Compounded Drug Products 69 3.5.2.1. Types of Compounded Orders 70 3.5.2.2.1. Formulation Based on Total Quantity 70 3.5.2.3.2. Formulation Based on Single Dosage Unit 71 3.6. Inpatient Medication Orders 72 3.7. Interpretation 77 3.8. Calculations to Check “DEA” Numbers 77 3.9. Reducing and Enlarging Formulas 80 3.10. Parts Formulas 87 Practice Problems 90 Chapter 4 Weighing and Measuring in Pharmacy Practice 103 4.1. Measurement Errors 103 4.2. Indication of Error 104 4.2.1. Absolute Error: Indication of Error Based on Maximum Deviation and Significant Figures 104 4.2.2. Relative Error: Indication of Error Based on Percentage of Estimated Value 107 4.3. Tolerance in Prescription Compounding and Pharmaceutical Manufacturing 108 4.4. Weighing and Measuring 109 4.4.1. Electronic Balances 109 4.4.2. Prescription Balances: Class A, Torsion 110 4.4.2.1. Sensitivity Requirement (SR) 110 4.4.2.2. Minimum Weighable Quantity (MWQ) or Least Weighable Quantity (LWQ) 110 4.4.2.3. Percent Error 111 4.4.3. Volumetric Devices for Pharmaceutical Measurements 114 4.4.3.1. The Meniscus and Effect of Viscosity 114 4.4.3.2. Graduates 114 4.4.3.3. Pipets (Pipettes) 115 4.4.3.4. Syringes 115 4.4.3.5. Droppers 116 4.5. Aliquot Method and Triturations 119 4.5.1. Solid–Solid Aliquot Method 119 4.5.2. Solid–Solid Triturations 122 4.5.3. Liquid–Liquid Aliquots and Triturations 131 4.5.4. Solid–Liquid Aliquots 136 4.5.5. Serial Dilutions 140 4.6. Density 142 4.7. Specific Gravity 144 Practice Problems 145 Chapter 5 Dosage Calculations 160 5.1. Calculations Involving Dose, Size, Number of Doses, Amount Dispensed, and Quanity of a Specific Ingredient in a Dose 161 5.2. Dosage Measured By Drops 169 5.3. Dosage Based on Body Weight 171 5.4. Dosage Based on Body Surface Area (BSA) 174 5.5. Pediatric and Geriatric Dose Calculations 181 5.6. Chemotherapy Dose Calculations 184 Practice Problems 187 Chapter 6 Drug Concentration Expressions 203 6.1. Concentration 204 6.2. Percentage Strength Expressions 204 6.2.1. Percent Volume-in-Volume 204 6.2.2. Percent Weight-in-Weight 205 6.2.3. Percent Weight-in-Volume 206 6.2.4. Default Rules for Percentage Expressions 208 6.2.5. Prescriptions and Formulations with Ingredients Listed as Percentage 210 6.2.6. Using Specific Gravity to Calculate the Exact Amount of Solvent in a Solution 215 6.2.7. Converting % w/w into %w/v Using Specific Gravity 217 6.3. Stock Solutions, Concentrates, and Triturations 218 6.4. Saturated Solutions 222 6.5. Ratio Strength Expressions 224 6.5.1. Ratio Volume-in-Volume 224 6.5.2. Ratio Weight-in-Volume 225 6.5.3. Ratio Weight-in-Weight 226 6.6. Other Pharmaceutical Expressions of Drug Concentration 230 6.6.1. Milligrams Per Milliliter (mg/mL) 230 6.6.2. Milligrams Percent (mg%) and Miligrams Per Deciliter (mg/dL) 231 6.6.3. Parts Per Million (ppm) and Parts Per Billion (ppb) 232 6.6.4. Millimols, Milliequivalents, and Milliosmols Per Unit of Volume 234 Practice Problems 235 Chapter 7 Dilution and Concentration 257 7.1. Problem-Solving Methodologies 258 7.1.1. Concentration Principle 258 7.1.2. Mass Balance Equation 260 7.1.2.1. Dilution of Powders or Solid Mixtures 261 7.1.2.2. Mixing Different Strengths 265 7.1.2.3. Modifying the Drug Concentration of a Prepared Product: Increasing Drug Concentration 267 7.1.3. The CQ Equation: Concentration X Quantity 268 7.1.3.1. Expanded CQ Equation 272 7.1.4. Algebraic Calculations Using the Concentration Equation and the CQ Equation 275 7.1.5. Alligation Alternate 283 7.1.5.1. Use of Alligation When Combining More Than Two Products 287 7.2. So, Which Method Should I Use? 291 7.2.1. Stock Solutions Diluted by the Patient 293 Practice Problems 296 Chapter 8 Isotonicity 310 8.1. Principles 310 8.2. Sodium Chloride Equivalent Values 312 8.3. Isotonicity by the Sodium Chloride Equivalent Method 315 8.3.1. Sodium Chloride Equivalent: Method 1 315 8.3.2. Sodium Chloride Equivalent: Method 2 318 8.4. Other Tonicity Agents 319 8.5. Isotonicity When One Ingredient is Already Isotonic 321 8.6. Isotonic Buffered Solutions 323 8.6.1. Using the White–Vincent Method to Adjust Tonicity 323 8.7. Other Methods 326 8.8. Determination of the Tonicity of a Solution (Hypotonic, Isotonic, or Hypertonic) 329 Practice Problems 330 Chapter 9 Dosage Calculations of Electrolytes 340 9.1. Molarity and Molality 341 9.1.1. Mols and Millimols 341 9.1.2. mmol/mL, mmol/L 344 9.2. Electrolyte Dissociation, Valence, Equivalent, and Equivalent Weight 344 9.3. Milliequivalents, mEq/mL, mEq/L 347 9.3.1. Problem-Solving Methods for Milliequivalents 348 9.4. Osmolarity (Osmolar Strength) 354 9.4.1. Milliosmoles and mOsm/L 355 Practice Problems 366 Chapter 10 Calculations for Injectable Medications And Sterile Fluids 378 10.1. Reconstitution of Dry Powders 378 10.1.1. Reconstituting with Volumes Other Than Those on Manufacturer’s Label 380 10.1.2. Considering Powder Volume 383 10.1.3. Powders as Compounding Sources of Drugs 385 10.2. Calculations Related to Units/ml (Insulin, Heparin) and Other Units of Potency 386 10.2.1. Calculations of Insulin Single Dose and Combinations 387 10.2.2. Calculations of Heparin Doses 391 10.3. Intravenous Admixtures 392 10.4. Extemporaneous IV Fluids 395 10.5. Flow Rates in Intravenous Sets 397 Practice Problems 399 Chapter 11 Enteral and Parenteral Nutrition 413 11.1. Screening and Assessment of Nutritional Needs 414 11.1.1. Body Mass Index (BMI), Waist Circumference, and Associated Disease Risks 414 11.1.2. Assessment of Malnutrition 416 11.2. Enteral Nutrition 416 11.3. Parenteral Nutrition (PN): 2-in-1 and 3-in-1 Formulations 418 11.4. Calculation of Nutritional Requirements 420 11.4.1. Caloric Requirement Equations 420 11.4.2. Fluid Requirement 425 11.4.3. Protein Requirement (Nitrogen) 425 11.4.4. Carbohydrate and Fat Requirements 428 11.4.5. Micronutrient Requirements (Electrolytes, Vitamins, and Trace Elements) 428 11.5. Calculations for Compounding Parenteral Nutrition 429 11.5.1. Calculation of Electrolytes 430 11.5.2. Calculation of Carbohydrate and Fat 433 11.5.3. Calculation of Protein 435 11.5.4. Calculation of Other Additives 438 11.6. Calculations Related to the Design of a PN 444 Practice Problems 446 Chapter 12 Miscellaneous Practical Calculations in Contemporary Compounding 458 12.1. Compounding with Manufactured Dosage Forms 459 12.1.1. Nonsterile Products 460 12.1.2. Sterile Products 463 12.2. Suppository Calculations 465 12.2.1. Calibration of Molds 465 12.3. Determination of Amount of Base/powder Occupied by the Drug(s): Solid Dosage Forms 466 12.3.1. Density Factor Method 467 12.3.2. Quantity/Volume of Base Occupied by Drug (or Density Ratio Method) 474 12.3.3. Dosage Replacement Factor Method 475 12.4. Lozenges and Lollipops 479 12.4.1. Lozenge/Lollipop Mold Calibration 479 12.5. Selecting a Capsule Size 480 12.5.1. The Rule of Sixes 480 12.5.2. The Rule of Seven 482 12.5.3. Volume Occupied by Active Ingredient in a Capsule 484 12.6. Primary Emulsion Calculations (4:2:1 Ratio) 485 12.7. A Little Touch of Veterinary Compounding 487 Practice Problems 489 Appendices 499 Appendix 1 Systems of Measurement 500 Appendix 2 Chemical Elements and Atomic Weights 502 Appendix 3 Calibration of Medicinal Dropper 503 Appendix 4 Solutions Used to Compound PN 504 Appendix 5 Conversions: Temperature, Time, Proof Strength 507 Appendix 6 HLB System 511 Appendix 7 Drug as a Base Versus Salt or Ester 514 Appendix 8 pH, Buffers, and Buffer Capacity 517 Appendix 9 Normal Concentration 525 Appendix 10 Biologics for Immunization 527 Literature Consulted 529 Index 531

Read more less

Book SynopsisCovering a key topic due to growing research into the role of signaling mechanisms in toxicology, this book focuses on practical approaches for informatics, big data, and complex data sets. Combines fundamentals / basics with experimental applications that can help those involved in preclinical drug studies and translational research Includes detailed presentations of study methodology and data collection, analysis, and interpretation Discusses tools like experimental design, sample handling, analytical measurement techniques Table of ContentsList of Contributors xv About the Editors xvii Preface xix 1 Introduction to Cellular Signal Transduction: The Connection Between a Biological System and Its Surroundings 1Jonathan W. Boyd, Richard R. Neubig, Alice Han, and Maren Prediger 1.1 Starting Big, but Ending Small 3 1.1.1 Key Features of Signal Transduction 3 1.2 Responding to Our Environment: Sensory Perception Begins and Ends with Signal Transduction 4 1.2.1 Taste (Gustation) 4 1.2.2 Smell (Olfaction) 5 1.2.3 Sight (Vision) 6 1.2.4 Sound (Audition) 6 1.2.5 Touch (Somatosensation) 8 1.3 Primary Transport Systems Involved in Signal Transduction 8 1.3.1 Ion Channels, Transporters, and Ion Pumps 9 1.3.2 Receptors 10 1.3.3 Endocytosis 10 1.3.4 Exosomes 11 1.4 Key Organelles Involved in Signal Transduction 12 1.4.1 Mitochondria 12 1.4.2 Endoplasmic Reticulum 14 1.4.3 Nucleus 15 References 16 2 Mechanisms of Cellular Signal Transduction 21Richard R. Neubig, Jonathan W. Boyd, Julia A. Mouch, and Nicole Prince 2.1 Posttranslational Modifications and Their Roles in Signal Transduction 22 2.1.1 Phosphorylation 22 2.1.2 Acylation 24 2.1.3 Alkylation 25 2.1.4 Glycosylation 26 2.1.5 Other PTMs 27 2.2 Receptors 27 2.3 Receptor Signaling Mechanisms 29 2.3.1 Basic Principles of Signal Transduction Mechanisms 29 2.3.1.1 Selectivity and Recognition 31 2.3.1.2 Flexible Modularity 31 2.3.1.3 Molecular Switches 34 2.3.1.4 GPCRs and Second Messengers 36 2.3.1.5 Amplification 39 2.3.1.6 Turn‐Off Mechanisms 40 2.3.1.7 Localization 40 2.3.1.8 Biased Signaling/Functional Selectivity 41 2.4 Receptor Tyrosine Kinases 42 2.5 Steroid Receptors 43 2.6 Reactive Oxygen Species (ROS) 43 2.7 Summary 44 References 44 3 From Cellular Mechanisms to Physiological Responses: Functional Signal Integration Across Multiple Biological Levels 49Robert H. Newman 3.1 Introduction 49 3.2 Cellular Information Flow: Mechanisms of Cellular Signal Integration and Regulation 50 3.2.1 The InsR‐aPKC‐NF‐κB Signaling Axis 51 3.2.2 Modes of Regulation in InsR‐PKC‐NF‐κB Signaling Axis 54 3.2.3 Transcriptional Regulation 54 3.2.4 Regulating the Regulators: Phosphatase‐Mediated Regulation of Signaling Molecules 59 3.3 Crosstalk and Functional Signal Integration in Response to Insulin in Hepatocytes 60 3.4 Systemic Signal Integration 65 3.4.1 Pancreatic β‐Cells 65 3.4.2 Skeletal Muscles 66 3.4.3 Adipose Tissue 67 3.5 Dysregulation of Insulin Signaling in the Etiology of Type 2 Diabetes 67 References 69 4 Signal Transduction in Disease: Relating Cell Signaling to Morbidity and Mortality 73Patricia E. Ganey and Sean A. Misek 4.1 Introduction 73 4.2 Fibrosis as an Example of Complex Signaling 75 4.2.1 Development of Liver Fibrosis 75 4.2.2 Animal Models of Hepatic Fibrosis 76 4.2.3 Activation of Hepatic Stellate Cells 77 4.2.4 Epithelial‐to‐Mesenchymal Transition (EMT) 78 4.2.5 Other Cellular Interactions in Fibrosis 78 4.2.6 Intracellular Signaling Pathways Critical to Liver Fibrosis 80 4.2.6.1 TGF‐β1 80 4.2.6.2 Kinase Pathways Involved in Fibrotic Responses 82 4.2.6.3 HIF‐1α 83 4.2.6.4 miRNA 84 4.2.6.5 Toll‐Like Receptors (TLRs) 84 4.3 Cancer Drug Resistance: Complex Cellular and Population Changes 85 4.3.1 Genomic Resistance Mechanisms 85 4.3.2 Non‐genomic Mechanisms 88 4.3.3 Non‐cancer Drug Resistance Paradigms 88 4.3.4 Tumor Heterogeneity as a Driver of Drug Resistance 89 4.3.5 Mutational Drivers of Drug Resistance 90 4.3.6 Drug‐Induced Rewiring of Signaling Networks as a Mechanism of Drug Resistance 91 4.3.7 Parallel Pathways and Combination Treatments 93 4.3.8 Epigenetic Mechanisms of Drug Resistance 95 4.3.9 Summary of Cancer Drug Resistance 97 4.4 Summary 98 References 98 5 Experimental Design in Signal Transduction 113Weimin Gao, Meghan Cromie, Qian Wang, Zhongwei Liu, Song Tang, and Julie Vrana Miller 5.1 Overview of Basic Experimental Design 113 5.1.1 Independent Sample t Test 114 5.1.2 Completely Randomized Analysis of Variance (ANOVA) 114 5.1.3 t Test for Dependent Sample Design 115 5.1.4 Randomized Block Design 115 5.1.5 Completely Randomized Factorial Design 116 5.1.6 Summary 116 5.2 Aseptic Technique 116 5.2.1 Sterile Work Environment and Laminar‐Flow Hood 117 5.2.2 Good Personal Hygiene Practices 117 5.2.3 Sterile Reagents and Materials 118 5.2.4 Sterile Handling 118 5.3 Biological Sample Collection, Processing, and Pretreatment Technology 119 5.3.1 Sample Collection 119 5.3.1.1 Sample Collection In Vivo 119 5.3.1.2 Cell Culture In Vitro 120 5.3.2 Sample Processing 121 5.3.2.1 DNA Isolation 121 5.3.2.2 RNA Extraction 121 5.3.2.3 Protein Extraction 122 5.4 Sample Storage 122 5.5 Common In Vitro Studies in Toxicology/Pharmacology 123 5.5.1 Cytotoxicity Studies 123 5.5.2 Viability Assays 123 5.5.2.1 Trypan Blue 123 5.5.2.2 Erythrosin 124 5.5.2.3 Crystal Violet Staining 124 5.5.2.4 Neutral Red Staining 125 5.5.3 Survival Assays 125 5.5.3.1 Clonogenic or Colony Formation Assay 125 5.5.3.2 Cell Cycle Analysis: Flow Cytometry 126 5.5.4 DNA Damage Assays 126 5.5.4.1 Comet Assay 127 5.5.4.2 Sister Chromatid Exchange Assay 127 5.5.5 Southern Blot and DNA Sequencing 127 5.5.5.1 Southern Blot 127 5.5.5.2 DNA Sequencing 128 5.5.5.3 Transfection and Gene Silencing 128 5.5.6 RNA Quantification and Identification 128 5.5.6.1 Northern Blot 128 5.5.6.2 Promoter Deletion Analysis 129 5.5.6.3 RNase Protection Assay 129 5.5.7 Gene Expression 129 5.5.7.1 Quantitative Real‐Time Polymerase Chain Reaction (qRT‐PCR) 130 5.5.7.2 Microarray 130 5.5.8 Protein‐Related Assays 131 5.5.8.1 Bradford Assay 131 5.5.8.2 Enzyme-Linked Immunosorbent Assay (ELISA) 131 5.5.8.3 Western Blot and 2D Gel Electrophoresis 131 5.5.8.4 Immunolocalization 132 5.5.8.5 Immunoprecipitation Assays 132 5.5.8.6 Chromatin Immunoprecipitation (ChIP) 132 5.5.9 Epigenetics 133 5.5.9.1 Bisulfite Pyrosequencing 133 5.5.9.2 ChIP‐on‐Chip 133 5.5.9.3 Multiplex miRNA Profiling 134 5.6 Common In Vivo Studies in Toxicology 134 5.6.1 Toxicological Endpoints 134 5.6.1.1 Maximum Tolerated Dose (MTD) 134 5.6.1.2 Acute, Subchronic, and Chronic Toxicity 135 5.6.1.3 Reproductive and Developmental Toxicity 135 5.6.1.4 Genotoxicity and Carcinogenicity Studies 136 5.6.2 Routes of Exposure 136 5.6.2.1 Oral, Dermal, and Inhalation 136 5.6.2.2 Exposure via Injection 137 5.6.3 Animal Models 137 5.6.3.1 Rodent Studies 137 5.6.3.2 Other Studies 138 5.7 Basic Advantages and Disadvantages Associated with Sample Types 138 5.8 Human Epidemiology Studies 138 5.8.1 Nonexperimental Studies 139 5.8.2 Experimental Studies 139 5.8.3 Molecular Epidemiology 140 5.9 Examples of Tox‐ and Pharm‐Based Experiments Relevant to Signal Transduction Endpoints 140 5.9.1 Cytotoxicity 141 5.9.1.1 Nicotine‐Derived Nitrosamine Ketone (NNK) 141 5.9.1.2 Doxorubicin (DOX) 142 5.9.1.3 Curcumin 142 5.9.1.4 Combination Effects of Cisplatin and/or Leptomycin B (LMB) 143 5.9.2 DNA Damage 143 5.9.3 Cell Cycle and Apoptosis 145 5.9.4 ROS Induction in A549 Cells After LMB and Epigallocatechin Gallate (EGCG) Treatment 146 5.9.5 Signaling Pathways 146 5.9.5.1 Metabolizing Alterations After Chemical Exposure 146 5.9.5.2 p53 Signaling Pathways 148 5.9.6 Protein Kinase B (Akt/PKB)/Mechanistic Target of Rapamycin (mTOR) Pathway Analysis Using Multiblot 150 5.9.7 Discovery of Unrecognized Pathways/Molecules Using Proteomics 150 5.10 Coupling Experimental Results Within the Larger Literature Framework to Generate Information 152 5.10.1 Cell Proliferation–EGFR Pathway 152 5.10.2 Cell Cycle 154 5.10.3 Signal‐Mediated Cell Death 156 5.10.4 Reactive Oxygen Species (ROS) 161 References 162 6 Techniques for Measuring Cellular Signal Transduction 171Julie Vrana Miller, Weimin Gao, Meghan Cromie, and Zhongwei Liu 6.1 Introduction 171 6.2 High‐Throughput Versus High‐Content Data 172 6.2.1 Ergodic and Nonergodic Systems 173 6.3 Methods to Measure Signal Transduction Data 173 6.3.1 Microscopy 173 6.3.1.1 Widefield Epifluorescence Microscopy 173 6.3.1.2 Confocal Microscopy 174 6.3.1.3 Immunohistochemistry 175 6.3.1.4 FRET 178 6.3.2 Enzyme‐Linked Immunosorbent Assay (ELISA) 179 6.3.2.1 Competitive ELISA 179 6.3.2.2 Sandwich ELISA 180 6.3.2.3 Direct Cellular ELISA 180 6.3.2.4 Multiplex Suspension Array Assays 181 6.3.2.5 Electrochemiluminescence (ECL) Array 182 6.3.3 Gel Electrophoresis 183 6.3.4 Western Blot 183 6.3.5 Protein Nuclear Magnetic Resonance (NMR) 186 6.4 Techniques to Generate Large Datasets for Signal Transduction Network Analysis 187 6.4.1 ’‐omics Using Mass Spectrometry 187 6.4.1.1 Separation Techniques 188 6.4.1.2 Phosphoprotein Enrichment for Phosphoproteomics: IMAC, MOAC, and SMOAC 189 6.4.1.3 Quantitation with Chemical Tags: iTRAQ and TMT 190 6.4.2 RNA Sequencing (RNA‐Seq) 190 6.5 Bioenergetics 191 6.5.1 Oxygen Consumption 191 6.5.2 Reactive Oxygen Species (ROS) Fluorescent Probes 192 6.5.3 ATP Assays 193 6.5.4 Nicotinamide Adenine Dinucleotide (NADH) Assay 193 6.5.5 Mitochondrial Membrane Potential 194 6.6 Relating Signaling to Cellular Outcome Using Relevant Assays 194 6.6.1 MTT/MTS/WST Assays 194 6.6.2 LDH Assay 195 6.6.3 Resazurin Assay (Alamar Blue) 196 6.6.4 Cell Death: Plasma Membrane Degradation Assay 196 6.7 Summary 196 References 197 7 Computational Methods for Signal Transduction: A Network Approach 201Giovanni Scardoni, Gabriele Tosadori, John Morris, Sakshi Pratap, Carlo Laudanna, and Alice Han 7.1 Introduction 201 7.2 Network Construction 203 7.2.1 Introduction to Network Construction 203 7.2.2 Network Construction from a Probe 203 7.2.3 Mapping Methodology 204 7.2.4 Small Networks 208 7.2.5 Large Networks 208 7.3 Facing the Network Analysis 209 7.3.1 Centralities Definition and Description 211 7.3.2 Global Parameters 211 7.3.2.1 Diameter (ΔG) 211 7.3.2.2 Average Distance 212 7.3.3 Local Parameters 213 7.3.3.1 Degree 213 7.3.3.2 Eccentricity 214 7.3.3.3 Closeness 215 7.3.3.4 Radiality 215 7.3.3.5 Centroid Value 217 7.3.3.6 Stress 219 7.3.3.7 S.‐P. Betweenness 219 7.3.3.8 Eigenvector 220 7.3.3.9 Bridging Centrality 221 7.3.3.10 Edge Betweenness 221 7.3.3.11 Normalization and Relative Centralities 222 7.3.4 Clusters 222 7.4 Employing Centrality Analysis to Evaluate Stressed Biological Systems 224 7.5 Interference Notion: How to Perform Virtual Knockout Experiments on Biological Networks 226 7.5.1 Integrating Experimental Dataset into a Topological Analysis 227 7.5.2 Integrating Expression or Activation Levels as Nodes Attributes 228 7.5.3 Edge Attributes as Distance in a Computation 228 7.6 Network Analysis Software 229 7.6.1 Cytoscape and Its Apps 229 7.6.1.1 structureViz/RINalyzer 231 7.6.1.2 CentiScaPe 231 7.6.1.3 PesCa 231 7.6.1.4 Interference 231 7.6.1.5 clusterMaker2 232 7.6.1.6 chemViz 233 7.6.2 Other Tools 233 7.6.2.1 Gephi 233 7.6.2.2 D3.js 234 7.6.2.3 VisANT 234 7.7 Conclusions 236 References 236 8 A Toxicological Application of Signal Transduction: Early Cellular Changes Can Be Indicative of Toxicity 239Julie Vrana Miller, Nicole Prince, Julia A. Mouch, and Jonathan W. Boyd 8.1 Introduction 239 8.2 Classification of Toxic Agent and Exposure Effects: A Toxicological Perspective 240 8.2.1 Dose–Response for Chemical Exposure Toxicity Testing and Risk Assessment 240 8.2.2 Chemical Mixtures 241 8.2.3 Mode of Action Versus Mechanism of Action 242 8.3 Early Cellular Changes Post‐exposure 244 8.3.1 Intracellular Signaling Perturbations Associated with Exposure 245 8.3.2 Bioenergetic Changes Post‐exposure 248 8.3.3 Time Scale of Exposure Effects 249 8.4 Experimentally Testing Early Cellular Changes that May Contribute to Exposure Sensing and Response 250 8.4.1 Paradigm Shift Toward In Vitro Cell Culture 250 8.4.2 Real‐Time In Vitro Assays to Measure Early Cellular Changes 251 8.4.2.1 Using NADH and Oxygen Consumption to Predict ATP Generation 252 8.4.3 Prediction of Posttranslational Phosphorylation Response for Mixtures 253 8.4.3.1 Using Bliss Independence (Response Addition) to Predict Relative Phosphorylation During Critical Signaling Events 253 References 256 Appendix A 262 9 Future Research in Signaling 267Jonathan W. Boyd, Nicole Prince, and Marc Birringer 9.1 Translational Research and a Spatiotemporal Understanding of Signal Transduction 267 9.2 Integrating Second Messengers into Signal Transduction 270 9.3 Understanding Crosstalk in Signal Transduction 272 9.4 Posttranslational Modifications (PTMs) and Target Identification in Signal Transduction 274 9.5 Epigenetic Endpoints in Signal Transduction 276 9.6 The Integration of Nutrition and Signal Transduction 278 9.6.1 Cellular AMPK Signaling 281 9.6.2 Cellular TOR Signaling 282 9.6.3 Gut Microbiota 282 9.6.4 The Integration of Endocrine Gut Signaling 283 References 284 Index 291

Read more less

Book SynopsisPharmacovigilance is the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problems. This introductory guide is designed to aid the rapid understanding of the key principles of pharmacovigilance. Packed full of examples illustrating drug safety issues it not only covers the processes involved, but the regulatory aspects and ethical and societal considerations of pharmacovigilance. Covering the basics step-by-step, this book is perfect for beginners and is essential reading for those new to drug safety departments and pharmaceutical medicine students. The second edition is thoroughly revised and updated throughout and includes a new chapter on clinical aspects of pharmacovigilance.Table of ContentsForeword ix Preface to the Second Edition xi Preface to the First Edition xiii Acknowledgements xv List of Abbreviations xvii 1 What is Pharmacovigilance and How Has it Developed? 1 2 Basic Concepts 19 3 Types and Sources of Data 37 4 The Process of Pharmacovigilance 55 5 Regulatory Aspects of Pharmacovigilance 75 6 International Collaboration 95 7 Clinical Aspects of Adverse Drug Reactions 109 8 Ethical and Societal Considerations 123 9 Future Directions 135 10 Learning More About Pharmacovigilance 145 Glossary 151 Index 157

Read more less

Book SynopsisPhysiologically Based Pharmacokinetic (PBPK) Modeling and Simulations The first book dedicated to the emerging field of physiologically based pharmacokinetic modeling (PBPK) Now in its second edition, Physiologically Based Pharmacokinetic (PBPK) Modelling and Simulations: Principles, Methods, and Applications in the Pharma Industry remains the premier reference book throughout the rapidly growing PBPK user community. Using clear and concise language, author Sheila Annie Peters connects theory with practice as she explores the vast potential of PBPK modeling for improving drug discovery and development. This fully updated new edition covers key developments in the field of PBPK modelling and simulations that have emerged in recent years. A brand-new section provides case studies in different application areas of PBPK modelling, including drug-drug interaction, genetic polymorphism, renal impairment, and pediatric extrapolation. Additional chapters address Table of ContentsPreface xix Acknowledgements xxi About the companion xxiii Section I. Principles, Methods, andBackground Information 1 1 A Review of Pharmacokinetic and Pharmacodynamic Principles 3 1.1 Introduction 4 1.2 Pharmacokinetic Principles 4 1.2.1 Routes of Drug Administration 4 1.2.2 Intravenous Bolus 4 1.2.3 Plasma Protein Binding and Blood–Plasma Ratio 9 1.2.4 Hepatic, Renal, and Biliary Clearances 12 1.2.5 Extravascular (Subcutaneous, Intramuscular, and Per Oral) Absorption 16 1.2.6 Absorption from Solid Dosage Forms 20 1.2.7 Role of Transporters in ADME 22 1.2.8 Linear and Non-Linear Pharmacokinetics 24 1.2.9 Intravenous Infusion, Repeated Dosing, Steady State Kinetics, and Accumulation 25 1.2.10 Active Metabolite and Prodrug Kinetics 28 1.3 Pharmacokinetic Variability 32 1.4 Pharmacokinetics Optimization in Drug Discovery 34 1.5 Pharmacodynamic Principles 34 1.5.1 Pharmacological Targets and Drug Action 35 1.5.2 Functional Adaptation Processes 39 1.5.3 Biomarkers, Surrogate Endpoints, and Clinical Endpoints 41 Keywords 47 References 48 2 A Review of Drug–Drug Interactions 51 2.1 Introduction 51 2.2 Drug Interactions Mediated by Enzymes and Transporters at Various Sites 54 2.3 Factors Affecting DDI 54 2.4 In Vitro Methods to Evaluate Drug–Drug Interactions 56 2.4.1 Candidate Drug as a Potential Perpetrator 57 2.4.2 Candidate Drug as a Potential Victim of Inhibition 58 2.5 Sources of Uncertainty 59 2.6 Therapeutic Protein–Drug Interaction 59 References 61 3 Modeling Pharmacokinetics, Pharmacodynamics, And Drug Interactions 65 3.1 Introduction 66 3.2 Modeling Pharmacokinetics 66 3.2.1 Compartmental Modeling of Linear and Nonlinear Pharmacokinetics (Enzyme and/or Transporter Capacity Limitation as Well as Target-Mediated Drug Disposition) 67 3.2.2 Population Pharmacokinetics 76 3.3 Pharmacokinetics/Pharmacodynamics and PK/Efficacy (Exposure/ Response) Modeling 80 3.3.1 PK/PD Models for Direct Effect: Sigmoid Emax Model 84 3.3.2 PK/PD Models for Direct Effect: Classical Receptor Theory 86 3.3.3 PK/PD Models Accommodating Delayed Pharmacological Response 89 3.3.4 PK/PD Models Accommodating Functional Adaptation Leading to Nonlinearity in Pharmacological Response with Respect to Time 96 3.3.5 PK/Efficacy Modeling 97 3.3.6 Translation of PK/PD and PK/Efficacy Modeling to Human 100 3.3.7 Average, Minimum, and Maximum Steady-State Concentrations 104 3.3.8 Estimation of Biologically Effective Dose in Human 107 3.3.9 Therapeutic Window 109 3.3.10 Static Models for Drug Interactions 109 3.4 Physiologically Based Pharmacokinetic (PBPK) Modeling and Its Integration with Pharmacodynamics and Efficacy Models 112 3.4.1 PK Modeling Compartmental vs PBPK 112 3.4.2 PK Variability: Population PK (popPK) Modeling vs PBPK 114 3.4.3 Integration of PBPK with PD, Quantitative Systems Pharmacology (QSP) Models or Quantitative Systems Toxicologyand Safety (QSTS) 114 3.4.4 PBPK Models to Evaluate Drug–Drug Interactions 115 3.4.5 DDI Risk Assessment with PBPK vs Static Models 118 Keywords 123 References 125 4 Physiological Model For Absorption 129 4.1 Introduction 130 4.2 Drug Absorption and Gut Bioavailability 130 4.2.1 Solubility and Dissolution Rate 130 4.2.2 Permeability: Transcellular, Paracellular, and Carrier-Mediated Pathways 136 4.2.3 Barriers to Membrane Transport – Luminal Degradation, Efflux, and Gut Metabolism 138 4.3 Factors Affecting Drug Absorption and Gut Bioavailability 140 4.3.1 Physiological Factors Affecting Oral Drug Absorption and Species Differences in Physiology 140 4.3.2 Compound-Dependent Factors 144 4.3.3 Formulation-Dependent Factors 144 4.4 In Silico Predictions of Passive Permeability and Solubility 147 4.4.1 In Silico Models for Permeability 147 4.4.2 In Silico Models for Solubility 147 4.5 Measurement of Permeability, Solubility, Luminal Stability, Efflux, Intestinal Metabolism 148 4.5.1 In Vitro, In Situ, and In Vivo Models for Effective Permeability 148 4.5.2 Measurement of Thermodynamic or Equilibrium Solubility 153 4.5.3 Luminal Stability 154 4.5.4 Efflux 154 4.5.5 In Vitro Models for Gut Metabolism and Estimation of Fraction Escaping Gut Metabolism 155 4.6 Absorption Modeling 156 Keywords 162 References 163 5 Physiological Model For Distribution 169 5.1 Introduction 170 5.2 Factors Affecting Tissue Distribution of Xenobiotics 170 5.2.1 Physiological Factors and Species Differences in Physiology 171 5.2.2 Compound-Dependent Factors 176 5.3 In Silico Models of Tissue Partition Coefficients 176 5.4 Measurement of Parameters Representing the Rate and Extent of Tissue Distribution 181 5.4.1 Assessment of Rate and Extent of Brain Penetration 181 5.5 Physiological Model for Drug Distribution 186 5.6 Drug Concentrations at the Site of Action 187 Keywords 189 References 189 6 Physiological Models For Drug Metabolism And Excretion 193 6.1 Introduction 193 6.2 Factors Affecting Drug Metabolism and Excretion of Xenobiotics 194 6.3 Models for Hepatobiliary and Renal Excretion 197 6.3.1 In Silico Models 197 6.3.2 In Vitro Models for Hepatic Metabolism 197 6.3.3 In Vitro Models for Transporters 200 6.4 Physiological Models 203 6.4.1 Hepato-Biliary Elimination of Parent Drug and Metabolites 205 6.4.2 Renal Excretion 208 References 211 7 Generic Whole-Body Physiologically Based Pharmacokinetic Modeling 217 7.1 Introduction 217 7.2 Structure of a Generic Physiologically-Based Pharmacokinetic (PBPK) Model 218 7.3 Somatic Compartments 220 7.3.1 Lungs (LU) 220 7.3.2 Arterial Blood (ART) 220 7.3.3 Venous Blood (VEN) 220 7.3.4 Stomach (ST) 220 7.3.5 Gut (GU) 220 7.4 Model Assumptions 221 7.5 PBPK Software 221 References 223 8 Pbpk Modeling Of Biotherapeutics 225 8.1 Introduction 226 8.2 Therapeutic Proteins 226 8.2.1 Peptides and Proteins 226 8.2.2 Antibodies and Antibody-Based Therapies 227 8.3 Pharmacokinetics of Therapeutic Proteins 234 8.3.1 Absorption 234 8.3.2 Renal Elimination 235 8.3.3 Immunogenicity 235 8.3.4 PEGylation 239 8.3.5 Transport by Convective and Transcytotic Extravasation 239 8.3.6 Catabolic Elimination (Proteolysis) 239 8.3.7 FcRn-Mediated Protection of IgGs Against Catabolism in FcRn-Rich Cells 241 8.3.8 Distribution and lymphatic elimination 242 8.3.9 Target-Mediated Drug Disposition and Receptor-Mediated Endocytosis 243 8.4 PBPK Modeling of Monoclonal Antibodies 244 8.4.1 Full PBPK Model for Monoclonal Antibodies 244 8.4.2 Minimal PBPK Model for Monoclonal Antibodies 253 8.5 Applications of PBPK Modeling of Monoclonal Antibodies 253 8.5.1 Pharmacokinetic Scaling 253 8.5.2 PBPK Integration with Pharmacodynamics of Monoclonal Antibodies 255 Keywords 156 References 258 9 Uncertainty And Population Variability 263 9.1 Introduction 264 9.2 Distinguishing Uncertainty and Variability 264 9.3 Sources of Uncertainty in Drug-related Parameters 264 9.4 Sources of Variability in System Parameters 266 9.5 Handling Population Variability 269 9.5.1 A POSTERIORI and A PRIORI Approaches to Handling Population Variability 269 9.5.2 Correlations Between Parameters 271 9.6 Uncertainty and Sensitivity Analysis 272 9.6.1 Local Sensitivity Analysis (One-at-a-time (OAT) and Derivative-based Methods) 272 9.6.2 Parameter Interactions and Global Sensitivity Analysis (GSA) 275 9.6.3 Global Sensitivity Analysis for Correlated Parameters (cGSA) 278 9.6.4 Applications of Sensitivity Analysis for PBPK Models 280 9.6.5 Limitations of Global Sensitivity Analysis 281 9.7 Uncertainty and Population Variability in Clinical Efficacy and Safety 282 Keywords 285 References 285 10 Nonclinical, Clinical, and Model-Informed Drug Development 293 10.1 Introduction: An Overview of Different Phases of Drug Development 294 10.2 Nonclinical Development 295 10.2.1 Preclinical Pharmacology, PK/PD Modeling, and Human Dose Prediction 297 10.2.2 Safety and Toxicology Studies 297 10.2.3 Studies with Radiolabeled Compound 298 10.3 Clinical Pharmacology Studies 302 10.3.1 First-in-Human, Single, and Multiple Ascending Dose Studies 302 10.3.2 Biopharmaceutics – Absolute Oral Bioavailability and Bioequivalence Study 304 10.3.3 Food Effect Study 304 10.3.4 Organ (Hepatic and Renal) Impairment Study 305 10.3.5 Pediatric Assessment 306 10.3.6 Mass Balance Study 307 10.3.7 Drug Interaction Study 307 10.3.8 Pharmacogenomics Study 308 10.3.9 Thorough QT (TQT) and Concentration QT (C-QT) Study 308 10.3.10 Immunogenicity Assays and Comparability Study for Biologics 309 10.3.11 Drug Labelling 309 10.4 Clinical Development in Oncology 310 10.5 Fast Track Routes to Address Unmet Medical Need in the Treatment of Serious Conditions 311 10.6 Model-Informed Drug Development 312 10.7 Physiologically Based Pharmacokinetic Models Complementing Clinical Pharmacology Studies 314 10.8 PBPK in Oncology 315 Regulatory Guidelines 316 References 319 Section II. Applications In The Pharmaceutical Industry 323 11 Overview Of Pbpk Applications 325 11.1 Introduction 325 11.2 PBPK Applications for Internal Decisions 326 11.3 PBPK Applications for Regulatory Filing 328 11.4 PBPK Modeling and Simulations Along the Value Chain 332 References 335 12 Applications Of Hypothesis Generation And Testing With Pbpk Models 337 12.1 Introduction 338 12.2 Hypothesis Generation and Testing with PBPK Models 338 12.2.1 Parameter Estimation from Intravenous Pharmacokinetic Profiles 338 12.2.2 Simulation of Oral PK Profile 341 12.2.3 Sensitivity Analysis 342 12.2.4 Verification of Hypotheses 346 12.2.5 Auto-inhibition of Drug-Metabolizing Enzymes, Uptake and Efflux Transporters 347 12.3 Hypothesis Generation and Testing Along the Value Chain 348 12.4 Conclusions 351 References 351 13 Applications of Physiologically Based Pharmacokinetic Models Integrated With Drug Effect Models (Pbpk/Pd) 353 13.1 Introduction: Integration of PBPK with Drug Effect Models 354 13.2 Dosing in Specific Populations 355 13.3 PBPK/PD for Bottom-Up Prediction of Inter-Patient Variability in Drug Response 357 13.4 PBPK/PD for Predicting the Inter-Patient Variability in Response to Prodrugs and Active Metabolites 358 13.5 PBPK/PD When Systemic Concentrations are not the Driver forDrug Response 359 13.5.1 Pre-Systemic Drug Target 359 13.5.2 Effect-Site Drug Concentration Different from Systemic Concentration 360 13.6 PBPK/PD for Monoclonal Antibodies 362 13.7 PBPK Models Linked to Quantitative Systems Pharmacology and Toxicology Models 363 13.7.1 PBPK–QST Models to Predict Drug-Induced Liver Injury 363 13.7.2 PBPK–QST Models to Predict Drug-Induced Cardiotoxicity 367 13.8 Conclusions 371 References 371 14 Pbpk Modeling and Simulations to Evaluate Clinical Drug-Drug Interactions 375 14.1 Introduction 376 14.2 Clinical DDI Studies and Modeling Approaches to Address Key Questions Related to Drug–Drug Interactions 376 14.2.1 Dedicated Clinical DDI Studies 378 14.2.2 Investigation of Phenotypic Effects for NMEs Predominantly Cleared by Polymorphic Enzyme or Transporter 379 14.2.3 Prospective Nested DDI Study 380 14.2.4 Cocktail DDI Study 381 14.2.5 PBPK Modeling and Simulations 381 14.2.6 Claims Relating to Results of DDI Studies 381 14.2.7 Impact on Label 382 14.3 PBPK Modeling of Different Types of Drug Interactions 382 14.3.1 PBPK Modeling Strategy: New Molecular Entity as Victim of CYP-Based Drug Interactions 382 14.3.2 PBPK Modeling Strategy: New Molecular Entity as Perpetrator of CYP-Based Drug Interactions 383 14.3.3 Non-CYP Based Drug Interactions 384 14.3.4 Transporter-Mediated Drug Interactions 385 14.4 DDI Predictions with PBPK Modeling and Simulations in Clinical Drug Development and Regulatory Submissions 387 14.4.1 DDI Predictions Along the Value Chain (Figure 14.5) 387 14.4.2 Possible Regulatory Outcomes, Based on the Predictions from a Verified and Validated PBPK Model 389 14.4.3 Regulatory Acceptance of PBPK Analyses Included in Regulatory Submissions 390 14.4.4 Predictive Performance of PBPK Models 391 14.5 Comparison of DDI Prediction Using Static and Dynamic Models 392 14.6 Conclusions 393 References 394 15 Dose Extrapolation Across Populations (Healthy Adult Caucasian To Pediatric, Pregnant Women, Different Ethnicities, Geriatric, Smokers And Obese Populations) 397 15.1 Introduction 398 15.2 PBPK Modeling Strategy for Dose Extrapolation to Specific Populations 398 15.3 Potential Benefits of PBPK Modeling for Dose Extrapolations to Specific Populations 399 15.4 Dose Extrapolations to Specific populations 404 15.4.1 Pediatric Starting Dose Selection 404 15.4.2 Pregnancy 406 15.4.3 Ethnicity – Japanese Population 407 15.4.4 Geriatric Population 408 15.4.5 Obese 409 15.4.6 Smokers 410 15.5 Conclusions 410 References 411 16 Dose Extrapolation Across Populations: Healthy Adult To Hepatic And Renal Impairment Populations 417 16.1 Introduction 418 16.2 Pathophysiological Changes in Organ Impairment 419 16.2.1 Hepatic Impairment 419 16.2.2 Renal Impairment 420 16.3 PBPK Modeling Strategy: Model Development, Verification, Validation, and Application 420 16.4 Benefits of Applying Validated PBPK Models to Organ-Impaired Populations 421 16.4.1 Enhancing Regulatory Confidence in the Application of PBPK Modeling for the Prediction of Exposure in the Organ-Impaired Population 421 16.4.2 Contribution of PBPK to the Totality of Evidence in Evaluating the Effect of Renal Impairment on Drug Exposure to Inform Labelling 424 16.5 Conclusions 425 References 426 17 Absorption-Related Applications Of Pbpk Modeling 429 17.1 Introduction 429 17.2 In Vitro – In Vivo Disconnect, Parameter Non-Identifiability and the Importance of Identifying Factors Limiting Absorption Through a Deconvolution of the Mechanisms Contributing to Gut Bioavailability 431 17.3 Non-Regulatory Internal Applications of PBPK Modeling and Simulations 433 17.3.1 Prediction of Fraction Absorbed 433 17.3.2 Oral Formulation Development 433 17.4 Regulatory Applications of PBPK Modeling and Simulations 438 17.4.1 Food–Drug Interactions 438 17.4.2 Interactions of a Poorly Soluble Weak Base with Acid Reducing Agents (ARAs) 444 17.4.3 In Vitro – In Vivo Correlations (IVIVCs) to Serve as Surrogate for Bioequivalence Testing (Case Study 12) 445 17.4.4 Biowaivers Based on Virtual Bioequivalence 449 17.4.5 Virtual Bioequivalence of Locally Acting Products (LAPs) 450 17.5 Conclusions 450 References 452 18 Regulatory Guidelines On The Reporting Of Physiologically Based Pharmacokinetic (Pbpk) Modeling Analysis 457 18.1 Introduction 457 18.2 Food and Drug Administration (FDA) Guidelines 458 18.3 European Medicines Agency (EMA) Guidelines 459 18.4 Comparison of FDA and EMA Guidelines 461 18.5 Risk-Informed Evidentiary Framework to Assess PBPK Model Credibility 463 18.6 Drug Model Verification of Locally Acting Products (LAPs) 464 References 466 19 Resolving The Challenges To Establishing Confidence In Pbpk Models 469 19.1 Introduction 470 19.2 Requirements for Developing Mechanistically Credible PBPK Models for the Three Broad Categories of Applications 470 19.3 Challenges to Developing Mechanistically Credible PBPK Models and Consequences 473 19.3.1 Model Building 473 19.3.2 Model Verification of Predicted Exposure and Validation of Predictive Performance 476 19.4 Resolving the Challenges to Developing Mechanistically Credible PBPK Models 476 19.5 Totality of Evidence 478 19.6 Conclusions 480 References 481 20 Epilogue 483 20.1 PBPK Modeling Successes 483 20.2 Challenges 484 20.2.1 Drug Model Parameterization 484 20.2.2 Knowledge Gaps in Physiological Parameters 485 20.2.3 Prospective Validation of Prediction Performance 485 20.3 Meeting the Challenges 485 20.4 Future Directions for PBPK Modeling 486 References 488 Section III. Case Studies Of Pbpk Applications In The Pharmaceutical Industry 491 Case Study 1 Hypothesis Testing (Solubility) 493 Case Study 2 Hypothesis Testing (Gastric Emptying) 499 Case Study 3 Hypothesis Testing (Intestinal Loss) 505 Case Study 4 Pbpk/Pd 509 Case Study 5 Drug–Drug Interaction (Inhibition) 515 Case Study 6 Drug–Drug Interaction (Induction) 521 Case Study 7 Genetic Polymorphism 527 Case Study 8 Pediatric Extrapolation 535 Case Study 9 Pregnancy 541 Case Study 10 Hepatic Impairment 547 Case Study 11 Renal Impairment 555 Case Study 12 Absorption – Ivivc 561 Appendices 567 Index 579

Read more less

Book SynopsisLearn to implement effective control measures for mutagenic impurities in pharmaceutical development InMutagenic Impurities: Strategies for Identification and Control,distinguished chemist Andrew Teasdale deliversa thorough examinationof mutagenic impurities and their impact on the pharmaceutical industry. The book incorporates the adoption of the ICH M7 guideline and focuses on mutagenic impurities from both a toxicological and analytical perspective. The editor has created a primary reference for any professional or studentstudying or working with mutagenic impurities and offers readers a definitive narrative of applicable guidelines and practical, tested solutions. It demonstrates the development of effective control measures, including chapters onthe purge tool for risk assessment. The book incorporates a discussion of N-Nitrosamines which was arguably the largestmutagenic impurityissue ever faced by the pharmaceutical industry, resulting in thTable of ContentsList of Contributors xix Preface xxi Section 1 The Development of Regulatory Guidelines for Mutagenic/Genotoxic Impurities – Overall Process 1 1 Historical Perspective on the Development of the EMEA Guideline and Subsequent ICH M7 Guideline 3Andrew Teasdale 1.1 Introduction 3 1.1.1 CPMP – Position Paper on the Limits of Genotoxic Impurities –2002 4 1.1.1.1 Scope/Introduction 4 1.1.1.2 Toxicological Background 4 1.1.1.3 Pharmaceutical (Quality) Assessment 4 1.1.1.4 Toxicological Assessment 4 1.1.2 Guideline on the Limits of Genotoxic Impurities – Draft June 2004 5 1.1.3 PhRMA (Mueller) White Paper 6 1.1.4 Finalized EMA Guideline on the Limits of Genotoxic Impurities – June 2006 8 1.1.4.1 Issues Associated with Implementation 9 1.1.4.2 Control Expectations for Excipients 11 1.1.4.3 Control Expectations for Natural/Herbal Products 12 1.1.4.4 Identification of Potential Impurities 12 1.1.4.5 The Principle of Avoidance 12 1.1.4.6 The ALARP Principle 14 1.1.4.7 Overall 14 1.1.5 SWP Q&A Document 14 1.1.5.1 The Application of the Guideline in the Investigational Phase and Acceptable Limits for GIs Where Applied to Studies of Limited Duration 14 1.1.5.2 Application of the Guideline to Existing Products 15 1.1.5.3 Avoidance and ALARP 17 1.1.5.4 ICH Identification Threshold and its Relation to MI Assessment 17 1.1.6 FDA Draft Guideline 17 1.1.7 Other Relevant Guidance 17 1.1.7.1 Excipients 18 1.1.8 Herbals 18 1.1.9 ICH S9 18 1.1.10 Conclusions 19 References 19 2 ICH M7 – Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk 21Andrew Teasdale and Raphael Nudelman 2.1 Introduction 21 2.2 ICH M7 22 2.2.1 Introduction 22 2.2.2 Scope 22 2.2.2.1 Established Products 22 2.2.2.2 Anticancer Treatments 23 2.2.2.3 Nature of Therapeutic Agent/Excipients 23 2.2.3 General Principles 24 2.2.4 Considerations for Marketed Products 25 2.2.4.1 Post-approval Changes to Drug Substance, Chemistry, and Manufacturing Controls 26 2.2.4.2 Post-approval Changes to Drug Product Chemistry, Manufacturing, and Controls 26 2.2.4.3 Changes to the Clinical Use of Drug Products 26 2.2.5 Other Considerations for Marketed Products 27 2.2.6 Drug Substance and Drug Product Impurity Assessment 27 2.2.6.1 Synthetic Impurities 28 2.2.6.2 Degradation Products 28 2.2.7 Hazard Assessment 29 2.2.8 Risk Characterization 32 2.2.8.1 Acceptable Intakes Based on Compound-specific Risk Assessments 32 2.2.8.2 Acceptable Intakes for Class 2 and Class 3 Compounds 33 2.2.8.3 Multiple Impurities 34 2.2.8.4 Exceptions and Flexibility in Approaches 35 2.2.9 Control Strategy 35 2.2.9.1 Considerations for Control Approaches 37 2.2.9.2 Considerations for Periodic Testing 37 2.2.9.3 Control of Degradation Products 38 2.2.10 Lifecycle Management 38 2.2.11 Documentation 38 2.2.11.1 Clinical Trail Applications 38 2.2.11.2 Common Technical Document (Marketing Application) 39 2.2.12 Other Aspects 39 2.2.12.1 Relationship Between ICH M7 and ICH Q3A 39 2.3 Conclusions 40 2.4 Commentary on ICH M7 Questions and Answers 40 2.4.1 Section 1 – Introduction 41 2.4.1.1 Question 1.1 41 2.4.1.2 Question 1.2 42 2.4.1.3 Question 1.3 42 2.4.1.4 Question 1.4 42 2.4.2 Section 2 – Scope 43 2.4.2.1 Question 2.1 43 2.4.3 Section 3 – General Principles 43 2.4.3.1 Question 3.1 44 2.4.3.2 Question 3.2 44 2.4.4 Section 4 – Considerations for Marketed Products 44 2.4.4.1 Question 4.1 45 2.4.5 Section 5 – Drug Substance and Drug Product Impurity Assessment 45 2.4.6 Section 6 – Hazard Assessment Elements 45 2.4.6.1 Question 6.1 45 2.4.6.2 Question 6.2 46 2.4.6.3 Question 6.3 47 2.4.6.4 Question 6.4 48 2.4.7 Section 7 – Risk Characterization 48 2.4.7.1 Question 7.1 48 2.4.7.2 Question 7.2 49 2.4.7.3 Question 7.3 49 2.4.7.4 Question 7.4 50 2.4.7.5 Question 7.5 51 2.4.8 Section 9 – Documentation 53 References 55 3 Control Strategies for Mutagenic Impurities 57Andrew Teasdale, Michael Burns, and Michael Urquhart 3.1 Introduction 57 3.2 Assessment Process 58 3.2.1 General 58 3.2.2 Step 1 – Evaluation of Drug Substance and Drug Product Processes for Sources of Potentially Mutagenic Impurities 60 3.2.3 Step 2 – Structural Assessment 61 3.2.4 Step 3 – Classification 61 3.2.5 Step 4 – Assessment of Risk of Potential Carryover of Impurities 63 3.2.6 Overall Quantification of Risk 63 3.2.6.1 Predicted Purge Factor 64 3.2.6.2 Required Purge Factor 65 3.2.6.3 Purge Ratio 66 3.2.6.4 High Predicted Purge 67 3.2.6.5 Moderate Predicted Purge 67 3.2.6.6 Low Predicted Purge 67 3.2.6.7 ICH M7 Control Option 1, 2, or 3 67 3.2.6.8 Step 5 – Further Evaluation 67 3.2.6.9 Safety Testing 67 3.2.7 Quantification of Level Present 68 3.3 Step 6 – Overall Risk Assessment 69 3.4 Further Evaluation of Risk – Purge (Spiking) Studies 70 3.5 Conclusion 70 3.6 Case Studies 71 3.6.1 Case Study 1 – GW641597X 71 3.6.1.1 Ethyl Bromoisobutyrate 2 73 3.6.1.2 Hydroxylamine 74 3.6.1.3 Alkyl Chloride 8 75 3.6.1.4 Additional Evidence for the Purging of Ethyl Bromoisobutyrate and Alkyl Chloride 8 76 3.6.2 Proposed ICH M7-aligned Potential Mutagenic Control Regulatory Discussion 78 3.6.3 Case Study 2 – Candesartan 78 References 84 Section 2 In Silico Assessment of Mutagenicity 87 4 Use of Structure–Activity Relationship (SAR) Evaluation as a Critical Tool in the Evaluation of the Genotoxic Potential of Impurities 89Catrin Hasselgren and Glenn Myatt 4.1 Introduction 89 4.2 (Q)SAR Assessment 90 4.2.1 Looking-up Experimental Data 90 4.2.2 (Q)SAR Methodologies 91 4.2.2.1 Overview 91 4.2.2.2 OECD Validation Principles 91 4.2.3 Expert Rule-Based Methodology 92 4.2.4 Statistical-Based Methodology 95 4.2.5 Applying (Q)SAR Models 97 4.2.6 Expert Review 98 4.2.6.1 Overview 98 4.2.6.2 Refuting a Statistical-Based Prediction 100 4.2.6.3 Mechanistic Assessment 101 4.2.6.4 Assessing Lack of Chemical Reactivity 101 4.2.7 Class Assignment 103 4.2.7.1 Overview 103 4.2.8 Documentation 109 4.3 Discussion 109 4.4 Conclusions 110 Acknowledgments 111 References 111 5 Evolution of Quantitative Structure–Activity Relationships ((Q)SAR) for Mutagenicity 115James Harvey and David Elder 5.1 Introduction 115 5.2 Pre ICH M7 Guideline 116 5.3 Post ICH M7 117 5.3.1 Evolution of (Q)SAR Platforms 117 5.3.2 Robust Negative In Silico (Q)SAR Predictions 118 5.3.3 Development of Composite (Q)SAR Models 119 5.3.4 Expansion of Training Data Sets to Enhance the Predictive Power of (Q)SAR Tools 120 5.3.5 Focused Data Sharing Initiatives on Specific Chemical Classes 120 5.3.5.1 Understanding In Vitro Mechanisms Leading to Mutagenicity 121 5.3.5.2 Shared Data, Shared Progress 122 5.3.6 Novel Data Mining Approaches 125 5.3.6.1 Case Study: Primary Aromatic Amines (PAAs) 125 5.3.6.2 Case Study: Aromatic N-oxides 125 5.4 Expert Knowledge 127 5.5 Future Direction 129 References 131 Section 3 Toxicological Perspective on Mutagenic Impurities 137 6 Toxicity Testing to Understand the Mutagenicity of Pharmaceutical Impurities 139Andrew Teasdale, John Nicolette, Joel P. Bercu, James Harvey, Stephen Dertinger, Michael O’Donovan, and Christine Mee 6.1 Introduction 139 6.2 In Vitro Genotoxicity Tests 141 6.2.1 Background 141 6.2.2 Bacterial Reverse Mutation or “Ames” Test 142 6.2.3 Modifications to the Standard Ames Test 145 6.2.3.1 Six-well Ames Assay 146 6.2.4 Test Strategy 146 6.3 In Vivo Mutation Assays 148 6.3.1 In Vivo Pig-a Gene Mutation Assay 148 6.3.2 Rodent Micronucleus Test 152 6.3.3 Rodent “Comet” Assay 155 6.3.4 Transgenic Rodent (TGR) Mutation Assay 155 6.4 Conclusions 158 Glossary 159 References 160 7 Compound-and Class-Specific Limits for Common Impurities in Pharmaceuticals 165Joel P. Bercu, Melisa J. Masuda-Herrera, Alejandra Trejo-Martin, David J. Snodin, Kevin P. Cross, George E. Johnson, James Harvey, Robert S. Foster, David J. Ponting, and Richard V. Williams 7.1 Introduction 165 7.2 Monograph Development 167 7.2.1 Exposure to the General Population 167 7.2.2 Mutagenicity/Genotoxicity 170 7.2.3 Noncarcinogenic Effects 170 7.2.4 Carcinogenic Effects 170 7.2.5 Mode of Action (MOA) and Assessment of Human Relevance 171 7.2.6 Toxicokinetics 171 7.2.7 Regulatory/Published Limits 171 7.3 Derivation of the Compound-specific Limit 171 7.3.1 PoD Selection 172 7.3.2 Limited Data Sets 172 7.3.3 PDE Development 172 7.3.4 AI Development 172 7.3.5 Class-specific Limit 173 7.3.6 Less than Lifetime (LTL) AIs 173 7.4 Examples of Published Compound-specific Limits 173 7.4.1 Mutagenic Carcinogens 173 7.4.2 Nonmutagenic Carcinogens 176 7.4.3 Mutagenic Noncarcinogens 176 7.4.4 Nonmutagenic Compounds 176 7.4.5 Mutagenic In vitro but not In vivo 176 7.4.6 Route of Administration-specific Limits 177 7.5 Class-specific Limits 177 7.5.1 Alkyl Chlorides 177 7.5.2 Alkyl Bromides 178 7.5.3 N-Nitrosamines 178 7.5.3.1 Regulatory Limits for N-Nitrosamines 178 7.5.3.2 Additional Proposed Limits for N-Nitrosamines 180 7.5.3.3 N-Nitrosamine Exposure in the General Population 181 7.5.3.4 Developing a Class-specific Limit for N-Nitrosamines 182 7.5.4 Arylboronic Acids and Esters 193 7.6 EMS Case Study and Updated Toxicity Analysis 196 7.6.1 Potential for Human Exposure 196 7.6.2 Mutagenicity/Genotoxicity 196 7.6.3 Noncarcinogenic Effects 198 7.6.4 Carcinogenicity 199 7.6.5 Regulatory and/or Published Limits 199 7.6.6 Permitted Daily Exposure 199 7.7 Extractables and Leachables 202 7.8 Lhasa AI/PDE Database for Impurities 203 7.9 Conclusions and Future Directions 203 Acknowledgments 204 References 204 8 Genotoxic Threshold Mechanisms and Points of Departure 213George E. Johnson, Shareen H. Doak, Gareth J.S. Jenkins, and Adam D. Thomas 8.1 Introduction to Genotoxic Dose Responses 213 8.1.1 The Linear Default Position for Genotoxic Carcinogens 213 8.1.2 Theoretical Evidence for Rejecting the Linear Approach 214 8.1.3 In Vitro Experimental Evidence for Threshold Mechanism 215 8.1.4 In Vivo Evidence for Genotoxic Thresholds 218 8.2 Threshold Mechanisms 221 8.2.1 Statistical Assessment of Dose Response Data Sets 224 8.2.2 Extrapolation from One Chemical to Another 224 8.2.3 Extrapolation of Threshold Mechanisms and PoDs to Populations 225 8.3 Conclusions 227 References 227 Section 4 Quality Perspective on Genotoxic Impurities 233 9 Mutagenic Impurities – Assessment of Fate and Control Options 235Michael W. Urquhart, Andrew Teasdale, and Michael Burns 9.1 Introduction/Background 235 9.2 Reactivity 236 9.2.1 Reactivity Classification 238 9.3 Solubility – Isolated Stages 238 9.4 Recrystallization 239 9.4.1 Solubility – Liquid/Liquid Partitioning 239 9.5 Volatility 241 9.6 Chromatography 241 9.7 Other Techniques 242 9.7.1 Activated Charcoal 242 9.7.2 Scavenger Resins 242 9.8 Overall Quantification of Risk 243 9.9 Alignment to ICH M7 – Control Options 244 9.10 Control Option Selection 247 9.10.1 Predicted Purge Factor 248 9.10.2 Required Purge Factor 249 9.10.3 Purge Ratio 249 9.10.4 High Predicted Purge 250 9.10.5 Moderate Predicted Purge 250 9.10.6 Low Predicted Purge 250 9.10.7 ICH M7 Control Option 1, 2, or 3 251 9.10.8 Representative Data to be Supplied in Regulatory Submission Under an ICH M7 Control Strategy 251 9.10.9 Summary of PMI Purging Across the Synthetic Route 251 9.10.10 Details of Individual Impurity Purging Through the Subsequent Downstream Chemistry 253 9.10.11 Development of a Knowledge Base Expert In Silico System 254 9.10.12 Experimental Work to Assess Reactivity 257 9.11 Utilizing Mirabilis for a Purge Calculation 259 9.11.1 Utility of In Silico Predictions 260 9.11.1.1 Case Study – Camicinal [38] 260 References 266 10 N-Nitrosamines 269Andrew Teasdale, Justin Moser, J. Gair Ford, and Jason Creasey 10.1 Background 269 10.2 Generation of N-Nitrosamines 270 10.3 Article 31 273 10.4 Further Issues – Cross Contamination and Ranitidine 275 10.4.1 Article 5(3) and Associated Q&A Document 276 10.5 How to Assess the Risk Posed in Pharmaceuticals 278 10.5.1 Drug Substance 278 10.5.1.1 Where do Nitrites Come Within Drug Substance Come From? 278 10.5.1.2 What Other Sources Are There? 278 10.5.1.3 Other Factors Associated with Drug Substance Synthesis 280 10.5.2 Process to Assess Drug Substance-Related Risk 280 10.5.3 Drug Product-Related Risk 282 10.5.3.1 Related Risks of Contamination and Formation in Drug Products 282 10.5.4 Container Closure Systems 289 10.5.5 Elastomeric Components 291 10.5.6 Nitrosamine Impurities in Biologics 293 10.5.6.1 Active Substance 293 10.5.6.2 The Water Used in Formulation Is Depleted in Nitrosating Agents 295 10.5.6.3 Bioconjugated or Chemically Modified Products 295 10.5.6.4 Excipients 296 10.6 Regulatory Guidance Pursuant to N-Nitrosamines and its Implications 297 10.6.1 Article 31 Process and Outcomes 297 10.6.1.1 Article 31 Request 297 10.6.2 Sartans Lessons Learnt Report 298 10.6.2.1 Reflection on the Initial Section of the EMA Report 299 10.6.3 Article 5(3) Report 299 10.6.3.1 Quality 299 10.6.3.2 Consideration for Analytical Method Development to Identify and Quantify N-Nitrosamines in Drug Substances and Medicinal Products 300 10.6.3.3 Safety 301 10.6.3.4 Conclusions 305 10.6.4 EMA Question and Answer Document [6] 305 10.6.4.1 Further Revision of the EMA Question and Answer Document 310 10.6.5 FDA Guideline 310 10.6.5.1 Introduction and Background 310 10.6.5.2 Recommendations 310 10.6.5.3 Acceptable Intakes (section III.A) 313 10.6.5.4 Quality/Chemistry and Controls 314 10.7 Way Forward 315 Acknowledgments 316 References 317 11 Conditions Potentially Leading to the Formation of Mutagenic Impurities 321Lucie Lovelle, Andrew Teasdale, Ian Ashworth, Adrian Clarke, and Alan Steven 11.1 Problematic Reagent Combinations per Structural Alert 323 11.1.1 N-Nitroso Compounds (COC) 323 11.1.1.1 Amines and Nitrosating Agents [10] 323 11.1.1.2 Amine Derivatives and Nitrosating Agents 324 11.1.1.3 Other 324 11.1.2 Alkyl-azoxy Compounds (COC) 325 11.1.2.1 Reduction [52–54] 325 11.1.2.2 Oxidation 325 11.1.2.3 Others 325 11.1.3 Other N-O Compounds 326 11.1.3.1 Reduction of Nitro Groups 326 11.1.3.2 Oxidation of Amines and Hydroxylamines 326 11.1.4 Nitration 326 11.1.5 Other N-N Compounds [59, 60] 326 11.1.6 Aflatoxin-like Compounds [62] (COC) 327 11.1.7 Dioxin-like Compounds (Including Polychlorinated Biphenyls = PCBs) [63] 327 11.1.8 Alkyl and Acyl Halides 327 11.1.8.1 ROH + HCl → RCl + H2O 327 11.1.8.2 Ether Opening with Halides 328 11.1.9 Methyl Sulfoxides and Pummerer Rearrangement 328 11.1.10 Acyl Chlorides Formation [82] 329 11.1.11 Halogenation of Unsaturated Compounds 329 11.1.12 Ammonium Salts (Hofmann Elimination) 329 11.1.12.1 Alkyl Sulfonates [90] 329 11.1.13 Epoxides and Aziridines [95–97] 330 11.2 Miscellaneous 331 11.2.1 B and P Based Compounds 331 11.2.2 Formation of N-Methylol 331 11.2.3 Acetamide 332 11.2.4 Quinones and Quinone Derivatives 332 11.2.5 Anilines [100] 332 11.2.6 Michael Acceptors 333 11.2.7 Others 333 11.3 Mechanism and Processing Factors Affecting the Formation of N-nitrosamines 333 11.3.1 Introduction 333 11.3.2 Mechanisms of Amine Nitrosation 333 11.3.2.1 Nitrosation of Secondary Amines 333 11.3.2.2 Aqueous Nitrosation 334 11.3.2.3 Nitrosation in Organic Solvents 336 11.3.3 Nitrosation of Tertiary Amines 337 11.3.3.1 Nitrosation of Quaternary Amines 337 11.3.3.2 Nitrosation of Amine Oxides 338 11.3.4 Sources of Nitrosating Agents 338 11.3.4.1 Process Water 338 11.3.4.2 Nitric Acid 339 11.3.4.3 Atmospheric Sources 339 11.3.4.4 Excipients Used in Drug Product Manufacture 340 11.3.4.5 Nitrocellulose 340 11.3.4.6 Nitrosating Agent Scavengers 340 11.3.4.7 Removal of Nitrosamines 341 11.4 Formation, Fate, and Purge of Impurities Arising from the Hydrogenation of Nitroarenes to Anilines 341 11.4.1 Primary Reaction Mechanism 341 11.4.2 Mass and Heat Transfer Effects 342 11.4.3 Condensation Chemistry 344 11.4.4 Factors Affecting Aryl Hydroxylamine Accumulation 346 11.4.5 Aryl Hydroxylamine Control 347 11.4.5.1 Use of Cocatalysts 347 11.4.5.2 Physical Adsorption 348 11.4.5.3 Kinetic Understanding Around Formation and Consumption 349 11.4.5.4 Holistic Control of Impurity Profile 349 11.4.6 Controlling Residual Nitroarene 351 11.4.7 Specific Considerations of Alkyl Nitro Reductions 353 11.4.8 Closing Comments on Hydrogenation of Nitroarenes to Anilines 353 11.5 Mechanism and Processing Parameters Affecting the Formation of Sulfonate Esters – Summary of the PQRI Studies 353 11.5.1 Introduction 353 11.5.2 Reaction Mechanism 355 11.5.3 Experimental Results 357 11.5.3.1 Experimental Results from Study of the Ethyl Methanesulfonate (EMS) System 357 11.5.3.2 Other Methanesulfonic Acid Systems 359 11.5.3.3 Experimental Results from Study of the Isopropyl Methanesulfonate (IMS) System 360 11.5.4 Experimental Results from Study of Toluenesulfonic (Tosic) Acid Systems 361 11.5.4.1 Experimental Results from Study of the Ethyl Tosylate (ETS) System 362 11.5.4.2 Kinetic Modeling 363 11.5.4.3 Key Learnings and Their Implications for Process Design 365 11.5.4.4 Processing Rules 366 11.5.5 What About Viracept™? 366 11.5.6 What About Other Sources of Sulfonate Esters? 367 11.5.7 Potential for Ester Formation in the Solid Phase 368 11.5.8 Conclusions 369 References 369 12 Strategic Approaches to the Chromatographic Analysis of Mutagenic Impurities 381Frank David, Gerd Vanhoenacker, Koen Sandra, Pat Sandra, Tony Bristow, and Mark Harrison 12.1 Introduction 381 12.2 Method Development and Validation 384 12.3 Analytical Equipment for Mutagenic Impurity Analysis 385 12.4 Alkyl Halides and Aryl Halides 388 12.4.1 Method Selection 388 12.4.2 Typical Conditions Used for Alkyl-and Aryl Halide Analysis by SHS-GC-MS and SPME-GC-MS 390 12.4.2.1 Sample Preparation 390 12.4.2.2 GC-MS Parameters 391 12.4.3 Typical Results Obtained for Alkyl-and Aryl Halide Analysis by SHS-GC-MS and SPME-GC-MS 391 12.5 Sulfonates 393 12.5.1 Method Selection 393 12.5.2 Typical Conditions Used for Sulfonate Analysis by Derivatization SHS-GC-MS 394 12.5.2.1 Sample Preparation 395 12.5.2.2 Synthesis of Deuterated Internal Standards 395 12.5.2.3 GC-MS Parameters 395 12.5.3 Typical Results Obtained Using Derivatization – SHS – GC-MS 395 12.5.4 Confirmation Analysis by PTV-GC-MS 396 12.6 S-and N-mustards 398 12.6.1 Method Selection 398 12.6.2 Typical Analytical Conditions for the Analysis of N-mustards by Derivatization – SPME-GC-MS 399 12.6.2.1 Sample Preparation 399 12.6.3 Typical Results for N-mustards by Derivatization – SPME-GC-MS 399 12.7 Michael Reaction Acceptors 400 12.7.1 Method Selection 400 12.7.2 Typical Analytical Conditions for Michael Reaction Acceptors 400 12.7.2.1 Sample Preparation 401 12.7.2.2 Parameters for SHS-GC-MS 401 12.7.2.3 Parameters for Liquid Injection and GC-MS with Back-flush 402 12.7.3 Typical Results Obtained for Trace Analysis of Michael Reaction Acceptors 402 12.7.3.1 SHS with PTV 402 12.7.3.2 Liquid Injection GC-MS 403 12.8 Epoxides 404 12.8.1 Method Selection 404 12.8.2 Typical Analytical Conditions for the Analysis of Volatile Epoxides by SHS-GC-MS 406 12.8.2.1 Sample Preparation 406 12.8.2.2 SHS-GC-MS Parameters 406 12.8.3 Typical Results Obtained for Volatile Epoxides Using SHS-GC-MS 407 12.9 Haloalcohols 407 12.9.1 Method Selection 407 12.9.2 Analytical Conditions for Trace Analysis of Halo-alcohols by Derivatization and Liquid Injection - 2DGC-MS 409 12.9.2.1 Sample Preparation 409 12.9.2.2 2D-GC-MS Parameters 410 12.9.3 Typical Results for Analysis of Halo-alcohols by Derivatization and Liquid Injection - 2DGC-MS 410 12.10 Aziridines 411 12.10.1 Method Selection 411 12.10.2 Typical Analytical Conditions for RPLC-MS and HILIC-MS Analysis of Aziridines 412 12.10.2.1 Sample Preparation 412 12.10.2.2 RPLC-MS Method Parameters 413 12.10.2.3 HILIC-MS Method Parameters 413 12.10.3 Typical Results Obtained for Aziridine Analysis Using RPLC and HILIC 413 12.11 Arylamines and Amino Pyridines 414 12.11.1 Method Selection 414 12.11.2 Typical Analytical Conditions for Arylamines and Aminopyridines by RPLC-MSD 415 12.11.2.1 Sample Preparation 415 12.11.2.2 HPLC-MS Parameters 416 12.11.3 Typical Results for Arylamines and Aminopyridines by RPLC-MSD 417 12.12 Hydrazines and Hydroxylamine 419 12.12.1 Method Selection 419 12.12.2 Analytical Conditions for the Analysis of Hydrazines Using Derivatization and HPLC-MS 420 12.12.2.1 Sample Preparation 421 12.12.2.2 HPLC-MS Parameters 421 12.12.3 Typical Results Obtained for Hydrazines Using Derivatization LC-MS 421 12.13 Aldehydes and Ketones 423 12.13.1 Method Selection 423 12.13.2 Typical Analytical Conditions for Analysis of Aldehydes and Ketones by DNPH Derivatization, Followed by LC-MS Analysis 423 12.13.2.1 Sample Preparation 424 12.13.2.2 Derivatization Reagent Solution 425 12.13.2.3 HPLC-MS Parameters 425 12.13.3 Typical Results Obtained for Aldehyde Analysis by DNPH Derivatization – LC-MS 426 12.14 Nitrosamines 426 12.14.1 Method Selection 426 12.14.2 Sample preparation for SHS-GC-MS Analysis (according to ref [85]) 428 12.14.2.1 SHS-GC-MS Analysis [85] Sample Preparation 428 12.14.2.2 GC-MS (HRAM-MS) Conditions 428 12.14.2.3 UHPLC-MS Analysis 429 12.14.2.4 Sample Preparation for Hydrophilic Samples (e.g. Metformin) 429 12.14.2.5 Sample Preparation for Hydrophobic Matrices 430 12.14.2.6 UHPLC Conditions 430 12.14.2.7 HRAM-MS and MS/MS Conditions 430 12.14.3 Typical Results Obtained for Volatile N-nitrosamines Using SHS-GC-MS 430 12.14.4 Typical Results Obtained for N-nitrosamines Using LC-MS 431 12.15 Nontarget Analysis of PMI/MIs 434 12.16 Conclusions 435 Acknowledgements 436 References 436 13 Analysis of Mutagenic Impurities by Nuclear Magnetic Resonance (NMR) Spectroscopy 439Andrew R. Phillips and Stephen Coombes 13.1 Introduction to NMR 439 13.2 Why Is NMR an Insensitive Technique? 439 13.2.1 Nuclear Spin 439 13.2.2 Boltzmann Distribution 440 13.3 How Could NMR Be Used for Trace Analysis? 440 13.3.1 Generating an NMR Spectrum 440 13.3.2 Chemical Shift 442 13.3.3 Scalar Coupling 443 13.3.4 The Quantitative Nature of NMR 444 13.3.5 Relaxation 445 13.3.6 Summary 446 13.4 What Can Be Done to Maximize Sensitivity? 446 13.4.1 System Performance 447 13.4.1.1 Field Strength 447 13.4.2 Probe Performance 447 13.4.2.1 Probe Design 447 13.4.2.2 Probe Diameter 448 13.4.2.3 Cryogenically Cooled Probes 448 13.4.3 Substrate Concentration 449 13.4.4 Molecular Weight Ratio 451 13.4.5 Acquisition Time and Signal Averaging 451 13.4.6 Number of Protons and Linewidth 453 13.4.7 Resolution 455 13.4.8 Dynamic Range 455 13.4.8.1 Selective Excitation 458 13.4.8.2 Shaped Pulses 458 13.4.8.3 Quantification Using Selective Pulses 460 13.4.8.4 Excitation Sculpting 461 13.4.9 Limit Tests 461 13.4.9.1 Method Development 462 13.4.9.2 Validation 463 13.4.9.3 Unresolved Signals 463 13.4.9.4 Rapid Analysis 464 13.4.10 Expanded Use of MI NMR Methodology 464 13.4.11 Summary 464 13.5 Case Studies 464 13.5.1 Case Study 1 – An Aldehyde Functionalized MI 464 13.5.2 Case Study 2 – Use of 19F NMR 466 13.5.3 Case Study 3 – Epoxide and Chlorohydrin MIs 468 13.5.4 Case Study 4 – Sulfonate Esters 469 13.5.5 Case Study 5 – Limit Test for Poorly Resolved Signals 470 13.5.6 Case Study 6 – Using NMR MI Methodology for Cleaning Validation 472 13.6 Conclusion 473 References 475 14 Addressing the Complex Problem of Degradation-Derived Mutagenic Impurities in Drug Substances and Products 477Steven W. Baertschi and Andrew Teasdale 14.1 Introduction 477 14.1.1 Background 477 14.2 Working Definitions 478 14.3 Challenges Associated with the Assessment of Risk Posed by (Potentially) Mutagenic Degradation Products 479 14.4 Risk Assessment Process for Mutagenic Degradants 479 14.4.1 Stability-Related MRA Process Overview 479 14.4.2 Stress Studies 480 14.4.3 Accelerated Stability Studies 480 14.4.4 Long-term ICH Stability Studies 481 14.4.5 Deciding Which Products to Include in the MRA 481 14.4.6 In Silico Tools for the Prediction of Potential Degradation Products 482 14.5 Using Stress Testing to Select Degradation Products for Identification 482 14.5.1 Approach 1: Criteria for Structure Identification After Observation in Accelerated and Long-term Stability Studies 483 14.5.2 Approach 2: Criteria for Structure Identification Through Use of an Algorithm in Stress Testing Studies 483 14.5.3 Approach 3: Structure Identification Through Use of Kinetic Equivalence and Scaled ICH Q3B Thresholds 485 14.5.3.1 Kinetic Equivalence 485 14.5.3.2 Scaled ICH Q3B Thresholds 486 14.6 Development Timeline Considerations 487 14.6.1 Drug Discovery Stage 487 14.6.2 Preclinical to Phases 1/2 487 14.6.3 Phase 3 to New Drug Application (NDA) Regulatory Submission 488 14.6.4 Post-marketing/Line Extensions 488 14.7 Developing Control Strategies for (Potential) Mutagenic Degradation Products 488 14.7.1 Determining Relevancy of Potential Degradation Products and Developing Control Strategies for Actual Degradation Products 488 14.7.2 Accelerated Stability (40 °C/75% RH Six months) or Kinetic Equivalent 489 14.7.3 Photostability Studies 489 14.7.4 Degradation Chemistry Knowledge 490 14.8 Risk Assessment Process Illustrated 491 14.8.1 Case Study #1: Molecule A 491 14.8.2 Case Study #2: Galunisertib 492 14.8.3 Case Study #3: Naloxegol 494 14.8.4 Case Study #4: Selumetinib Side Chain 496 14.9 Significance of the Risk of Forming Mutagenic Degradation Products 498 14.9.1 Frequency of Alerting Structures in Degradation Products 498 14.10 Degradation Reactions Leading to Alerting Structures in Degradation Products 499 14.10.1 Frequency of Alerting Structures Giving Rise to Ames Positive Tests 503 14.10.2 Mutagenic Degradation Products: Overall Predicted Frequency 503 14.11 N-Nitrosamines: Special Considerations 503 14.11.1 Evaluation of Potential Formation of N-Nitrosamines in Drug Product 504 14.12 Conclusions 506 References 507 Index 513

Read more less

Book SynopsisORAL BIOAVAILABILITY AND DRUG DELIVERY Improve the performance and viability of newly-developed and approved drugs with this crucial guide Bioavailability is the parameter which measures the rate and extent to which a drug reaches a user's circulatory system depending on the method of administration. For example, intravenous administration produces a bioavailability of 100%, since the drugs are injected directly into the circulatory system; in the case of oral administration, however, bioavailability can vary widely based on factors which, if not properly understood, can result in a failure in drug development, adverse effects, and other complications. The mechanics of oral bioavailability are therefore critical aspects of drug development. Oral Bioavailability and Drug Delivery provides a comprehensive coverage of this subject as well as its drug development applications. Beginning with basic terminology and fundamental concepts, it provideTable of ContentsList of Contributors xxix Foreword xxxix Preface xli 1 Barriers to Oral Bioavailability – An Overview 1 Ming Hu and Xiaoling li 1.1 Introduction 1 References 4 2 Solubility of Pharmaceutical Solids 5 Pramila Sharma, Yi Gao, Heran li, Bhaskara R. Jasti, Sanming li, and Xiaoling li 2.1 Introduction 5 2.2 Fundamentals of Solubility 6 2.3 Solubility and Oral Bioavailability 19 2.4 Strategies to Improve Solubility 21 2.5 Summary 24 Abbreviations 25 References 25 3 In Vitro Dissolution of Pharmaceutical Solids 31 Tze Ning Hiew and Paul W.S. Heng 3.1 Dissolution Theory and Fundamentals 31 3.2 Dissolution of Drug Products 34 3.3 In Vitro Dissolution Methods for Ensuring Quality of Commercial Drug Products 36 3.4 In Vitro Dissolution Methods in Product Development 38 3.5 Automation in Dissolution Testing and Prediction 40 3.6 Conclusions 42 References 42 4 Biological and Physiological Features of the Gastrointestinal Tract Relevant to Oral Drug Absorption 47 Paul C.L. Ho 4.1 Introduction 47 4.2 Biological Features of Gastrointestinal Tract 47 4.3 Physiological Features of Gastrointestinal Tract 51 4.4 Other Physiological Factors 54 4.5 Conclusion 56 References 56 5 Absorption of Drugs Via Passive Diffusion and Carrier-Mediated Pathways 61 Amit Kokate, Jae H. Chang, and Miki S. Park Disclaimer 61 5.1 Introduction 61 5.2 Passive Diffusion 62 5.3 Carrier-Mediated Transport 67 5.4 Summary 75 References 75 6 Determinant Factors for Passive Absorption of Drugs 79 Wei Zhu and Mikolaj Milewski 6.1 Introduction 79 6.2 Fundamentals of Drug Absorption 79 6.3 Absorption Determining Factors 82 6.4 Rate Limiting Steps in Absorption and Prediction of Dosing Amount Absorbed 86 6.5 Overview of In Silico Prediction of Absorption and Pharmacokinetics for Oral Dosage Forms 88 6.6 Summary 89 References 90 7 Protein Binding and Drug Distribution 95 HaiAn Zheng and Marcel Musteata 7.1 Introduction 95 7.2 Protein–Drug Binding in Plasma 95 7.3 Modeling of Binding Equilibria 97 7.4 Bioanalytical Methods for Studying Drug–Protein Binding 98 7.5 Impact of Drug–Protein Binding on Pharmacokinetic Parameters 105 7.6 Physicochemical Factors that Affect Protein–Drug Binding and Drug Distribution 106 7.7 Physiological and Pathological Factors that Affect Protein–Drug Binding and Drug Distribution 107 References 107 8 Drug Transport Across the Placental Barrier 111 Valentina Bryant, Mansi Shah, Jennifer Waltz, and Erik Rytting 8.1 Introduction 111 8.2 Pharmacokinetics of Drugs Administered During Pregnancy 111 8.3 Placental Development and Structure 112 8.4 Functions of the Human Placenta 113 8.5 Mechanisms of Drug Transport Across the Placenta 114 8.6 Mechanisms of Drug Metabolism Within the Placenta 116 8.7 Strategies to Alter Drug Transport Across the Placenta 117 8.8 Experimental Models of the Human Placenta 118 References 122 9 Biopharmaceutics Classification System: Theory and Practice 131 Mehul Mehta, Jayabharathi Vaidyanathan, and Lawrence Yu 9.1 Introduction 131 9.2 Theory 131 9.3 BCS-based Biowaiver 134 9.4 BCS Waiver Case Studies 136 9.5 BCS: Additional Regulatory Applications 138 9.6 Summary 138 References 139 10 Effects of Food on Drug Absorption 141 Zhu Zhou, Venugopal P. Marasanapalle, Xiaoling Li, and Bhaskara R. Jasti 10.1 Introduction 141 10.2 Mechanisms of Food Effects 147 10.3 Prediction of Food Effects 149 10.4 Summary 149 Abbreviations 150 References 150 11 Drug Metabolism in Gastrointestinal Tract 155 Rashim Singh, Dinh Bui, and Ming Hu 11.1 Introduction 155 11.2 Role of Intestinal Efflux Transporters in the Drug Disposition 161 11.3 Drug Metabolism–Transporter Coupling in Drug Disposition in GIT 163 11.4 Factors Affecting Intestinal Drug Metabolism 168 11.5 Biopharmaceutics Drug Disposition Classification System 170 11.6 Metabolism-Based Drug–Drug and Drug–Natural Product Interactions 171 11.7 Metabolic Interactions Between Gut Microbiome and Drugs in GIT 173 11.8 Metabolism-Based Xenobiotic-Induced Toxicity 174 11.9 GIT Metabolism-Based Drug-Designing and Lead Optimization in Drug Development 174 11.10 Summary 175 Abbreviations 176 References 176 12 Liver Drug Metabolism 189 Ritika Kurian, Leslie T. Steen, and Hongbing Wang 12.1 Introduction 189 12.2 Hepatic Structure and Function 189 12.3 Phase I Drug Metabolism 191 12.4 Phase II Drug Metabolism 199 12.5 Novel Platforms for Drug Metabolism Studies 204 12.6 Drug Metabolism and Its Impact on Adverse Drug Reactions 205 12.7 Conclusion 207 References 207 13 Urinary Excretion of Drugs and Drug Reabsorption 213 Jessica T. Babic, Jack Cook, and Vincent H. Tam 13.1 Introduction 213 13.2 Kidney as an Eliminating Organ 213 13.3 Drug Transporters and Their Role in Renal Elimination 220 13.4 Renal Elimination and Bioavailability 222 13.5 Augmented Renal Clearance 227 References 228 14 Excretion of Drugs and Their Metabolites into the Bile 233 Song Gao, Imoh Etim, Robin Sunsong, Christabel Ebuzoeme, Ting Du, and Dinh Bui 14.1 Introduction 233 14.2 Anatomy and Physiology of the Liver and Biliary System 234 14.3 Biliary Excreted Drugs and Metabolites 235 14.4 Impact of Biliary Excretion on ADME and Pharmacokinetics 235 14.5 Hepatic Transporters Involved in Biliary Excretion 245 14.6 Factors Affecting Biliary Secretion 248 14.7 Biliary Excretion Research Models 250 14.8 Concluding Remarks 255 Abbreviations 255 References 255 15 Pharmacokinetic Behaviors of Orally Administered Drugs 267 Hamdah Al Nebaihi, Dion R. Brocks, Jaime A. Yáñez, Marcus Laird Forrest, and Neal M. Davies Objectives 267 15.1 Introduction 267 15.2 Physicochemical Factors Affecting Oral Concentration Time Profiles 274 15.3 Physiological Factors Affecting Oral Concentration Time Profiles 281 15.4 Food-Effects and Oral Concentration Time Profiles 296 15.5 The Impact of the Lymphatic System on Oral Bioavailability 298 15.6 Summation 303 Abbreviations 304 References 304 16 In Vitro-In Vivo Correlations of Pharmaceutical Dosage Forms 315 Deliang Zhou and Yihong Qiu 16.1 Introduction 315 16.2 Categories of In Vitro-In Vivo Correlations 316 16.3 Convolution and Deconvolution 317 16.4 Development and Assessments of an IVIVC 321 16.5 Applications of an IVIVC 324 16.6 Challenges 325 16.7 Physiologically Based Biopharmaceutics Models (PBBM) 326 16.8 Summary 328 References 329 17 Advanced Concepts in Oral Bioavailability Research – An Overview 333 Baojian Wu, Min Chen, and Ming Hu Abbreviations 336 References 336 18 Expression and Pharmaceutical Relevance of Intestinal Transporters 339 Melanie A. Felmlee, Michael Ng, and Annie Lee 18.1 Introduction 339 18.2 Intestinal Drug Transport 340 18.3 Uptake Transporters 341 18.4 Efflux Transporters 350 18.5 Summary 353 References 353 19 Amino Acid Transporters 361 Liping Wang, Xiaoyan Li, Mengdi Ying, Ming Hu, and Zhongqiu Liu 19.1 Introduction 361 19.2 Classification of Amino Acid Transporters and their Functions 364 19.3 Epithelial Amino Acid Transporters 372 19.4 Endothelial Amino Acid Transporters 378 19.5 Regulation of Amino Acid Transport 380 19.6 Conclusion 382 Abbreviations 382 References 383 20 Drug Transporters and Their Role in Absorption and Disposition of Peptides and Peptide-Based Pharmaceuticals 393 David J. Lindley, Stephen M. Carl, Dea Herrera-Ruiz, Li F. Pan, Lori B. Ward, Jonathan M.E. Goole, Olafur S. Gudmundsson, Matthew Behymer, and Gregory T. Knipp 20.1 Introduction 393 20.2 Transport Systems Mediating Peptide-based Pharmaceutical Absorption and Disposition: The Solute Carrier (SLC) Family 397 20.3 ATP Binding Cassette (ABC) Transporters 399 20.4 Gastrointestinal Tract-Specific Transporter Activity 400 20.5 Conclusions 407 Acknowledgments 408 References 408 21 OATP Transporters in Hepatic and Intestinal Uptake of Orally Administered Drugs 417 Wei Yue, Taleah Farasyn, Alexandra Crowe, Khondoker Alam, Lucila Garcia-Contreras, Yifan Tu, and Lu Wang 21.1 Introduction 417 21.2 Hepatic OATP1B1 and OATP1B 3 417 21.3 OATP2B1 in the Intestine 420 21.4 OATP1A2 in the intestine 421 21.5 Summary 422 Acknowledgement 422 References 422 22 ABC Transporters in Intestinal and Liver Efflux 429 Marilyn E. Morris and Tianjing Ren 22.1 Introduction 429 22.2 Apical Membrane Efflux Proteins 430 22.3 Basolateral/Lateral Membrane Efflux Proteins 442 22.4 Clinical Relevance of ABC Transporters in Oral Bioavailability of Drugs 444 22.5 Pharmacogenomics of ABC Transporters 445 22.6 Regulation of Efflux Transporters 445 22.7 Summary 446 Abbreviations 446 Acknowledgments 447 References 447 23 Interplay Between Metabolic Enzymes and Transporters 455 Zuoxu Xie, Lu Wang, Zicong Zheng, Yifan Tu, Yi Rong, Ming Hu, and Stephen Wang 23.1 Pathways and Functions of Drug Metabolic Enzymes and Transporters 455 23.2 Interplay Between Metabolic Enzymes and Transporters 462 23.3 Conclusion 467 References 468 24 Systemic Versus Local Bioavailability Enabled by Recycling 473 Yifan Tu, Lu Wang, and Ming Hu 24.1 Introduction 473 24.2 Systemic Bioavailability 473 24.3 Local Bioavailability 474 24.4 Factors Affecting Bioavailability 474 24.5 Enterohepatic Recycling (EHR) 475 24.6 Hepatoenteric Recycling (HER) 479 24.7 Enteroenteric Recycling (EER) 480 24.8 Summary 480 References 480 25 Intestinal Microbiome and Its Impact on Metabolism and Safety of Drugs 483 Xin Y. Chu and Paul C.L. Ho 25.1 Introduction 483 25.2 Direct Metabolism by Intestinal Microbiome 483 25.3 Indirect Mechanisms Affecting Drug Metabolism 489 25.4 Impact of Intestinal Microbiome on Drug Treatment in Clinical Practice 492 25.5 Conclusion and Future Perspectives 492 References 493 26 Drug–Drug Interactions and Drug–Dietary Chemical Interactions 501 Mengbi Yang, Yuanfeng Lyu, and Zhong Zuo 26.1 Introduction 501 26.2 Drug–Drug Interactions (DDIs) 501 26.3 Drug–Dietary Chemical Interactions in Oral Bioavailability 510 26.4 Summary 517 Abbreviations 517 References 518 27 Regulatory Considerations in Metabolism- and Transport-Based Drug Interactions 523 Xinning Yang, Sue-Chih Lee, Xinyuan Zhang, and Lei Zhang Disclaimer 523 27.1 Overview of Drug–Drug Interactions 523 27.2 Regulatory Recommendations of DDI Studies 527 27.3 Highlights of the Final Guidances for Industry: In Vitro and Clinical Drug Interaction Studies – Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions 528 27.4 Role of Physiologically Based Pharmacokinetic (PBPK) Modeling in DDI Assessment 544 27.5 A Labeling Example to Illustrate the Translation of Complicated Drug Interaction Results to Labeling: Tipranavir 547 27.6 Examples to Illustrate the Use of PBPK in Supporting Labeling for Drugs that are Dual CYP3A/P-GP Substrates 549 27.7 Summary 549 Acknowledgement 550 References 550 28 Formulation Approaches to Improve Oral Bioavailability of Drugs 559 Zeren Wang, Chandan Bhugra, and Shun Chen 28.1 Introduction 559 28.2 Theoretical Considerations for Formulation Development of Poorly Water-Soluble Drugs 560 28.3 Formulation Considerations for the Development of Poorly Water-Soluble Drugs 563 28.4 Other Formulation Approaches 571 References 571 29 Lipid-Based and Self-Emulsifying Oral Drug Delivery Systems 575 Pushkaraj Wagh, Jonathan Moreno, Christopher Nayar, and Jeffrey Wang 29.1 Introduction 575 29.2 Lipid-based Drug Delivery Systems 575 29.3 Advantages and Limitations of Lipid-Based and Self-Emulsifying Drug Delivery Systems 586 29.4 Summary 586 References 586 30 Oral Delivery of Nanoparticles: Challenges and Opportunities 591 Qing Lin, Ling Zhang, and Zhirong Zhang 30.1 Introduction 591 30.2 Role of Nanoparticle Shape, Size, and Surface in Oral Delivery of Nanoparticles 592 30.3 Characterization Methods of Nanoparticles for Oral Delivery 593 30.4 State-of-the-Art Carriers Designed and Applied in Oral Delivery of Nanoparticles 594 30.5 Challenges and Coexisting Opportunities 594 References 595 31 Oral Delivery of Therapeutic Peptides: Strategies for Product Development 599 Puchun Liu 31.1 Introduction 599 31.2 Overview of Approaches to Enabling Oral Peptide Delivery 604 31.3 Observation and Data Analysis of Low BA with Large Variabilities 607 31.4 Recommended Strategies for Oral Peptide Product Development 609 Abbreviations 613 References 613 32 Prodrugs to Improve Oral Delivery 619 Arjun D. Patel, Shuchi Gupta, and Mamoun Alhamadsheh 32.1 Introduction 619 32.2 Factors Associated With Oral Drug Absorption 620 32.3 Intestinal Physiology and Background 620 32.4 Strategies to Improve the Bioavailability of Orally Administered Drugs 621 32.5 Prodrug Overview and Classification 622 32.6 Prodrug Strategies to Improve Aqueous Solubility 630 32.7 Prodrug Approaches for Enhancing Absorption 631 32.8 Prodrug Approaches for Targeting Enzymes 631 32.9 Prodrug Approaches for Targeting Membrane Transporters 632 32.10 Conclusion 633 Abbreviations 634 References 634 33 Gastroretentive Drug Delivery Systems 637 Vrushali Waknis and Ajit S. Narang 33.1 Introduction 637 33.2 Oral Drug Delivery – Challenges and Opportunities 637 33.3 Human Gastric Physiology Relevant to GRDDS Design 638 33.4 Technologies 639 33.5 New Drug Development Considerations 645 33.6 Commercial GRDDS Products and Investigational New Products 649 33.7 Future Outlook 653 Acknowledgments 654 References 654 34 Enhancing Oral Bioavailability Using 3D Printing Technology 657 Timothy Tracy, Senping Cheng, Lei Wu, Xin liu, and Xiaoling li 34.1 Introduction 657 34.2 3D Printing in Pharmaceutical Applications 657 34.3 Novel Tablet Structures Possible with 3D Printing 660 34.4 Application of 3D Printing in Oral Bioavailability Enhancement 663 34.5 Future Outlook for 3D Printing and Bioavailability Enhancement 672 34.6 Summary 673 References 673 35 Anatomical and Physiological Factors Affecting Oral Drug Bioavailability in Rats, Dogs, Monkeys, and Humans 677 Ayman El-Kattan 35.1 Introduction 677 35.2 Determinants of Oral Bioavailability 677 35.3 Summary 691 References 691 36 In Vivo Methods for Oral Bioavailability Studies 701 Ana Ruiz-Garcia and Marival Bermejo 36.1 Introduction 701 36.2 Factors that Affect Oral Availability 701 36.3 In Vivo Animal Techniques 706 36.4 Animals Used in Bioavailability Studies 706 36.5 General Considerations for Blood Sampling 708 36.6 Statistical Considerations for Data Handling. (AUC Calculations in Sparse Sampling Designs) 708 36.7 Practical Examples in Rat Model 709 36.8 Intestinal Perfusion (see also Chapter 42) 710 36.9 Mathematical Considerations 711 References 712 37 Caco-2 Cell Culture Model for Oral Drug Absorption 715 Kaustubh Kulkarni, Lu Wang, and Ming Hu 37.1 Introduction 715 37.2 Description 717 37.3 Utility 719 37.4 Recent Progress 720 37.5 Significance of Caco-2 Cell Culture Model in Drug Discovery and Development 722 37.6 Example 722 37.7 Concluding Remarks 727 References 727 38 OATP Overexpressed Cells and Their Use in Drug Uptake Studies 729 Lu Wang, Zuoxu Xie, Yifan Tu, and Ming Hu 38.1 Introduction to OATP Cell Assay 729 38.2 Materials 731 38.3 Methods 731 38.4 Data Analysis 732 38.5 Notes 733 References 735 39 Use of Human Intestinal and Hepatic Tissue Fractions and Microbiome as Models in Assessment of Drug Metabolism and its Impact on Oral Bioavailability 737 Hani Zaher and George Zhang 39.1 Introduction 737 39.2 Gastrointestinal Tract and Absorption (see Also Chapter 5) 737 39.3 Mechanisms of Drug Absorption and Concept of Oral Bioavailability (see also Chapters 4–6) 738 39.4 Intestinal Metabolism and Oral Bioavailability (see Also Chapter 11) 739 39.5 In Vitro Systems Applied to Assess Intestinal Metabolism 740 39.6 In Vitro Systems Applied to Assess Human Hepatic First-Pass Metabolism (see Also Chapter 12) 743 39.7 Long-Term Hepatocyte Culture and Slow Metabolizing Drug Candidate 745 39.8 Microbiome and Absorption: A New Perspective 747 39.9 Summary 748 Acknowledgments 748 Abbreviations 749 References 749 40 Liver Perfusion and Primary Hepatocytes for Studying Drug Metabolism and Metabolite Excretion 757 Paresh P. Chothe, Sean Xiaochun Zhu, Sandeepraj Pusalkar, Chuang Lu, and Cindy Xia 40.1 Introduction 757 40.2 Liver Perfusion 758 40.3 Primary Hepatocytes 762 40.4 Organ Perfusion Versus Hepatocyte Studies 771 40.5 Perspectives 772 Acknowledgements 772 Abbreviations 772 References 772 41 Determination of Regulation of Drug Metabolizing Enzymes and Transporters 779 Sergio C. Chai, Taosheng Chen, and Wen Xie 41.1 Introduction 779 41.2 In vivo Methods 779 41.3 In vitro Methods 784 41.4 Biochemical, Biophysical and Structural Analysis of NRs Using Purified Proteins 789 41.5 Conclusions 796 Acknowledgments 796 References 796 42 Intestinal Perfusion Methods for Oral Drug Absorptions 801 li li, Dinh Bui, Wei Zhu, and Eun-Jung (Zenobia) Jeong 42.1 Introduction 801 42.2 Application and Recent Development of the Intestinal Perfusion Method 801 42.3 Data Interpretation and Method Comparison 803 42.4 Common In Vitro Methods Studying Intestinal Permeability and Metabolism 803 42.5 Summary 807 42.6 Methodologies and Experimental Data Analysis 807 Acknowledgment 813 References 815 43 In Silico Prediction of Oral Drug Absorption 819 Jin Dong, Zhu Zhou, Yujuan Zheng, and Miki Susanto Park 43.1 Introduction 819 43.2 QSPR Modeling 819 43.3 PBPK Modeling 821 43.4 PBBM Modeling as a Subset of PBPK Modeling 823 43.5 Applications of PBPK/PBBM Modeling 824 43.6 PBPK Software 827 43.7 Summary 839 References 839 44 Computational Modeling of Drug Oral Bioavailability 843 Lon W.R. Fong, Beibei Huang, Rajan Chaudhari, and Shuxing Zhang 44.1 Introduction 843 44.2 Computational Modeling of Bioavailability 844 44.3 Conclusions 851 Acknowledgment 852 References 852 45 Blood–Brain Barrier Permeability Assessment for Small-Molecule Drug Discovery Using Computational Techniques 857 Yankang Jing and Xiang-Qun Xie 45.1 Introduction 857 45.2 Basic Principle of the BBB Permeation 857 45.3 Role of the BBB in Drug Delivery 858 45.4 Experimental Methods for Assessing BBB Permeability 858 45.5 Computational Method to Predict BBB Permeability 859 Abbreviations 867 References 867 Index 871

Read more less

Book SynopsisTable of Contents Preface xi Contributing Authors xiii Part I Infectious Disease Drugs 1 Chapter 1 Relebactam (Recarbrio), A β-Lactamase Inhibitor for the Treatment of cIAI/cUTI/HABP/ VABP 3 1 Background 3 2 Pharmacology 5 3 Structure–Activity Relationship (SAR) 6 4 Pharmacokinetics and Drug Metabolism 9 5 Efficacy and Safety 10 6 Syntheses 10 7 Summary 14 8 References 14 Chapter 2 Vaborbactam (in Combination with Meropenem as Vabomere), a Non-β-Lactam β-Lactamase Inhibitor for Treatment of Complicated Urinary Tract Infections and Pyelonephritis 17 1 Background 17 2 Discovery Medicinal Chemistry 21 3 Vaborbactam/Vabomere Clinical Trials 27 4 Vaborbactam Medicinal Chemistry Synthesis 29 5 Vaborbactam Process Chemistry Synthesis 30 6 Conclusions 37 7 References 38 Chapter 3 Baloxavir Marboxil (Xofluza), A Cap-Dependent Endonuclease Inhibitor for Treating Influenza 41 1 Background 41 2 Mechanism of Action 43 3 Structure–Activity Relationship 45 4 Pharmacokinetics and Drug Metabolism 49 5 Efficacy and Safety 50 6 Syntheses 50 7 Summary 54 8 References 54 Chapter 4 Process Chemistry Development of the HIV Protease Inhibitor Drug Kaletra: A Mixture of Ritonavir and Lopinavir 57 1 Background 58 2 Ritonavir Portion of Kaletra Synthesis 58 3 Discovery Synthesis of the Ritonavir Core 60 4 Discovery Synthesis of Ritonavir Wing Pieces 63 5 Large-Scale Process Chemistry Synthesis of the Ritonavir Core 65 6 Large-Scale Syntheses of the 5-Hydroxymethyl Thiazole Wing Portion 69 7 The Large-Scale Coupling of the Thiazole Wing Pieces to the Core 70 8 Lopinavir Portion of Kaletra— Discovery Synthesis and Process Development 72 9 Discovery Synthesis of Lopinavir 73 10 Discovery Synthesis of Wing Pieces 74 11 Process Improvements to the Wing Pieces 76 12 Optimization of Lopinavir Synthesis with Intermediates 78 13 Conclusions 81 14 References 81 Chapter 5 Eravacycline (Xerava), A Novel and Completely Synthetic Fluorocycline Antibiotic 85 1 Background 85 2 Pharmacology 89 3 Structure–Activity Relationship (SAR) 91 4 Pharmacokinetics and Drug Metabolism 93 5 Efficacy and Safety 93 6 Syntheses 93 7 Summary 98 8 References 99 Chapter 6 Albuvirtide (Aikening), A gp41 Analog as an HIV-1 Fusion Inhibitor 101 1 Background 101 2 Pharmacology 102 3 Structure–Activity Relationship (SAR) 106 4 Pharmacokinetics and Drug Metabolism 107 5 Efficacy and Safety 110 6 Syntheses 112 7 Summary 114 8 References 115 Part II Cancer Drugs 119 Chapter 7 Darolutamide (Nubeqa): An Androgen Receptor Antagonist for Treating Nonmetastatic, Castration-Resistant 121 1 Background 121 2 Pharmacology 124 3 Structure–Activity Relationship (SAR) 126 4 Pharmacokinetics and Drug Metabolism 132 5 Efficacy and Safety 134 6 Syntheses 135 7 The Future 137 8 References 138 Chapter 8 Venetoclax (Venclexta): A BCL-2 Antagonist for Treating Chronic Lymphocytic Leukemia 143 1 Background 143 2 Pharmacology 144 3 Structure–Activity Relationship (SAR) 147 4 Pharmacokinetics and Drug Metabolism 153 5 Efficacy and Safety 154 6 Syntheses 155 7 Summary 160 8 References 161 Chapter 9 Osimertinib (Tagrisso), A Potent and Selective Third-Generation EGFR Inhibitor for the Treatment of Both Sensitizing and T790M-Resistance Mutations 165 1 Background 165 2 Pharmacology 167 3 Structure–Activity Relationship (SAR) 170 4 Pharmacokinetics and Drug Metabolism 173 5 Efficacy and Safety 174 6 Syntheses 175 7 Summary 180 8 References 180 Chapter 10 Sotorasib (LUMAKRA), An Irreversible Covalent Inhibitor of KRASG12C 183 1 Background 183 2 Pharmacology 184 3 Structure–Activity Relationship (SAR) 186 4 Pharmacokinetics and Drug Metabolism 191 5 Efficacy and Safety 191 6 Syntheses 192 7 Summary 196 8 References 196 Chapter 11 Lorlatinib (Lorbrena), An ALK Inhibitor for Treating NSCLC 201 1 Background 201 2 Pharmacology 203 3 Structure–Activity Relationship (SAR) 205 4 Pharmacokinetics and Drug Metabolism 210 5 Efficacy and Safety 211 6 Syntheses 213 7 Summary 226 8 References 227 Chapter 12 Niraparib (Zejula) A Small Molecule, PARP1/2 Inhibitor for Treating Breast, Ovarian, and Pancreatic Cancers 231 2 Pharmacology 235 3 Structure–Activity Relationship (SAR) 238 4 Pharmacokinetics and Drug Metabolism 243 5 Efficacy and Safety 243 6 Syntheses 244 7 Summary 248 8 References 248 Chapter 13 Selinexor (Xpovio), An XPO1 Inhibitor and a New Class of Therapeutics for Treating Multiple Myeloma 253 1 Exportin1 (XPO1) 253 2 Overview of Multiple Myeloma 255 3 Development of Selinexor 256 4 Pharmacology and Mechanism 257 5 Pharmacokinetics, Pharmacodynamics and Drug Metabolism 258 6 Efficacy and Safety 259 7 Syntheses 259 8 Summary and Future 262 9 References 262 Part III Cns Drugs 265 Chapter 14 Sage 217 (Zuranolone) for Treating Major of Depressive Disorder267 1 Background 267 2 Pharmacology 270 3 Structure–Activity Relationship (SAR) 272 4 Pharmacokinetics and Drug Metabolism 279 5 Efficacy and Safety 280 6 Syntheses 281 7 Summary 282 8 References 283 Chapter 15 Risdiplam (Evrysdi), A Small Molecule, SMN2-directed RNA Splicing Modifier for Treating Spinal Muscular Atrophy 287 1 Background 287 2 Pharmacology 289 3 Structure–Activity Relationship (SAR) 290 4 Pharmacokinetics and Drug Metabolism 297 5 Efficacy and Safety 297 6 Syntheses 298 7 Summary 300 8 References 301 Part IV Miscellaneous Drugs 305 Chapter 16 Esaxerenone (Minnebro), An Oral, Non-steroidal, Selective Mineralocorticoid Receptor Blocker for the Treatment of Essential Hypertension307 1 Background 307 2 Pharmacology 310 3 Structure–Activity Relationship (SAR) 311 4 Pharmacokinetics and Drug Metabolism 313 5 Efficacy and Safety 315 6 Syntheses 316 7 Summary 320 8 References 321 Chapter 17 Voclosporin (Lupkynis), A Macrocyclic Peptide Inhibitor of Calcineurin for the Treatment of Lupus Nephritis 323 1 Background 323 2 Pharmacology 326 3 Structure–Activity Relationship (SAR) 326 4 Pharmacokinetics and Drug Metabolism 329 5 Efficacy and Safety 331 6 Syntheses 333 7 References 336 Chapter 18 Computational-Aided Drug Design 339 1 Background 339 2 Structure-based Drug Design (SBDD) 341 3 Ligand-based Drug Design (LBDD) 352 4 Summary 361 5 References 362 Index 373

Read more less

Book Synopsis

Read more less

Book SynopsisNow there is an up-to-date guide for optimizing pharmacologic therapy in treating patients with heart failure. Reflecting current practice at leading medical centers, Heart Failure: Pharmacologic Management provides both the biologic and pathologic underpinnings of each pharmacologic agent in current use. It also supplies detailed discussions of the clinical investigations that support current understanding of the risks and benefits associated with the use of these drugs. Thorough references make the book useful to the novice as well as the experienced clinician. Initial chapters focus on agents that are considered standard care: diuretics ACE inhibitors angiotensin receptor antagonists aldosterone antagonists beta-blockers The discussion moves to agents currently Table of ContentsContributors. Introduction. 1. Diuretics in congestive heart failure (Alicia Ross, Ray E. Hershberger and David H. Ellison). 2. Use of digoxin in the treatment of heart failure (Deborah DeEugenio and Paul J. Mather). 3. Renin-angiotensin system and angiotensin converting enzyme inhibitors in chronic heart failure (Rimvida Obeleniene and Marrick Kukin). 4. Angiotensin receptor blockers in the treatment of hart failure (Anita Deswal and Douglas L. Mann). 5. Beta blockers (Peter F. Robinson and Michael R. Bristow). 6. Aldosterone antagonism in the pharmacological management of chronic heart failure (Biykem Bozkurt). 7. Inotropic therapy in clinical practice (Sharon Rubin and Theresa Pondok). 8. Antiarrhythmic therapy in heart failure (Igino Contrafatto and Leslie A. Saxon). 9. Treating the hypercoagulable state of heart failure: modifying the risk of arterial and venous thromboembolism (Geno J. Meril and Hoard H. Weitz). 10. Vasodilator and nitrates (Abdul Al-Hesayen and John D. Parker). 11. Natriuretic peptides fro the treatment of heart failure (Jonathan D. Sackner-Bernstein, Hal Skopicki and Keith D. Aaronson). 12. Immune modulatory therapies in heart failure: using myocarditis to gain mechanistic insights (Grace Chan, Koichi Fuse, Mei Sun, Bill Ayach and Peter P. Liu). 13. The role of vasopressin and vasopressin antagonists in heart failure (Olaf Hedrich, Maervin A. Konstam and James Eric Udelson). 14. Role of erythropoietin in the correction of anemia in patients with heart failure (Revecca P. Streeter and Donna M. Mancini). 15. Endothelin antagonism cardiovascular disease (Srinivas Murali). 16. Pharmacogenetics (Richard Sheppard and Dennis M. McNamara). 17. Management of diastolic dysfunction (Arthur M. Feldman and Bonita Fakner). 18. Multidrug pharmacy for treatment of heart failure: an algorithm for the clinician (Mariell Jessup). Index.

Read more less

Book SynopsisMedication Management in Care of Older People is an accessible introduction to medication management and its role in the management of older people and their medicines. It addresses key issues in medication management, evaluates professional roles and clinical practice initiatives and explores healthcare policy and prescribing initiatives.Table of ContentsChapter 1: Older People and Their Medicines: Health Objectives and Health Initiatives. Development of the National Service Framework (NSF) for older people. Management of medicines. The NHS Improvement Plan. Building a safer NHS for patients; the role of medication safety. Prescribing drugs. Dispensing medicines. Access to medicines- out of hours. The administration of drugs. Helping patients and carers to safely self administer medicines at home or in care homes. Community Matrons and the management of medicines. Patient case study. Chapter 2: The Physiology of Human Ageing. Homeostasis and ageing. Ageing and the cardiovascular system. Changes to the vascular system. Changes to cardiac tissue. Changes to cardiovascular function and control. Changes to cardiovascular cells. Implications for practice. Hepatic ageing. Changes to hepatic tissue. Changes to hepatic cells. Changes to hepatic molecular biology. Implications for practice. Renal ageing. Changes to tubular function. Implications for practice. Ageing and the immune system. Changes to organs and tissues. Changes to immune cells. Changes to immune molecules. Ageing and the inflammatory response. Chapter 3: The Application of Applied Pharmacology to the Older Person. Drug absorption. Factors that alter the absorption of drugs. Drug distribution. Drug metabolism. Factors affecting drug metabolism. Drug excretion. Biliary excretion. Pharmacodynamics. Receptor agonism. Pharmacodynamics and the effects of ageing. Chapter 4: Medication Management and the Older Person. Medication review and the older person. Medication review structure. The Single Assessment Process. Trigger questions. Care plans. Health care professional involvement. Prescribing practice. Principles of prescribing for the older person. Rational prescribing and prescribing support. Conclusions. Implications for practice. Chapter 5: Medication Errors and the Older Person. Introduction. The extent of the problem. The UK perspective. The potential dangers of medication errors. Definitions of medication error. Classification of medication errors. Causes of medication error. Forms of medication error. Medication errors that arise due to the supply and administration of medicines. Factors contributing to the development of medication errors. The nurse prescriber’s role in the prevention of medication errors. Prescription writing education. Preventative measures involving prescriptions. Computerised prescribing systems. Conclusions. Implications for practice. Chapter 6: Concordance with Medication and Older People. Introduction. Difficulties establishing a rationale. Characteristics of the non-concordant individual. Psychological theory. Medication related issues that underpin non-concordance. i. Polypharmacy and complicated medication regimens. ii. Lack of education. iii.Patient comprehension of the need to adhere to prescribed medication. administration protocols. Promoting concordance with medication regimens. Patient self-medication schemes. The prescriber’s role in the augmentation of concordance with medication for. older people. The art of teaching. Teaching practicalities. Reinforcing education. Barriers to teaching. Time management difficulties. Planning early discharge. Comprehension of applied pharmacology and therapeutics. Conclusions. Implications for practice. Chapter 7: Neurophysiology, and Neuropathology of Ageing. Introduction. In search of a nerve cell. Neurochemicals and synaptic transmission. Major neurotransmitters in the brain. The dynamic neurone, plasticity and memory. Changes in neuronal activity and communication in the ageing brain. What causes cellular damage with ageing. Neuropathology of Alzheimer’s disease. Pharmacological strategies. Neuropathology of Parkinson’s disease. Pharmacological approach in the treatment of PD. Conclusions. Implications for practice. Chapter 8: The Management of the Older Person with a Long-term Condition. Introduction. Government policy and long-term conditions. The NHS Improvement Plan. The evolvement of the community matron. The education and training of the community matron. Case finding and case management. Interprofessional working. Lay carer’s role. The future management of older people with long-term conditions. Conclusions. Implications for practice. Chapter 9: The Community Pharmacist’s Role in the Management of Older People and their Medicines. Introduction. Education and training Community pharmacy contractual framework. Repeat dispensing. Medicine Use Reviews (MUR’s). Medication Review. Services to residential homes Swallowing difficulties Domiciliary visiting schemes. Compliance aids. Physical problems. Prescribing support Multidisciplinary working. Conclusions. Implications for practice.

Read more less

Book SynopsisThis fifth edition of Principles and Practice of Pharmacology for Anaesthetists continues to provide a comprehensive scientific basis and a readable account of the principles of pharmacology, as well as practical guidance in the use of drugs that is relevant to clinical anaesthesia. With these concepts in mind: Every chapter in this new edition has been thoroughly revised and updated An additional chapter on Adverse Drug Reactions is included For ease of reference, the structures of many commonly used agents are featured, with their sites of isomerism, when appropriate Recommended International Non-proprietary Names (rINNs) are generally used for generic agents, although preference has been given to the current nomenclature for adrenaline and noradrenaline As in previous editions, a comprehensive glossary covering abbreviations and acronyms is included to aid the reader. Principles and Practice of PharmTrade Review"This fifth edition … continues to provide a comprehensive scientific basis and a readable account of the principles of pharmacology, as well as practical guidance in the use of drugs that is relevant to clinical anaesthesia. This book presents valuable insight into anesthetic pharmacology and reinforces essential concepts. It offers an excellent overview of the basic pharmacologic principles and their practical applications." (Doodys Reviews)Table of ContentsForeword to the First Edition. Preface. 1 Drug Absorption, Distribution and Elimination. 2 Pharmacokinetics. 3 Drug Action. 4 Drug Interaction. 5 Variability in Drug Response. 6 Adverse Drug Reactions. 7 Intravenous Anaesthetic Agents. 8 Inhalational Anaesthetic Agents. 9 Local Anaesthetics. 10 Drugs that act on the Neuromuscular Junction. 11 Analgesic Drugs. 12 Drugs used in Premedication and Antiemetic Agents. 13 Drugs and the Autonomic Nervous System. 14 Antihypertensive Agents: Drugs that Are Used to Induce Hypotension. 15 Antiarrhythmic and Antianginal Drugs. 16 Antiplatelet Drugs, Anticoagulants and Fibrinolytic Agents. 17 Corticosteroids and Hypoglycaemic Agents. Glossary. Index

Read more less

Book SynopsisConventional pharmaceutical approaches to pain management are not always successful. Using only those medications that have an official indication for a certain condition reduces substantially the chance of the patient gaining pain relief and may expose them to intolerable side effects. However evidence now exists on the use of other drugs, produced for non-pain conditions, and how they can substantially increase the chances of pain relief. Covering the most recent developments in this field, McCleane offers an alternative solution to pain treatment when conventional treatments fail. This pioneering book proposes evidence-based alternatives to current options in pain management, using well-grounded rationales for each given treatment. This book is an ideal reference for the specialist and non-specialist prescriber alike and for practitioners from a wide variety of disciplines. It provides the evidence required and treatment algorithms for readers to use the drugs apprTrade Review“The author is clearly an expert in all of the topics covered in the book. It is one of the few books that offers a well informed, thoughtful discussion of the off-label use of a wide variety of drugs in the treatment of pain and is a valuable addition to the literature. This is a terrific quick reference that should be readily available in any clinic where patients with pain are managed.” (Doody's Book Reviews, November 2008)Table of ContentsForeword. 1 Introduction. 2 Conventional Pain Treatment. 3 Using Drugs Outside Their Licensed Indication. Part 1. 4 Topical Nitrates. 5 Topical Tricyclic Antidepressants. 6 Topical Opioids. 7 Topical Local Anesthetics. 8 Topical Glutamate Receptor Antagonists. 9 Topical, Oral, and Perineural-Adrenoreceptor Agonists. 10 Lamotrigine. 11 5HT3 Antagonists. 12 Cholecystokinin Antagonists. 13 Parenteral Anti-epileptics. 14 Intravenous Lidocaine. 15 L-Carnitine. 16 Other Pharmacological Options (Botulinum, Cimetidine, Glucosamine). Part 2. 17 Neuropathic Pain. 18 Complex Regional Pain Syndrome. 19 Joint Pain. 20 Fracture Pain. 21 Postoperative Pain. 22 Fibromyalgia. 23 Muscle Spasm and Pain. 24 Tendinopathies. 25 Low Back Pain. 26 Cancer Pain. Appendix: Suggested Doses and Modes of Administration of Novel Pharmacological Options. Index.

Read more less

Book SynopsisAre you about to sit your pharmacology exams? Do you lack confidence in prescribing? Would it help to have a quick reference, pocket-sized reassurance on common drugs and the conditions that they are used in? The Hands-on Guide to Clinical Pharmacology is the perfect companion for students, doctors, nurses, pharmacists and other health care professionals who need help on the ward or are preparing for exams. It includes sections containing both treatment regimens of common conditions and detailed information on the relevant drugs that help you obtain a better understanding of therapeutic management. The benefits include: A-Z of over 100 key drugs in a one-drug-per-page format A systems-based approach Fully indexed text Clear explanations of drug mechanisms - a regular feature of pharmacology exams Management guidelines for common conditions within each system Brand new two-colour design to help with inTrade Review"The book is most suitable for practitioners who need rapid information on medications for their day-to-day activities . . . This is an excellent resource for practitioners who prefer pocket manuals over electronic devices as a quick reference during their busy day." (Doody's, 19 August 2011) Since the publication of the Oxford Handbook of Clinical Medicine in 1985, a plethora of similar pocket-sized guides to a wide variety of medical specialities has appeared in the white coats of both medical students and junior doctors. The popularity of these books can be attributed to the concise and well-structured ‘page per topic’ format introduced by the original handbook and employed almost universally by subsequent authors. This slim volume applies the same successful formula to the subject of Clinical Pharmacology, aiming to provide a concise source of relevant information on commonly used drugs. The authors (themselves medical undergraduates) have written their book as both a revision guide for medical students and as an aide-memoire for junior doctors, but have they been successful? The book certainly passes the first test, fitting easily into a white coat pocket. Approximately 100 drugs are described, grouped into chapters by organ system in a similar fashion to the British National Formulary. One page is devoted to each drug, the information presented in consistent tabular format. Indications, mechanism of action, adverse effects, contra–indications and interactions are listed, although drug doses have not been included. The authors have coped well with the limitation of space imposed by the ‘pocket’ format, including only the most clinically relevant information. Although most major drug classes are dealt with in adequate depth, future editions may need to find room for pages describing the newer anticonvulsants and antiplatelet agents. Some extra space could be found with the omission of the guides to management of common conditions, which have been presented at the beginning of each chapter in heavily truncated bullet point format. These are too brief to be of practical use and are much better addressed by the more general medical handbooks. The Hands-on Guide to Clinical Pharmacology will prove popular among medical students as it provides answers to commonly asked questions in a format that is concise and easy to use. The omission of drug doses renders it rather less attractive to junior medical staff whom I suspect will continue to rely upon the British National Formulary. (British Journal of Clinical Pharmacology) Table of ContentsPreface to the third edition vi Acknowledgements vii Abbreviations viii 1. Cardiovascular System 1 2. Respiratory System 41 3. Gastrointestinal System 53 4. Neurological System 81 5. Psychiatry 95 6. Musculoskeletal System 111 7. Diabetes and Endocrine System 125 8. Dermatology 137 9. Pain Management 143 10. Infection 153 11. Immunization 183 12. Obstetrics and Gynaecology 197 13. Anaesthesia 207 14. Poisoning and Overdose 217 15. Cancer Therapy 221 Index 225

Read more less

Book SynopsisThe new edition of Principles and Practice of Pharmaceutical Medicine is a comprehensive reference guide to all aspects of pharmaceutical medicine. New content includes chapters and coverage on regulatory updates, increasing international harmonization, transitional and probabilistic approaches to drug development, the growing sophistication and regulatory importance of pharmacovigilance, personalized medicine and growth in biotechnology as a source of new experimental drugs.Trade Review"Written at a high level, this comprehensive compilation of the many aspects of pharmaceutical medicine should be a must read for those involved in or contemplating a career in this specialty area." (Doody's, 7 October 2011) "This third edition offers a comprehensive reference on the subject of pharmaceutical medicine, a relatively new and very diverse field." (Booknews, 1 April 2011) "The new edition of Principles and Practice of Pharmaceutical Medicine is a comprehensive reference guide to all aspects of pharmaceutical medicine." (Financial Technology, 1 March 2011)Table of ContentsContributors. Preface to the First Edition. Preface to the Second Edition. Preface to the Third Edition. About the Editors. Section I Overview of Pharmaceutical Medicine. 1 The Practice and Practitioners of Pharmaceutical Medicine (Anthony W. Fox). 2 Pharmaceutical Medicine as a Medical Specialty (Michael D. Young & Peter D. Stonier). 3 Clinical Research Education and Training for Biopharmaceutical Staff (Peter Marks & Sheila Gwizdak). Section II Drug Discovery and Development. 4 Drug Discovery: Design and Development (Ronald R. Cobb & Leslie J. Molony). 5 Translational Medicine, Pharmaceutical Physicians, Patients, and Payers (Robert Sands & Douglas Roy). 6 Pharmaceutics (Anthony W. Fox). 7 Nonclinical Toxicology (Frederick Reno). 8 Informed Consent (Anthony W. Fox). 9 Phase I: The First Opportunity for Extrapolation from Animal Data to Human Exposure (Stephen H. Curry, Helen H. DeCory, & Johan Gabrielsson). 10 Phase II and Phase III Clinical Studies (Anthony W. Fox). 11 Phase IV Drug Development: Post-marketing Studies (Lisa R. Johnson-Pratt). 12 Site Management (Barry Miskin). 13 Good Clinical Practices (Lionel D. Edwards). 14 Quality Assurance, Quality Control and Audit (Rita Hattemer-Apostel). 15 The Unique Role of Over-the-Counter Medicine (Paul Starkey). Section III Special Populations and Required Special Studies. 16 Drug Research in Older Patients (Lionel D. Edwards). 17 Drug Development Research in Women (Lionel D. Edwards). 18 Clinical Research in Children (Lionel D. Edwards). 19 Racial and Ethnic Issues in Drug Regulation (Lionel D. Edwards, J-M. Husson, E. Labbe, C. Naito, M. Papaluca Amati, S. Walker, R.L., Williams, & H. Yasurhara). 20 Special Populations: Hepatic and Renal Failure (Anthony W. Fox). 21 Drug Interactions (Anthony W. Fox & Anne-Ruth van Troostenburg). 22 Orphan Drugs (Bert Spilker). 23 QT Interval Prolongation and Drug Development (Bruce H. Morimoto & Anthony W. Fox). Section IV Applied Aspects. 24 Biotechnology Products and Their Development (David A. Shapiro & Anthony W. Fox). 25 Health Economics (Daniel C. Malone, Edward P. Armstrong, & Mirza I. Rahman). 26 Pharmacoeconomics: Economic and Humanistic Outcomes (Raymond J. Townsend, Jane T. Osterhaus, & J. Gregory Boyer). 27 Pharmacoepidemiology and the Pharmaceutical Physician (Hugh H. Tilson). 28 Statistical Principles and Application in Biopharmaceutical Research (Dan Anbar). 29 Data Management (T.Y. Lee, Michael Minor, & Lionel D. Edwards). 30 Patient Compliance: Pharmionics, A New Discipline (Dr. Jean-Michel Metry). 31 Monitoring Drug Concentrations in Clinical Practice (Anthony W. Fox). 32 Generics (Gabriel Lopez & Thomas Hoxie). 33 Complementary Medicines (Anthony W. Fox). Section V Drug Regulation. 34 United States Regulations (William Kennedy & Lionel D Edwards). 35 Special US Regulatory Procedures: Emergency and "Compassionate" INDs and Accelerated Product Approvals (Anthony W. Fox). 36 The Development of Human Medicines Control in Europe from Classical Times to the 21st Century (John P. Griffin). 37 Medicines Regulation in the European Union (A-R. van Troostenburg & G. Tabusso). 38 Japanese Regulations (Etienne Labbe). 39 Drug Registration and Pricing in the Middle East (Edda Freidank-Mueschenborn & Anja Konig). 40 China's Regulated Pharmaceutical Market (Yan Yan Li Starkey). 41 India's New Era in Pharmaceuticals (Darshan Kulkarni). Section VI Medical Services. 42 Medical Affairs (Gregory P. Geba). 43 Drug Labeling (Anthony W. Fox). 44 Data Mining (Mirza I. Rahman & Robbert P. van Manen). 45 Risk Management in Product Approval and Marketing (Anthony W. Fox). 46 Publishing Clinical Studies (Anthony W. Fox). 47 Organizing and Planning Local, Regional, National, and International Meetings and Conferences (Zofia Dziewanowska & Linda Packard). 48 When Things Go Wrong: Drug Withdrawals from the Market (Ronald D. Mann). 49 International Trials: Successful Planning and Conduct (Katie P.J. Wood). Section VII Legal and Ethical Aspects of Pharmaceutical Medicine. 50 Introduction to Bioethics for Pharmaceutical Professionals (Andrew J. Fletcher). 51 Pharmaceutical Medicine and the Law (Sarah Croft). 52 Fraud and Misconduct in Clinical Research (Jane Barrett). Section VIII Business Aspects. 53 The Multinational Corporations: Cultural Challenges, the Legal/Regulatory Framework and the Medico-commercial Environment (R. Drucker & R. Graham Hughes). 54 Advertising and Marketing (Jonathan Belsey). 55 Pharmaceutical Product Liability (Han W. Choi & Jae Hong Lee). 56 Patents (Gabriel Lopez). 57 Outsourcing Clinical Drug Development Activities to Contract Research Organizations (CROs): Critical Success Factors (John R. Vogel). 58 The Impact of Managed Care on the US Pharmaceutical Industry (Robert J. Chaponis, Christine Hanson-Divers, & Marilyn J. Wells). Appendix: Useful Web Links. Index.

Read more less